From small molecules to nano-scale architectures - a supramolecular approach by Scott, Benjamin M. T.
  
 
FROM SMALL MOLECULES TO NANO-SCALE ARCHITECTURES - A 
SUPRAMOLECULAR APPROACH  
 
 
by 
 
 
BENJAMIN M. T. SCOTT 
 
 
B.S., The Nottingham Trent University, 2003 
 
 
 
AN ABSTRACT OF A DISSERTATION 
 
 
submitted in partial fulfillment of the requirements for the degree 
 
 
DOCTOR OF PHILOSOPHY 
 
 
Department Of Chemistry  
College of Arts and Sciences 
 
 
 
 
 
 
 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
 
 
2008 
 Abstract 
We have shown that supramolecular synthons can be used to construct discrete two or 
three component co-crystals and 1-D inorganic-organic chains and dramatically influence the 
arrangement of nanoparticle assemblies. 
A collection of supramolecular reagents (SR’s) have been designed and synthesised to 
carry out a systematic study into hydrogen bonding.  In order to test Etter’s guideline “the best 
proton donor and acceptor remaining after intramolecular hydrogen-bond formation will form 
an intermolecular hydrogen-bond” and to develop a hierarchy of interactions, a series of co-
crystals between the supramolecular reagents and hydrogen-bond donors (carboxylic acids) have 
been synthesised. 
Co-crystals with pyrazole benzamide SR’s have demonstrated the ability to fine-tune 
hydrogen-bond formation.  By utilising a poor hydrogen-bond acceptor (pyrazole) the incoming 
carboxylic acid opts to form a heteromeric acid-amide dimer via N-H•••O hydrogen bonds.  
Additionally, we have shown that the hydrogen-bond acceptor strength of the pyrazole can be 
turned up through simple covalent modifications (i.e. isomer change or addition of methyl 
groups to the pyrazole ring).  Although the heteromeric acid-amide dimer is observed, O-H•••N 
hydrogen bonds to the pyrazole are also observed in cases when more than one donor site is 
present (i.e. di-carboxylic acids and 4-hydroxybenzoic acid).  
Furthermore, co-crystals with picolyl-indazole and pyrimidine-pyrazole SR’s agree with 
Etter’s guideline.  In all cases, the incoming carboxylic acid forms an O-H•••N hydrogen bond to 
the best acceptor (pyridine and pyrazole, respectively). 
The homomeric amide-amide dimer has been used to construct inorganic-organic hybrid 
materials.  The reaction between the pyrazole benzamide ligands with acac or “paddle-wheel” 
complex ions yielded 1-D chains.  Furthermore, pyrimidine-bispyrazole and functionalised 1,3-
bisbenzylpyrazole ligands have been utilised as chelating-ligands for reliable metal coordination. 
Finally, the power of supramolecular synthons to control the arrangement of much larger 
nanoparticle assemblies has been shown.  Both homomeric (acid-acid, alcohol-alcohol) and 
heteromeric (acid-imidazole, alcohol-imidazole) hydrogen bonding cause significant changes in 
nanoparticle assemblies. 
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CHAPTER 1 - Introduction 
 
1.1 Supramolecular Chemistry 
Supramolecular chemistry is described as “chemistry beyond the molecule”,1 and 
supramolecular synthesis focuses on the bringing together of molecules without making or 
breaking covalent bonds to form more complex species (supermolecules) via non-covalent 
interactions (e.g. hydrogen bonds, halogen bonds, van der Waals interactions and coordination 
bonds).   
The ability to bring two (or more) molecules (supramolecular reagents) together via 
intermolecular interactions to form a supermolecule (a distinct entity independent of the 
individual components), is an important goal of supramolecular chemistry. 
Furthermore, supramolecular chemistry strives to achieve effective control (based upon 
molecular recognition1 and self-assembly1) over intermolecular interactions, which govern the 
formation of supermolecules, just like the synthetic chemist has control over the covalent bond. 
1.1.1 Molecular recognition 
Molecular recognition is defined as “the energy and information involved in binding 
(with a purpose) and selection of substrate by a receptor (ligands with a purpose)”.
1 
In order to understand the concept of molecular recognition one can look to Nature, the 
most efficient synthetic chemist, which utilises molecular recognition within most biological 
systems. 
A good example of natural molecular recognition is the interaction between a substrate 
and the receptor (active site) of an enzyme, Fig 1.1. 
2  
 
Figure 1.1 Representation of the interaction between a substrate and receptor of an enzyme. 
 
From a more “general” point of view, molecular recognition can be considered as the 
selective binding (via non-covalent interactions) of two (or more) building blocks based on 
complementarity and binding strength, Figure 1.2. 
 
Figure 1.2 General representation of molecular recognition.  
1.1.2 Self-assembly 
Self-assembly or more specifically supramolecular self-assembly can be defined as  
“recognition-directed spontaneous association of molecular components via non-covalent 
interactions to generate a supermolecule”.1 
As with molecular recognition, self-assembly is observed throughout Nature.  A good 
example of natural self-assembly is provided by the tobacco mosaic virus, Figure 1.3.2  Upon 
binding of a bilayer disk onto a RNA site, 2200 protein subunits (each weighing 18000Da) of the 
tobacco mosaic virus self-assemble into a helical arrangement, 300nm in length and 18nm in 
diameter.  This clearly demonstrates the power of self-assembly with such large subunits being 
efficiently organised on the nanoscale. 
3  
 
Figure 1.3 Self-assembly of the tobacco mosaic virus (1-RNA, 2-capsomer, 3-capsid).2c  
 
In more general terms, self-assembly is the bringing together of building blocks in a 
preconceived manner (based on molecular recognition), which results in the formation of the 
desired supermolecule, Figure 1.4. 
 
Figure 1.4 General representation of self-assembly. 
 
Additionally, the binding preference of building blocks can be fine-tuned, thus providing 
a handle by which molecular recognition and self-assembly can be controlled.  This allows for 
the tailored construction of supermolecules via simple adjustments to the individual components. 
1.1.3 Using molecular recognition and self-assembly to construct supermolecules 
This ability to utilise both molecular recognition and self-assembly principles has 
allowed for the construction of some very elegant supermolecules.  For example, the reaction 
between a Zn(II) porphyrin complex and a 2,4,6-triaminopyrimidine based species demonstrates 
(i) selective metal coordination to the porphyrin and (ii) recognition between the hydrogen-
bonding sites of the uracil functionality appended to the porphyrin and the amino-pyrimidine, 
Figure. 1.5.3 
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Figure 1.5 Construction of a supramolecular porphyrin cage via molecular recognition and 
self-assembly.3 
1.2 Supramolecular vs. Covalent synthesis 
Organic synthetic chemists have the power to construct, through the making and breaking 
of covalent bonds, a vast range of molecules with varying degrees of complexity via well-
established synthetic procedures.4  From the simplest small molecules to more complex natural 
products, Figure 1.6, the synthetic chemist has an endless number of tools that can be exploited 
for developing sequential multi-step synthesis, in which intermediate ‘products’ are isolated and 
purified at each step, before being subjected to further modifications in later steps.  This a major 
advantage in covalent synthesis that allows for modifications and route changes to take place 
with the same final molecular goal retained. 
N
S
Ac
Br                      S
N
HO
NH
O
O
 
         (a)              (b) 
Figure 1.6 From the simplest small molecules to more complex natural products.  Both 
compounds (a) and (b) are synthesised from the same starting material via one and 18 steps, 
respectively.5,6 
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In contrast to synthetic chemists, the supramolecular chemist does not have a large 
synthetic library to consult with.  Furthermore, many supramolecular syntheses are carried out as 
single step, one-pot, reactions with no intermediate species isolated and no additional 
modifications or purification steps carried out, resulting in clear limitations within 
supramolecular synthesis.  
The principles of both synthetic chemistry and supramolecular chemistry can be 
combined to develop a strategy for supramolecular synthesis, in which known synthetic 
procedures are utilised to design and synthesise ‘tunable’ molecules (‘receptors’) via covalent 
modifications that possess reliable binding sites which can, via molecular recognition, combine 
with a complementary ‘substrate’ to form supermolecules. 
1.3 Crystal Engineering 
“One of the continuing scandals in the physical sciences is that it remains in general impossible 
to predict the structure of even the simplest crystalline solids from a knowledge of the chemical 
composition”
7
 
 
Although supramolecular chemists still face more challenges when it comes to efficient, 
construction of supermolecules, significant advances have been made.  The concept of crystal 
engineering,8 which can be considered a sub-section of supramolecular chemistry, has allowed 
supramolecular chemists to go about efficiently designing crystal structures (and in a sense the 
desired supermolecules).  Understanding how supramolecular reagents interact is key to crystal 
engineering and possessing such knowledge will allow for the reliable construction of 
supermolecules and functional materials. 
1.3.1 Using crystal engineering (and supermolecules) to synthesise covalent products 
An elegant example of how crystal engineering has been used is the solid-state 2+2 
photodimerisation reactions carried out by MacGillivray et al.9 Supermolecules capable of 
controlling solid-state photodimerisation reactions to produce cyclobutane-based products were 
targeted.  In order for such photodimerisation reactions to occur the two olefins need to be 
parallel and within 4Å of each other.  
6  
The simple organic molecule, resorcinol, acts as a template, locking (via O-H•••N 
hydrogen bonds) two 4,4’-bis(ethylene)pyridine species into a suitable orientation (parallel 
alignment of the olefins) which meets the strict distance requirements, allowing for successful 
transformations to occur, Figure 1.7. 
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Figure 1.7 Using crystal engineering to design supermolecules for reliable covalent 
modifications.9 
1.4 Hydrogen bonding as a tool for supramolecular synthesis 
Arguably the most effective non-covalent interaction, “the hydrogen bond is the most 
frequently encountered and hence most important non-van der Waals interaction…”.8  The 
hydrogen bond is present in some of Nature’s supermolecules10 for example nucleic acid base 
pairs interact via hydrogen bonds, Fig. 1.8.11  Hydrogen bonds have also been used to carry out 
supramolecular synthesis with varying degrees of complexity, Fig. 1.9. 3, 12 
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Figure 1.8 DNA base pairs interacting via hydrogen bonds. 
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 (a)             (b) 
Figure 1.9 Examples of supermolecules containing hydrogen bonds; (a) barbituric in a 
macrocycle receptor;12a (b) 1:1 complex of barbituric acid and 2,4,6-triaminopyrimidine.12b 
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1.4.1 Supramolecular synthons 
Supramolecular synthons are defined as “structural units within supermolecules which 
can be formed and/or assembled by known or conceivable synthetic operations using 
intermolecular interactions”.13 Knowing that molecules will organise themselves in a certain 
way in the solid-state can be exploited in the design and synthesis of supermolecules.  A few 
examples of these powerful tools will be discussed below. 
1.4.1.1 Homomeric hydrogen-bond synthons 
Complementarity plays a big role within hydrogen bonding and the formation of 
homomeric interactions between two or more molecules of the same chemical species provides 
important information regarding the interactions as well as the orientation of the molecules. 
Homomeric dimers are often seen between molecules containing a binding site with 
complementary donor and acceptor sites e.g. carboxylic acids,14 amides15 and amino-pyridines,16 
Figure 1.10. 
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         (a)          (b)      (c) 
Figure 1.10 Examples of homomeric dimers; (a) acid-acid; (b) amide-amide and (c) 
aminopyridine-aminopyridine. 
 
Homomeric dimers occur regularly throughout organic solid-state chemistry and with this 
continuity within families of molecules it can be applied as a reliable tool for construction of 
supermolecules. 
There are other homomeric interactions that can take place, with chains often seen 
notably in secondary amides17 and alcohols,18 Figure 1.11. 
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     (a)       (b) 
Figure 1.11 Examples of homomeric chains; (a) secondary amide and (b) alcohol. 
1.4.1.2 Heteromeric hydrogen-bond synthons 
Reliable and recurring hydrogen bonds are also observed between two different chemical 
entities resulting in heteromeric synthons.19  Dimers can be formed between two different 
molecules, e.g acid•••amide,20 acid•••pyridine,21, 20a-b acid•••aminopyridine,22 Figure 1.12. 
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  (a)         (b)             (c) 
Figure 1.12 Examples of heteromeric hydrogen-bond synthons; (a) acid-amide; (b) acid-
pyridine and (c) acid-aminopyridine. 
1.4.2 Graph-set notations 
Graph-set notation23 is used to identify specific hydrogen-bonding interactions and allows 
for recurring trends to be identified. 
The general formula, Figure 1.13, incorporates a hydrogen-bond motif (G), the number of 
hydrogen-bond acceptors (a), the number of hydrogen-bond donors (d) and the total number of 
atoms contained in the specific motif (x). 
)X(G
a
d  
Figure 1.13 General formula for graph-set notations. 
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There are four types of motifs (G) used in the assignment of graph sets, ring (R), chain 
(C), dimer (D) and intramolecular (S). 
Graph sets are broken down into levels, Nx, where “x” is the number of different 
hydrogen bonds involved.  The first level (N1) considers each hydrogen bond individually, the 
second level (N2) incorporates two different hydrogen bonds, N3 involves three different 
hydrogen bonds etc. 
For example, benzoic acid,14i-k Figure 1.14, has two equivalent O-H•••O hydrogen bonds 
present and consequently N1 is assigned )8(R
2
2 (a ring motif with two hydrogen-bond donors, two 
hydrogen-bond acceptors and a total of eight atoms in the ring). 
O
O H O
OH
)8(R22
 
Figure 1.14 )8(R22  graph-set notation for benzoic acid. 
 
Benzamide,15j-m Figure 1.15, however, has two different N-H•••O hydrogen bonds and 
consequently has two levels of graph sets.  N1 for benzamide is )8(R
2
2 ; )4(C
1
1 and N2 is )8(R
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Figure 1.15 Graph sets for benzamide. 
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1.4.3 Etter’s guidelines 
Having guidelines in place to confidently assess hydrogen bonding in supramolecular 
synthesis is essential and provides a deeper understanding of which hydrogen bonds will form.  
This has been developed over the past twenty years and began with Etter23c-d introducing the idea 
of systematically looking at hydrogen-bond patterns (identified by graph-set notations) in 
molecular aggregates.  An extensive study of the Cambridge Structural Database (CSD),24 led to 
a family of guidelines that can be followed when attempting to design and synthesise 
supermolecules; 
 
1) All proton donors and acceptors will participate in hydrogen bonding 
2) A six-membered intramolecular arrangement will form if possible 
3) The best proton donor and acceptor remaining after intramolecular hydrogen-bond 
formation will form an intermolecular hydrogen-bond 
1.4.4 Co-crystals 
Co-crystals are the result of controlled, predictable supramolecular synthesis that utilise 
both homomeric and heteromeric synthons.  Defined as “structurally homogeneous crystalline 
materials that contain two or more neutral building blocks (that are solids under ambient 
conditions) that are present in definite stoichiometric amounts”,25 co-crystals have gained 
attention due to their ability to control the inherent properties of simple organic compounds 
(including active pharmaceutical ingredients) via non-covalent interactions.26 
Co-crystals are generally formed via solution-based “reactions” (although solid-state 
grinding,27 melting,28 and vapour digestion27e, 29 are also suitable methods for co-crystal 
synthesis) in which a solution containing stoichiometric amounts of each component is allowed 
to evaporate in an attempt to form the single solid form.  The general process is very similar to 
recrystallisation techniques that are used extensively (A Sci-Finder search for the term 
“recrystallisation” yielded 26905 hits) in synthetic chemistry to obtain pure products, Figure 
1.16. 
How then do co-crystallisation reactions prevail when the probability of forming the 
heteromeric (co-crystal) product is much lower than forming the homomeric (recrystallisation) 
product?  With the odds stacked against co-crystal formation, the chemical species have to be 
11  
tailored to drive the reaction toward the heteromeric interaction.  This can be achieved by 
considering the guidelines that have been put in place (i.e. Etter’s guidelines and Deiraju’s 
synthons) which provide valuable tools for driving the formation of a co-crystal instead of the 
homomeric recrystallisation product. 
Recrystallisation
Co-crystallisation
 
Figure 1.16 Recrystallisation vs. co-crystallisation. 
1.4.4.1 Examples of co-crystals 
Many binary (two component) co-crystals have been synthesised, which agrees with 
Etter’s third guideline “the best proton donor and acceptor remaining after intramolecular 
hydrogen-bond formation will form an intermolecular hydrogen bond”
 23c-d and demonstrates the 
reliability of ‘heterosynthons’.19  Heteromeric acid-acid dimers have been observed, Figure 
1.17a,20b, 30 along with acid-amide heterodimers, Figure 1.17b20 and more complex systems 
featuring a carboxylic acid interacting with an N-heterocycle, Figure 1.17c.20a-b, 21, 31 
         
     (a)        (b) 
 
 
(c) 
Figure 1.17 Examples of binary heteromeric co-crystals – (a) acid-acid heterodimer; 20b (b) 
acid-amide heterodimer; 20a (c) acid-pyridine. 21c 
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In some instances, both homomeric and heteromeric interactions are observed.20b  For 
example, the binary co-crystal between isonicotinamide and 4-fluorobenzoic acid possesses both 
the homomeric amide-amide dimer as well as the heteromeric O-H•••N acid-pyridine interaction, 
Figure 1.18. 
 
Figure 1.18 Binary 1:1 co-crystal of isonicotinamide and 4-fluorobenzoic acid. 
 
Homo- and heteromeric interactions have also been combined to increase the level of 
complexity of co-crystals to the ternary (three component) level.21d  Isonicotinamide was utilised 
as a primary hub for ternary co-crystallisations having two different binding sites (the pyridine 
and the amide).  Two different carboxylic acids form heteromeric hydrogen bonds (acid-amide 
dimer via N-H•••O and O-H•••O hydrogen bonds and acid-pyridine via an O-H•••N hydrogen 
bond) to the different binding sites, Figure 1.19.  These ternary co-crystals agree with Etter’s 
guideline “the best proton donor and acceptor remaining after intramolecular hydrogen-bond 
formation will form an intermolecular hydrogen bond”.23c-d 
 
Figure 1.19 Ternary 1:1:1 co-crystal of isonicotinamide, 3,5-dinitrobenzoic acid and 3-
methylbenzoic acid.21d 
1.4.5 What do molecules want? 
The complexity and difficulty surrounding the formation of 1:1:1 ternary co-crystals is 
demonstrated by the limited number of structures (there are only seven 1:1:1 ternary co-crystals 
in the CSD).  Although it seems relatively straightforward, reliable supramolecular synthesis is 
13  
restricted at present due to a limited understanding of “what molecules want” with regards to 
non-covalent interactions. 
Considering a system that possesses three different binding sites capable of accepting or 
donating a hydrogen bond, Figure 1.20.  How do we design a hub, such that three incoming 
species will recognise and selectively bind to the desired site? 
+ ++
 
Figure 1.20 General representation of selective binding. 
 
Previous work has utilised supramolecular synthons to construct supermolecules of 
varying size and complexity, Figure 1.21.  From 1:1 binary20, 21, 26a, 30, 31b-c and 1:1:1 ternary21d, 31a 
co-crystals to inorganic-organic hybrid materials32 to heteromeric capsules.33  The ability to 
control assembly over a range of 30nm3 to 180nm3 demonstrates the robustness of 
supramolecular synthons and ultimately leads to the question “can supramolecular synthons be 
used to control even larger assemblies (e.g. nanoparticles)?” 
?
M
M
1:1 co-crystal 1:1:1 co-crystal Inorganic-organic 
hybrid material
(M = complex ion)
Heteromeric 
capsule
 
Figure 1.21 Using supramolecular synthons to construct a variety of supermolecules. 
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1.5 Goals 
Supramolecular synthons can be used to construct supermolecules, however, the 
uncertainty surrounding non-covalent interactions still provides a challenge to reliable and robust 
synthetic strategies.   
A hierarchy of non-covalent interactions needs to be developed.  If a level of consistency 
can be attained for supramolecular synthesis similar to that for covalent synthesis (i.e when “A” 
is reacted with “B” the product is always “C”), then construction of supermolecules becomes far 
more reliable. 
Consequently, the goals of this thesis are to: 
 
I. Develop a hierarchy of reliable hydrogen-bond interactions via co-crystallisation 
reactions 
In order to test Etter’s guideline23c-d “the best proton donor and acceptor remaining after 
intramolecular hydrogen-bond formation will form an intermolecular hydrogen-bond” and to 
continue developing a hierarchy of interactions, a collection of supramolecular reagents will be 
designed and synthesised.  Subsequent co-crystallisation reactions between supramolecular 
reagents and hydrogen-bond donors will allow for a systematic study into hydrogen-bond 
preference to be carried out. 
 
II. Build inorganic-organic hybrid materials using non-covalent interactions 
The robustness of the amide-amide dimer will be tested in the presence of potentially 
disruptive forces (e.g. solvent, counter-ions) by attempting to construct 1-D inorganic-organic 
hybrid materials.  Additionally, reliable chelating ligands (acac, “paddle-wheel”, pyrimidine-
pyrazole and 1,3-bisbenzylpyrazole) will be utilised to control unpredictable metal coordination. 
 
III. Test the synthetic capability of supramolecular synthons on a much larger scale by 
studying hydrogen-bond effects on nanoparticle assembly 
Nanoparticles functionalised with hydrogen-bond terminated ligands will be synthesised.  
The structure of homomeric (acid-acid; alcohol-alcohol) and heteromeric (acid-imidazole; 
alcohol-imidazole) hydrogen-bond assemblies will be compared to assemblies with non 
hydrogen bonding (methyl and imidazole) terminated ligands, thus providing information 
regarding the influence of hydrogen bonding (or more specifically, supramolecular synthons) on 
such a large scale. 
15  
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CHAPTER 2 - How robust is the hydrogen-bonded amide 
‘ladder’ motif? 
 
2.1 Introduction 
The way in which discrete molecules equipped with a variety of functional groups 
interact, bind and communicate with each other through non-covalent intermolecular forces1 is 
central to the understanding of biological chemistry as well as to many areas of materials science 
(pharmaceutical compounds,2 polymers,3 liquid crystals,4 organogelators,5 and lithographic 
plates6).  On a fundamental level it is important to be able to identify patterns of behavior of 
functional groups but not just in terms of their chemical reactivity.  We also need to acquire an 
improved understanding of non-covalent interactions in order to reliably predict molecular 
organization, assembly, and connectivity in the solid state as this ultimately controls many 
physical properties of the bulk materials.7  In this context, single-crystal structural data have 
offered invaluable information regarding recurring intermolecular motifs, supramolecular 
synthons,8 and interactions involving specific chemical functional groups, with the concept of 
synthons becoming key to advancing all practical manifestations of crystal engineering.9 
The structural chemistry of the amide moiety has received considerable attention partly 
due to the self-complementary nature of its hydrogen-bond donors/acceptors, but also because of 
the abundance of amide moieties in biological systems.10  The amide is, on its own, frequently 
associated with an infinite ladder-like motif typically composed of two pairs of symmetry related 
N-H•••O hydrogen bonds.11  The ladder is the result of a self-complementary, )8(R22  homomeric 
amide•••amide dimer, Figure 2.1a, accompanied by N-H•••O interactions between the anti 
hydrogen atom of the –NH2 group and the carbonyl oxygen of an adjacent amide moiety 
(producing an )8(R
2
2  motif).  This intermolecular arrangement satisfies both hydrogen-bond 
donors (the –NH2 hydrogen atoms) and the two hydrogen-bond acceptor sites (the lone-pairs) on 
the carbonyl oxygen atom, Figure 2.1b.   
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Complications may arise, however, if additional hydrogen-bond acceptors are present on 
the same molecule as the amide.  For example, in one of the polymorphs of 4-nitrobenzamide, 
the –NO2 moiety disrupts the ladder-motif by acting as a hydrogen-bond acceptor for the –NH2 
anti hydrogen atom of the amide.12 
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N
O
H
H
N
O
H
H
N
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H
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O
H
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N
O
H
H
N
O
H
H
(a)
(b)  
Figure 2.1 (a) Homomeric amide dimer and (b) Extended ladder. 
 
In order to address this challenge, we have carried out a systematic structural study of a 
family of new compounds comprising an amide moiety and an N-heterocyclic fragment, Figure 
2.2.  The relative basicity, and thus ability to form hydrogen bonds, of the N-heterocycle can be 
varied through simple covalent modifications, which offer a practical tool for establishing 
correlations between molecular structure/function and supramolecular assembly/organization.  
N
N
R
R
R1
2, R&R1=H
4, R=Me & R1=H
6, R=Me & R1=Br
NH2
O
N
N
R
R
R1
8, R&R1=H
10, R=Me & R1=H
12, R=Me & R1=Br
O
H2N
 
Figure 2.2 Target ligands. 
 
We have also supplemented the new structural information with relevant data obtained 
from the CSD.13 The literature search was confined to (a) compounds containing a benzamide-
type fragment accompanied by an additional functional group capable of acting as a hydrogen-
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bond acceptor only (such as  –NO2,-OMe -CN, -Cl, -Br), and (b) compounds comprising a N- 
heterocyclic fragment substituted with an amide moiety, Figure 2.3.   
(a) (b) (c) (d)
CONH2
R
N
CONH2
N
CONH2
O
N
N CONH2
 
Figure 2.3 CSD search parameters; (a) substituted benzamides; (b) isonicotinamide and 
nicotinamide; (c) N-Oxide of isonicotinamide and nicotinamide; (d) pyrazine amide). 
 
The combination of our new structural data with relevant information from the CSD 
produces a sufficiently large number of structures to enable us to explicitly address three 
questions: 
 
I. How reliable is the amide ladder in the organic solid state if competing hydrogen-bond sites 
are present? 
 
II. How reliable is the amide•••amide dimer in the presence of competing hydrogen-bond 
acceptors? 
 
III. Is it possible to rank different functional groups according to how likely they are to disrupt 
the ladder by interacting with the amino anti hydrogen atom of the amide moiety? 
2.2 Experimental 
2.2.1 Synthesis 
All chemicals were purchased from Aldrich and Fischer and used without further 
purification.  4-Bromo-3,5-dimethylpyrazole was synthesised via a previously published 
procedure.14  Melting points were determined on a Fisher-Johns melting point apparatus and are 
uncorrected. 
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2.2.1.1 Synthesis of 4-[(pyrazol-1-yl)methyl]benzonitrile, 1 
CN
Br
CN
N
Pyrazole, NaOH, THF
N
 
To a round bottom flask, pyrazole (1.50g, 22.1mmol) and THF (80mL) were added.  To 
this solution, NaOH pellets (8.82g, 221mmol) were added and the reaction was stirred at room 
temperature for 2 hours.  On completion of the stir, α-bromo-p-tolunitrile (4.32g, 22.1mmol) in 
THF (80mL) was added and the reaction mixture stirred at room temperature overnight.  On 
completion, water was added to dissolve any excess NaOH, the organic layer was separated off, 
dried over MgSO4 and the solvent removed under vacuum to yield 1 as a white solid (3.36g, 
83.3%).  Mp: 71-73oC.  1H NMR (δH; 400MHz, CDCl3): 5.39 (s, 2H), 6.34 (t, J = 2.2Hz, 1H), 
7.24 (d, J = 8Hz, 2H), 7.45 (s, 1H), 7.58 (s, 1H), 7.62 (d, J = 8.4Hz, 2H), Figure B.1; IR (KBr 
pellet): υ 3112, 2939, 2223, 1620, 1501, 1448, 1388, 1275, 1076, 1036, 950, 824, 745 cm-1. 
2.2.1.2 Synthesis of 4-[(pyrazol-1-yl)methyl]benzamide, 2 
CN
N
N
85% H2SO4
CONH2
N
N
 
To a round bottom flask, 4-[(pyrazol-1-yl)methyl]benzonitrile (2.86g, 15.6mmol) and 
85% H2SO4 (12mL) were added.  The mixture was heated to 80
oC and stirred for 4 hours.  On 
completion, the solution was poured slowly over ice and the resulting brown solution was 
adjusted to basic pH using 5M NaOH.  The aqueous solution was washed with CHCl3 and the 
organic extracts were separated, dried over MgSO4 and reduced to yield 2 as a white solid 
(2.63g, 83.7%).  Colourless plates suitable for X-ray diffraction were obtained via slow 
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evaporation of ethanol.  Mp: 135-137oC.  1H NMR, (δH; 400MHz, CDCl3): 5.39 (s, 2H), 5.79 (s, 
1H), 6.12 (s, 1H), 6.32 (t, J = 2 Hz, 1H), 7.25 (d, J = 8Hz, 2H), 7.43 (d, J = 2.4Hz, 1H), 7.58 (d, 
J = 1.6Hz, 1H), 7.78 (d, J = 4.4Hz, 2H), Figure B.2a; 13C NMR, (δC; 100MHz, CDCl3): 55.42, 
106.30, 127.64 127.91, 129.46, 133.03, 139.95, 140.91, 168.65, Figure B.2b; IR (KBr pellet): υ 
3370, 3171, 3019, 2926, 1660, 1408, 1302, 1143, 924, 758 cm-1.  MS: m/z = 201.983. 
2.2.1.3 Synthesis of 4-[(3,5-dimethylpyrazol-1-yl)methyl]benzonitrile, 3 
CN
Br
CN
N
3,5-dimethylpyrazole, 
NaOH, THF
N
 
To a round bottom flask, 3,5-dimethylpyrazole (0.500g, 5.20mmol) and THF (25mL) 
were added.  To this solution, NaOH pellets (2.10g, 52.0mmol) were added and the reaction was 
stirred at room temperature for 2 hours.  On completion, α-bromo-p-tolunitrile (1.04g, 
5.20mmol) in THF (25mL) was added and the reaction mixture stirred at room temperature for 3 
days.  On completion, water was added to dissolve any excess NaOH, the organic layer was 
separated off, dried over MgSO4 and the solvent removed under vacuum to yield 3 as a white 
solid (0.936g, 85.0%).  Mp: 63-65oC.  1H NMR (δH; 400MHz, CDCl3): 2.14 (s, 3H), 2.22 (s, 3H), 
5.26 (s, 2H), 5.88 (s, 1H), 7.14 (d, J = 8.4Hz, 2H), 7.54 (d, J = 8.4Hz, 2H) , Figure B.3; IR (KBr 
pellet): υ 3053, 2909, 2233, 1603, 1557, 1306, 1030, 810, 769, 549 cm-1. 
2.2.1.4 Synthesis of 4-[(3,5-dimethylpyrazol-1-yl)methyl]benzamide, 4 
CN
N
N
85% H2SO4
CONH2
N
N
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To a round bottom flask, 4-[(3,5-dimethylpyrazol-1-yl)methyl]benzonitrile (11.0g, 
52.1mmol) and 85% H2SO4 (100mL) were added.  The mixture was heated to 80
oC and stirred 
for 4 hours.  On completion, the solution was poured slowly over ice and the resulting brown 
solution was adjusted to basic pH using 5M NaOH.  The aqueous solution was washed with 
CHCl3 and the organic extracts were separated, dried over MgSO4 and reduced to yield 4 as a 
white solid (5.99g, 50.0%).  Colourless plates suitable for X-ray diffraction were obtained via 
slow evaporation of ethanol.  Mp: 172-175oC.  1H NMR, (δH; 400MHz, CDCl3): 2.14 (s, 3H), 
2.25 (s, 3H), 5.24 (s, 2H), 5.87 (s, 1H), 6.54 (s, 2H), 7.09 (d, J = 8.4Hz, 2H), 7.74 (d, J = 8.4Hz, 
2H) , Figure B.4a; 13C NMR, (δC; 100MHz, CDCl3): 11.26, 13.60, 52.26, 106.07, 126.93, 
128.06, 132.70, 139.70, 141.62, 148.09 169.41, Figure B.4b; IR (KBr pellet): υ 3447, 1680, 
1644, 1414, 1383, 1306, 1117 cm-1.  MS: m/z = 230.022.  
2.2.1.5 Synthesis of 4-[(4-bromo-3,5-dimethylpyrazol-1-yl)methyl]benzonitrile, 5 
CN
Br
CN
N
4-bromo-3,5-dimethylpyrazole, 
NaOH, THF
N
Br  
To a round bottom flask, 4-bromo-3,5-dimethylpyrazole (0.500g, 2.86mmol) and THF 
(25mL) were added.  To this solution, NaOH pellets (1.14g, 28.6mmol) were added and the 
reaction was stirred at room temperature for 2 hours.  On completion, α-bromo-p-tolunitrile 
(0.560g, 2.86mmol) in THF (25mL) was added and the reaction mixture stirred at room 
temperature for 2 days.  On completion, water was added to dissolve any excess NaOH, the 
organic layer was separated off, dried over MgSO4 and the solvent removed under vacuum to 
yield 5 as a white solid (2.08g, 81.5%).  Mp: 76-79oC.  1H NMR (δH; 400MHz, CDCl3): 2.17 (s, 
3H), 2.27(s, 3H), 5.33 (s, 2H), 7.19 (d, J = 16.4Hz, 2H), 7.63 (d, J = 16.8Hz, 2H) , Figure B.5; 
IR (KBr pellet): υ 3068, 2919, 2238, 1603, 1547, 1511, 1465, 1414, 1347, 1281, 1214, 1055, 
810, 543 cm-1. 
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2.2.1.6 Synthesis of 4-[(4-bromo-3,5-dimethylpyrazol-1-yl)methyl]benzamide, 6 
CN
N
N
85% H2SO4
CONH2
N
N
Br Br  
4-[(4-Bromo-3,5-dimethylpyrazol-1-yl)methyl]benzonitrile (2.08g, 8.57mmol) and 85% 
H2SO4 (20mL) were added to a round bottom flask,.  The mixture was heated to 80
oC and stirred 
for 4 hours.  On completion of the stir, the solution was poured slowly over ice and the resulting 
brown solution was adjusted to basic pH using 5M NaOH.  The aqueous solution was washed 
with ethyl acetate and the organic extracts were separated, dried over MgSO4 and reduced to 
yield 6 as a white solid (1.49g, 69.0%).  Colourless prisms suitable for X-ray diffraction were 
obtained from slow evaporation of acetonitrile.  Mp: 195-198oC.  1H NMR, (δH; 400MHz, 
CDCl3): 2.15 (s, 3H), 2.25 (s, 3H), 5.28 (s, 2H), 5.84 (s, 1H), 5.98 (s, 1H), 7.15 (d, J = 8Hz, 2H), 
7.77 (d, J = 8Hz, 2H) , Figure B.6a; 13C NMR, (δC; 100MHz, DMSO-d
6): 9.95, 12.04, 52.53, 
93.27, 126.80, 127.85, 133.55, 137.27, 140.26, 144.88, 167.56, Figure B.6b; IR (KBr pellet): υ 
3339, 3186, 1670, 1624, 1388, 1071, 717, 692, 646 cm-1.  MS: m/z =  307.969, 309.968. 
2.2.1.7 Synthesis of 3-[(pyrazol-1-yl)methyl]benzonitrile, 7 
CN
pyrazole, 
NaOH, THF
Br
CN
N
N  
To a round bottom flask, pyrazole (1.50g, 22.1mmol) and THF (80mL) were added.  To 
this solution, NaOH pellets (8.82g, 221mmol) were added and the reaction was stirred at room 
temperature for 2 hours.  On completion, α-bromo-m-tolunitrile (4.32g, 22.1mmol) in THF 
(80mL) was added and the reaction mixture stirred at room temperature overnight.  On 
completion, water was added to dissolve any excess NaOH, the organic layer separated off, dried 
over MgSO4 and the solvent removed under vacuum to yield 7 as a yellow oil (3.42g, 84.7%).  
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1H NMR (δH; 400MHz, CDCl3): 5.20 (s, 2H), 6.18 (t, J = 4Hz, 1H), 7.26 (s, 1H), 7.28 (d, J = 
2.8Hz 2H), 7.36 (t, J = 2.2Hz 1H), 7.38 (d, J = 4.4Hz, 1H), 7.43 (d, J = 2Hz, 1H), Figure B.7; IR 
(KBr pellet): υ 3119, 2930, 2231, 1583, 1511, 1434, 1395, 1291, 1089, 1055, 974, 685 cm-1. 
2.2.1.8 Synthesis of 3-[(pyrazol-1-yl)methyl]benzamide, 8 
85% H2SO4
CONH2
N
N
CN
N
N  
To a round bottom flask, 3-[(pyrazol-1-ylmethyl)]benzonitrile (2.59g, 14.1mmol) and 
85% H2SO4 (10mL) were added.  The mixture was heated to 80
oC and stirred for 4 hours.  On 
completion of the stir, the solution was poured slowly over ice and the resulting brown solution 
was adjusted to basic pH using 5M NaOH. The aqueous solution was washed with CHCl3 and the 
organic extracts were separated, dried over MgSO4 and reduced to yield 8 as a pale yellow solid 
(1.24g, 44.0%).  Colourless blocks suitable for X-ray diffraction were obtained via slow 
evaporation of ethanol.   Mp: 117-120oC.  1H NMR (δH; 400MHz, CDCl3): CDCl3, 5.37 (s, 2H), 
5.87 (s, 1H), 6.18 (s, 1H), 6.31 (t, J = 2Hz, 1H), 7.36 (d, J = 7.6Hz, 1H), 7.42 (d, J = 8Hz, 1H), 
7.44 (s, 1H), 7.57 (s, 1H), 7.70 (s, 1H), 7.73 (d, J = 7.6Hz, 1H), Figure B.8a; 13C NMR, (δC; 
100MHz, CDCl3): 55.43, 106.30, 126.68, 126.97, 129.16, 129.58, 131.08, 133.94, 137.25, 
139.76, 168.93, Figure B.8b; IR (KBr pellet): υ 3327, 3149, 1684, 1388, 1046, 769, 762 cm-1.  
MS: m/z = 201.983. 
2.2.1.9 Synthesis of 3-[(3,5-dimethylpyrazol-1-yl)methyl]benzonitrile, 9 
CN
3,5-dimethylpyrazole, 
NaOH, THF
Br
CN
N
N  
To a round bottom flask, 3,5-dimethylpyrazole (5.00g, 52mmol) and THF (125mL) were 
added.  To this solution, NaOH pellets (21.0g, 520mmol) were added and the reaction was stirred 
at room temperature for 2 hours.  On completion, α-bromo-m-tolunitrile (10.4g, 52mmol) in THF 
(125mL) was added and the reaction mixture stirred at room temperature for 3 days.  On 
completion, water was added to dissolve any excess NaOH, the organic layer was separated off, 
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dried over MgSO4 and the solvent removed under vacuum to yield 9 as a white solid (10.58g, 
96.3%).  Mp: 33-35oC.  1H NMR (δH; 400MHz, CDCl3): 2.17 (s, 3H), 2.25 (s, 3H), 5.24 (s, 2H), 
5.89 (s, 1H), 7.30 (d, J = 15.2Hz, 2H), 7.43 (t, J = 15.2Hz, 1H), 7.54 (d, J = 14.8, 1H) , Figure 
B.9; IR (KBr pellet): υ 3112, 2939, 2223, 1620, 1501, 1448, 1388, 1275, 1076, 1036, 950, 824, 
745 cm-1. 
2.2.1.10 Synthesis of 3-[(3,5-dimethylpyrazol-1-yl)methyl]benzamide, 10 
85% H2SO4
CN
N
N
CONH2
N
N  
3-[(3,5-dimethylpyrazol-1-yl)methyl]benzonitrile (0.300g, 1.42mmol) and 85% H2SO4 
(3mL) were added to a round bottom flask,.  The mixture was heated to 80oC and stirred for 4 
hours.  On completion of the stir, the solution was poured slowly over ice and the resulting 
brown solution was adjusted to basic pH using 5M NaOH.  The aqueous solution was washed 
with CHCl3 and the organic extracts were separated, dried over MgSO4 and reduced to yield 10 
as a white solid (0.203g, 62.4%). Colourless plates suitable for X-ray diffraction were obtained 
via slow evaporation of ethanol.   Mp: 158-161oC.  1H NMR, (δH; 400MHz, CDCl3): 2.15 (s, 
3H), 2.24 (s, 3H), 5.24 (s, 2H), 5.86 (s, 1H), 5.95 (s, 1H), 6.21 (s, 1H), 7.20 (d, J = 8Hz, 1H), 
7.38 (t, J = 7.6 Hz, 1H), 7.57 (s, 1H), 7.69 (d, J = 7.6Hz, 1H) , Figure B.10a; 13C NMR, (δC; 
50MHz, CDCl3): 11.17, 13.54, 52.17, 105.83, 125.70, 126.54, 129.13, 130.25, 133.86, 138.11, 
139.38, 147.97, 169.00, Figure B.10b; IR (KBr pellet): υ 3355, 3288, 3140, 2919, 1680, 1603, 
1547, 1455, 1373, 784, 707 cm-1.  MS: m/z = 230.033. 
2.2.1.11 Synthesis of 3-[(4-bromo-3,5-dimethylpyrazol-1-yl)methyl]benzonitrile, 11 
CN
4-bromo-3,5-dimethylpyrazole, 
NaOH, THF
Br
CN
N
N
Br
 
To a round bottom flask, 4-bromo-3,5-dimethylpyrazole (1.50g, 8.57mmol) and THF 
(25mL) were added.  To this solution, NaOH pellets (3.43g, 85.7mmol) were added and the 
reaction was stirred at room temperature for 2 hours.  On completion, α-bromo-m-tolunitrile 
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(1.68g, 8.57mmol) in THF (25mL) was added and the reaction mixture stirred at room 
temperature for 2 days.  On completion, water was added to dissolve any excess NaOH, the 
organic layer was separated off, dried over MgSO4 and the solvent removed under vacuum to 
yield 11 as a white solid (2.25g, 90.5%).  Mp: 72-75oC.  1H NMR (δH; 200MHz, CDCl3): 2.17 (s, 
3H), 2.22 (s, 3H), 5.27 (s, 2H), 7.35 (d, J = 7.8Hz, 2H), 7.44 (t, J = 7.4Hz, 1H), 7.55 (d, J = 
7.8Hz, 1H), Figure B.11; IR (KBr pellet): υ 3027, 2925, 2228, 1542, 1470, 1265, 1070, 907, 804, 
702 cm-1. 
2.2.1.12 Synthesis of 3-[(4-bromo-3,5-dimethylpyrazol-1-yl)methyl]benzamide, 12 
85% H2SO4
CN
N
N
Br
CONH2
N
N
Br
 
To a round bottom flask, 3-[(4-bromo-3,5-dimethylpyrazol-1-yl)methyl]benzonitrile 
(0.300g, 1.03mmol) and 85% H2SO4 (3mL) were added.  The mixture was heated to 80
oC and 
stirred for 4 hours.  On completion, the solution was poured slowly over ice and the resulting 
brown solution was adjusted to basic pH using 5M NaOH.  The aqueous solution was washed 
with chloroform and the organic extracts were separated, dried over MgSO4 and reduced to yield 
12 as a white solid (0.125g, 39.0%).  Colourless plates suitable for X-ray diffraction were 
obtained from the co-crystallisation reaction with fumaric acid via slow evaporation of 
acetonitrile.  Mp: 133-136oC.  1H NMR, (δH; 200MHz, CDCl3): 2.150 (s, 3H), 2.22 (s, 3H), 5.24 
(s, 2H), 6.51 (s, 2H), 7.19 (d, J = 7.8Hz, 1H), 7.28-7.40 (m, J = 8Hz, 1H), 7.64 (s, 1H), 7.70 (d, J 
= 7.8Hz, 1H) , Figure B.12a; 13C NMR, (δC; 50MHz, CDCl3): 10.41, 12.32, 53.40, 94.78, 
126.00, 126.74, 129.15, 130.25, 134.06, 137.20, 137.42, 146.49, 169.31, Figure B.12b; IR (KBr 
pellet): υ 3355, 3165, 2919, 1660, 1409, 1296, 1066, 805, 738, 661.  MS: m/z = 307.985, 309.985 
cm-1. 
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2.3 Results 
All hydrogen bond geometries are listed in Table 2.1.  A summary of the crystallographic 
information for each compound is displayed in Tables A.1-A.6. 
 
Table 2.1 Hydrogen bond geometries for 2, 4, 6, 8, 10 and 12. 
Compound D-H…A D-H / Å H…A / Å D…A / Å <(DHA) / o 
2i 
N(17)-H(17A)...O(17)#1 
N(17)-H(17B)...O(17)#2 
0.97(2) 
0.86(2) 
1.93(2) 
2.09(2) 
2.899(2) 
2.938(2) 
176.4(17) 
167(2) 
4ii 
N(17)-H(17A)...O(17)#1 
N(17)-H(17B)...N(22)#2 
0.85(2) 
0.91(2) 
2.08(2) 
2.23(2) 
2.913(2) 
3.112(2) 
168.3(19) 
162.7(17) 
6iii 
N(27)-H(27A)...O(27)#1 
N(27)-H(27B)...N(12)#2 
0.819(17) 
0.808(17) 
2.137(17) 
2.249(17) 
2.9488(15) 
3.0341(15) 
171.0(16) 
163.9(16) 
8iv 
N(27)-H(27A)...O(27)#1 
N(27)-H(27B)...N(12)#2 
0.901(15) 
0.857(15) 
2.018(15) 
2.208(15) 
2.9183(11) 
3.0580(12) 
177.2(13) 
170.9(14) 
10v 
N(17)-H(17A)...O(17)#1 
N(17)-H(17B)...N(22)#2 
0.914(15) 
0.921(14) 
2.002(15) 
2.110(14) 
2.9033(12) 
2.9997(12) 
168.4(12) 
161.9(12) 
12vi 
N(27)-H(27A)...N(32) 
N(47)-H(47A)...N(12)#1 
0.88 
0.88 
1.85 
1.83 
2.709(7) 
2.671(6) 
164.9 
160.1 
i) #1 -x,-y+1,-z, #2 x,-y+1/2,z+1/2; ii) #1 -x,-y+2,-z, #2 x,y+1,z; iii) #1 -x,-y+1,-z, #2 x-1/2,-
y+3/2,z-1/2; iv) #1 -x+2,-y,-z+1, #2 -x+1,-y+1,-z+1; v) #1 -x+2,-y+1,-z+1, #2 -x+1,-y+1,-
z+1; vi) #1 x,y+1,z-1 
2.3.1 MEP surface calculations 
In order to rank the hydrogen bonding capability of the N-heterocyclic compounds 
included in this study, we also calculated molecular electrostatic potential (MEP) surfaces for all 
compounds,15 Table 2.2 and Figure 2.4.  It has previously been shown16 that such an approach is 
feasible even if the calculations are performed at a relatively low level of theory (AM1), which 
makes this a versatile and readily accessible tool. 
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Table 2.2 Molecular electrostatic surface potential calculations. 
Ligand 
E(N) 
kJ/mol 
Ligand 
E(NPZ) 
kJ mol-1 
Isonicotinamide -247 2 -236 
Nicotinamide -255 4 -246 
Pyrazine -237 & -178 6 -229 
3-[Benzimidazol-1-yl) methyl]-benzamide -285 8 -255 
3-[(2-Chlorobenzimidazol-1-yl)methyl]-benzamide -277 10 -262 
4-[(2-Methylbenzimidazol-1-yl)methyl]-benzamide -303 12 -239 
 
 
      2        4       6 
 
 
       8      10      12 
Figure 2.4 Molecular electrostatic potential surfaces for (pyrazol-1-yl)methyl benzamide 
ligands. 
2.3.2 Crystal structure of 4-[(pyrazol-1-yl)methyl]benzamide, 2 
The primary intermolecular motif in the crystal structure of 2 is an amide-amide dimer 
constructed from two symmetry related N-H•••O hydrogen bonds (2.899(2)Å).  These dimers are 
subsequently linked into an infinite 1-D chain via secondary N-H•••O interactions (2.938(2)Å) 
CONH2
N
N
R
R
R1
CONH2
N
N
R
R1
R
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between the anti amide hydrogen atom and the carbonyl oxygen of an adjacent amide, Figure 
2.5.   
Although a ‘classic’ ladder is not formed, the same hydrogen-bond interactions are 
present in the structure of 2, as those that combine to form a ladder motif.  The potentially 
competing hydrogen-bond acceptor, the pyrazole moiety, does not participate in any strong 
hydrogen bonds. 
 
Figure 2.5 The dominating intermolecular hydrogen bonds observed in the crystal structure 
of 2. 
2.3.3 Crystal structure of 4-[(3,5-dimethylpyrazol-1-yl)methyl]benzamide, 4 
The crystal structure of 4 again shows the formation of the symmetry related homomeric 
amide:amide dimer via N-H•••O hydrogen bonds (2.913(2)Å), Figure 2.6.  The network is 
extended via secondary N-H•••N interactions (3.112(2)Å) between the anti amide hydrogen atom 
and the pyrazole nitrogen of an adjacent ligand which demonstrates how the ladder can be 
disrupted by a suitably competitive acceptor. 
 
Figure 2.6 Hydrogen-bond dimers (constructed from an amide•••amide synthon) observed in 
the crystal structure of 4.  Dimers are interconnected via N-H•••N interactions. 
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2.3.4 Crystal structure of 4-[(4-bromo-3,5-dimethylpyrazol-1-yl)methyl]benzamide, 6 
The crystal structure of 6 contains homomeric dimers between two amide moieties via N-
H•••O hydrogen bonds (2.9488(15)Å), Figure 2.7.  Again, the anti hydrogen atom of the amide 
forms a N-H•••N hydrogen bond (3.0341(15)Å) to an adjacent pyrazole moiety.  The bromo 
substituent on the pyrazole is not participating in any specific or directional non-covalent 
interactions. 
 
Figure 2.7 Homomeric amide•••amide dimer observed in the crystal structure 6.  Dimers are 
extended via N-H•••N hydrogen bonds. 
2.3.5 Crystal structure of 3-[(pyrazol-1-yl)methyl]benzamide, 8 
The N-H•••O hydrogen bond (2.9183(11)Å) is again observed in the crystal structure of 8 
resulting in a homomeric amide synthon, Figure 2.8.  Dimers interact via secondary N-H•••N 
interactions (3.0580(12)Å) between the anti amide hydrogen atom and an adjacent pyrazole site.  
The result is a 1:1 cyclic motif, which, combined with the amide•••amide dimer, leads to an 
extended 1-D motif. 
 
Figure 2.8 Hydrogen-bond dimers (constructed from an amide•••amide synthon) observed in 
the crystal structure of 8.  Dimers are interconnected via N-H•••N interactions. 
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2.3.6 Crystal structure of 3-[(3,5-dimethylpyrazol-1-yl)methyl]benzamide, 10 
The crystal structure of 10 shows the same type of arrangement observed in 8 with the 
formation of the self-complementary amide•••amide dimer via N-H•••O hydrogen bonds 
(2.9033(12)Å), Figure 2.9.  The network is extended into the cyclic type arrangement via 
secondary N-H•••N interactions (2.9997(12)Å) between the anti amide hydrogen atom and the 
pyrazole nitrogen of an adjacent ligand. 
 
Figure 2.9 Hydrogen-bond dimers (constructed from an amide•••amide synthon) observed in 
the crystal structure of 10.  Dimers are interconnected via N-H•••N interactions. 
2.3.7 Crystal structure of 3-[(4-bromo-3,5-dimethylpyrazol-1-yl)methyl]benzamide, 12 
The crystal structure of 12 is quite different from the other compounds in this study 
demonstrating how simple changes in molecular conformation and structure can play a major 
role in determining the overall arrangement in the solid-state structure.  The primary motif in 12, 
is a 1-D chain resulting from N-H•••N hydrogen bonds between the syn amide hydrogen atom 
and the pyrazole nitrogen, Figure 2.10.  Each ligand possesses two different N-H•••N interactions 
with distances of 2.709(7)Å and (2.671(6)Å, respectively.  The carbonyl moiety and the anti 
hydrogen atom of the amide functionality both interact with aromatic C-H groups and, as was the 
case in 6, the bromo substituent on the pyrazole is not participating in any specific non-covalent 
interaction. 
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Figure 2.10 1-D chain via N-H•••N hydrogen bonds observed in the crystal structure of 12. 
2.4 Discussion 
Although the new structures presented here offer some insight into the structural 
consequences of having the amide moiety presented with potentially disruptive hydrogen-bond 
moieties, it was necessary to complement our data with existing crystallographic information 
from the CSD13 in order to identify structural patterns and trends.  All compounds included in 
this search are listed in Tables 2.3 and 2.4, accompanied by their graph-set notation.17 
Ten of the seventeen benzamides (59%) decorated with a weak hydrogen-bond acceptor 
(such as a halogen, nitro, cyano or methoxy substituent), contain the ‘classic’ )8(R22 )8(R
2
4  
ladder.  It seems that moieties belonging to this group of relatively weak hydrogen-bond 
acceptors compete reasonably effectively for the anti hydrogen atom of the amide moiety leading 
to a disruption of the ladder.  The amide•••amide dimer, on the other hand, is present in thirteen 
of the seventeen structures (76%). 
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Table 2.3 Graph-set notations for substituted benzamides (CSD codes in parentheses). 
Ligand N1 N2 N3 N4 
2-Fluorobenzamide 
(BIGSUF) 
)4(C2 11 D2  )4(C4
2
2 )8(R
2
2  )7(C4
2
3  )8(R
2
4  
2-Chlorobenzamide #1 
(CLBZAM10) 
)4(C11 )8(R
2
2  )8(R
2
4  A/N  A/N  
2-Chlorobenzamide #2 
(CLBZAM11) 
)4(C2 11  )8(C
2
2  A/N  A/N  
2-Iodobenzamide 
(IBNZAM) 
)4(C11 )8(R
2
2  )8(R
2
4  A/N  A/N  
3-Fluorobenzamide 
(BENAFM10) 
)4(C11 )8(R
2
2  )8(R
2
4  A/N  A/N  
3-Bromobenzamide 
(BRBZAM) 
)4(C11  A/N  A/N  A/N  
3-Iodobenzamide 
(DUMNUU) 
)4(C11 )8(R
2
2  )8(R
2
4  A/N  A/N  
4-Fluorobenzamide 
(BENAFP01) 
)4(C11 )8(R
2
2  )8(R
2
4  A/N  A/N  
4-Bromobenzamide #1 
(BBEZAM) 
)4(C11 )8(R
2
2  )8(R
2
4  A/N  A/N  
4-Bromobenzamide #2 
(BBEZAM01) 
)4(C11 )8(R
2
2  )8(R
2
4  A/N  A/N  
4-Iodobenzamide 
(IOBZAM) 
)4(C11 )8(R
2
2  )8(R
2
4  A/N  A/N  
2-Nitrobenzamide 
(ONBZAM) 
)4(C11 )8(R
2
2  )8(R
2
4  A/N  A/N  
3-Nitrobenzamide 
(JACYOB) 
)4(C11 )8(R
2
2  )8(C
2
3  A/N  A/N  
4-Nitrobenzamide #1 
(NTBZAM01) 
)4(C11 )8(R
2
2  )18(C
4
4  A/N  A/N  
4-Nitrobenzamide #2 
(NTBZAM11) 
)4(C11 )9(C2
1
1  )4(R
2
1 )24(R2
4
4  )22(C
3
3  A/N  
3-Cyanobenzamide 
(WUKHUF) 
)8(R 22 )16(R
2
2  )20(C
4
4  A/N  A/N  
2-Methoxybenzamide 
(RECQIA) 
)4(C2 11  )8(C
2
2  A/N  A/N  
#1-polymorph 1; #2-polymorph 2 
 
However, the introduction of a more competitive hydrogen-bond acceptor, such as an N-
heterocyclic moiety does create major disruptions to amide•••amide interactions, Table 2.4.   
  When an N-heterocyclic compound (or the corresponding N-oxide) is present on the 
same molecular backbone as the amide itself, the ladder does not survive in any of the eighteen 
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cases examined in this study.  Instead, in eleven of eighteen structures, neighboring 
amide•••amide dimers are connected into a chain-like motif and in the remaining seven cases, not 
even the amide•••amide dimer survives. 
 
Table 2.4 Graph-set notations for N-heterocycles (CSD codes in parentheses). 
Ligand N1 N2 N3 N4 
Isonicotinamide #1 
(EHOWIH01) 
)4(C11 )8(R
2
2  )12(C
3
4  A/N
 
A/N
 
Isonicotinamide #2 
(EHOWIH02) 
)4(C2 11 )7(C2
1
1  )20(R2
4
4  A/N
 
A/N
 
Nicotinamide 
(NICOAM01) 
)4(C11 )6(C
1
1  )18(R
4
4  A/N
 
A/N
 
Pyrazine carboxamide #1 
(PYRZIN02) 
)8(R 22  A/N  A/N  A/N  
Pyrazine carboxamide #2 
(PYRZIN01) 
)4(C11 )8(R
2
2  )12(C
3
4  A/N
 
A/N
 
Pyrazine carboxamide #3 
(PYRZIN15) 
)8(R 22 )10(R
2
2  )14(C
4
4  A/N
 
A/N
 
Isonicotinamide N-Oxide 
(MEGDAE) 
)8(C2 11  )32(C
4
4  A/N
 
A/N
 
Nicotinamide N-Oxide 
(MEGDEI) 
)7(C11 )14(R
2
2  )18(C
3
4  A/N
 
A/N
 
Pyrazine carboxamide 
N-Oxide 
(MEGDUY) 
D3  )8(R2 24 )28(R
4
4  )32(C
5
5  A/N  
3-[Benzimidazol-1-yl) 
methyl]-benzamide 
(WANBUJ) 
D4  
)24(C2 44 )28(C2
4
4  
)8(R 22 )20(R
2
2  
)18(C2 34  )26(R
4
4  
3-[(2-Chlorobenzimidazol-1-
yl)methyl]-benzamide 
(WANCEU) 
D4  
)24(C2 44 )28(C2
4
4  
)8(R 22 )20(R
2
2  
)18(C2 34  )26(R
4
4  
4-[(2-Methylbenzimidazol-1-
yl)methyl]-benzamide 
(WANCAQ) 
)4(C11  )11(C
1
1  A/N
 
)26(C44  
2 )4(C11 )8(R
2
2  )12(C
3
4  A/N  
A/N
 
4 )10(C11 )8(R
2
2  )24(R
4
4  A/N  
A/N
 
6 )10(C11 )8(R
2
2  )24(R
4
4  A/N  
A/N
 
8 )8(R 22 )18(R
2
2  )22(C
4
4  A/N
 
A/N
 
10 )8(R 22 )18(R
2
2  )22(C
4
4  A/N  
A/N
 
12 D2  )36(C
4
4  A/N  
A/N
 
#1-polymorph 1; #2-polymorph 2; #3-polymorph 3 
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We are now in a position to provide answers to the questions posed at the beginning of 
this study.18  The ladder is shown to persist in 10 of the 35 structures (29%) examined herein, 
whereas the amide•••amide dimer is present in 24 of the 35 structures (69%).  There is a dramatic 
difference to the way in which weak and strong hydrogen-bond acceptors influence the outcome 
in structures containing an amide moiety.  For weak acceptors (such as  –NO2,-OMe -CN, -Cl, -
Br), the frequency of ladder and amide disruption is 41% and 23% respectively. 
However, with stronger hydrogen-bond acceptors (N-heterocycles and N-oxides thereof), 
the corresponding numbers are 100% and 39%, respectively.  It is noteworthy that it is possible 
to provide a more detailed ranking of the hydrogen-bond accepting capability within the latter 
group even further.  The calculated MEP values for the heterocycles included in this study, Table 
2.2, indicate that pyrazine, pyrazole, and pyridine are expected to be less competitive than the 
benzimidazole/N-oxide acceptors.  In fact, the dimer is broken 3/12 (25%) times for the former 
group, and 4/6 (67%) for the latter group.  The hydrogen-bond acceptor strength as determined 
by calculated MEPs, which is consistent with reported pKHB data,
19 is directly translated into 
structural consequences in these structures. 
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CHAPTER 3 - Breaking the amide•••amide homomeric dimer 
 
3.1 Introduction 
In supramolecular synthesis, desired products are typically held together by reversible 
intermolecular interactions, and therefore synthetic procedures normally have to take place in 
one-pot reactions.1  For such reactions to be effective, a modular assembly process based upon a 
hierarchy of intermolecular hydrogen-bond interactions needs to be put in place. 
A suitable starting point for developing a modular process is isonicotinamide, Figure 3.1, 
which has been shown2 to be a reliable tool for the construction of binary co-crystals.   
N
O
NH2  
Figure 3.1 Isonicotinamide. 
 
In 1:1 co-crystals of isonicotinamide and a carboxylic acid, the most commonly observed 
synthons are i) an acid-pyridine interaction via an O-H•••N hydrogen bond and ii) an amide-
amide homomeric dimer via N-H•••O hydrogen bonds, Figure 3.2.  A CSD3 search revealed 96% 
of 1:1 binary co-crystals between isonicotinamide and a carboxylic acid contain these 
interactions.  The consistency can be attributed to Etter’s “best donor-best acceptor”4 guideline 
as well as a need to satisfy all possible hydrogen-bond interactions.  First, the pyridine nitrogen 
is the best hydrogen-bond acceptor and the carboxylic acid -OH is the best hydrogen-bond donor 
and consequently they have a preference toward each other.  Second, the amide-amide dimer will 
form to satisfy the remaining hydrogen-bond donor/acceptors. 
N
O
N
H
H
N
O
N
H
H
H HO O
O
R
R
O  
Figure 3.2 Typical 1:1 binary co-crystal of isonicotinamide and a mono carboxylic acid. 
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The hierarchy observed with co-crystals of isonicotinamide needs further investigation in 
order to establish if such a “ranking” has any real value.  Unfortunately, isonicotinamide is not a 
suitable system in this context because it is not possible to modify one binding site without 
tampering with the other (i.e. adjusting the hydrogen-bond acceptor ability of the pyridine 
nitrogen through covalent modifications will also affect the nature of the amide site).  
Consequently, uncoupled amide-heterocycle supramolecular reagents (SR’s), Figure 3.3 need to 
be constructed that will allow for electrostatic tuning of the heterocycle without affecting the 
amide functionality. 
O
N
H
H
N
 
Figure 3.3 General design of decoupled amide-heterocycle species. 
 
Uncoupled amide-heterocycle SR’s were first developed using benzimidazole,5 providing 
a system that has a better hydrogen-bond acceptor, based on molecular electrostatic potential 
(MEP) surfaces,6 than isonicotinamide, Figure 3.4.   
N
O NH2
O NH2
N
N-260 kJ/mol
-300 kJ/mol
 
Figure 3.4 Isonicotinamide and benzimidazol-1-yl benzamide with MEP surface values.7 
 
The 1:1 binary co-crystals of benzimidazol-1-yl benzamide and a carboxylic acid show 
the same connectivity as isonicotinamide co-crystals, with the carboxylic acid interacting (via an 
O-H•••N hydrogen bond) with the benzimidazole and the amide forming a self-complementary 
dimer, Figure 3.5. 
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N
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H N
N
H
O
O
R
 
Figure 3.5 1:1 binary co-crystal of benzimidazol-1-yl benzamide and a carboxylic acid. 
 
The benzimidazole systems provide information regarding connectivity within co-crystals 
that utilise a better hydrogen-bond acceptor than isonicotinamide, however, in order to 
demonstrate the validity of this hierarchical approach, it should be possible to move an acid from 
the N-heterocycle to the amide if a sufficiently weak hydrogen-bond acceptor is used.   
 
Consequently, this chapter will address two questions: 
 
I. Can the hydrogen-bond acceptor ability (based on MEP surfaces) be lowered such that 
the incoming acid will form a heteromeric acid-amide heteromeric dimer via O-H•••O and 
N-H•••O hydrogen bonds? 
 
II. Can the hydrogen-bond acceptor ability (based on MEP surfaces) be fine-tuned through 
minor covalent modifications to “turn up” the acceptor strength of the N-heterocycle? 
 
With this in mind, the pyrazol-1-ylbenzamide SR’s discussed in Chapter 2, Figure 3.6, 
lend themselves well to this study due to their lower hydrogen-bond acceptor ability compared to 
isonicotinamide.  It is also worth noting, that through simple covalent modifications (adding 
electron donating methyl groups to the heterocycle ring or changing the isomer from para- to 
meta-) a range of heterocycle acceptor strengths can be obtained. 
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-236 kJ/mol
N
N
O NH2
N
N
O NH2 O NH2
N
N
-246 kJ/mol -255 kJ/mol
2 4 8  
Figure 3.6 Pyrazol-1-ylbenzamide SR’s and MEP surface values (in kJ/mol). 
 
Within these SR’s, there are two potential sites for the incoming carboxylic acid, Figure 
3.7.  Consequently, through a series of co-crystallisation reactions between pyrazol-1-
ylbenzamide SR’s and a range of carboxylic acids, it will be possible to probe the connectivity 
via single crystal X-ray crystallography. 
N
N
O
NH2
H
O
O
R1
H O
R1
O
R
R
N
N
O
N
R
R
H
H
or
(a) (b)  
Figure 3.7 Potential interactions in co-crystals between pyrazol-1-ylbenzamide (R=H or Me) 
and a carboxylic acid. 
3.2 Experimental 
3.2.1 Synthesis 
All chemicals were purchased from Aldrich and Fischer and used without further 
purification.  Melting points were determined on a Fisher-Johns melting point apparatus and are 
uncorrected.  Synthesis of the [(pyrazol-1-yl)methyl]benzamide SR’s is reported in Chapter 2.   
A wide range of carboxylic acids were allowed to co-crystallise with 2, 4 and 8, however, 
only reactions that produced crystals suitable for single crystal X-ray diffraction will be 
discussed. 
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3.2.1.1 Synthesis of 4-[(pyrazol-1-yl)methyl]benzamide : 4-nitrobenzoic acid (1:1), 2a 
2 (0.0250g, 0.124mmol) and 4-nitrobenzoic acid (0.0210g, 0.124mmol) were added to a 
test tube along with acetonitrile.  The mixture was heated gently until components were in 
solution.  Colourless plates suitable for X-ray diffraction were obtained after a few days via slow 
evaporation of acetonitrile.  Mp: 160-163oC.  IR (KBr pellet): υ 3333, 3171, 1709, 1526, 1421, 
1274, 762 cm-1. 
3.2.1.2 Synthesis of 4-[(pyrazol-1-yl)methyl]benzamide : 3,5-dinitrobenzoic acid (1:1), 2b 
2 (0.0250g, 0.124mmol) and 3,5-dinitrobenzoic acid (0.0260g, 0.124mmol) were added 
to a test tube along with acetonitrile.  The mixture was heated gently until components were in 
solution.  Colourless prisms suitable for X-ray diffraction were obtained after a few days via 
slow evaporation of acetonitrile.  Mp: 111-113oC.  IR (KBr pellet): υ 3357, 3165, 3085, 1719, 
1534, 1275, 738 cm-1. 
3.2.1.3 Synthesis of 4-[(pyrazol-1-yl)methyl]benzamide : 2-fluorobenzoic acid (1:1), 2c 
2 (0.0250g, 0.124mmol) and 2-fluorobenzoic acid (0.0140g, 0.124mmol) were added to a 
test tube along with acetonitrile.  The mixture was heated gently until components were in 
solution.  Colourless prisms suitable for X-ray diffraction were obtained after a few days via 
slow evaporation of acetonitrile.  Mp: 108-110oC.  IR (KBr pellet): υ 3350, 3185, 1693, 1308, 
758 cm-1. 
3.2.1.4 Synthesis of 4-[(pyrazol-1-yl)methyl]benzamide : 3-fluorobenzoic acid (1:1), 2d 
2 (0.0250g, 0.124mmol) and 3-fluorobenzoic acid (0.0140g, 0.124mmol) were added to a 
test tube along with acetonitrile.  The mixture was heated gently until components were in 
solution.  Colourless prisms suitable for X-ray diffraction were obtained after a few days via 
slow evaporation of acetonitrile.  Mp: 95-98oC.  IR (KBr pellet): υ 3344, 3175, 3085, 1719, 
1592, 1298, 756 cm-1. 
3.2.1.5 Synthesis of 4-[(pyrazol-1-yl)methyl]benzamide : benzoic acid (1:1), 2e 
2 (0.0250g, 0.124mmol) and benzoic acid (0.0140g, 0.124mol) were added to a test tube 
along with acetonitrile.  The mixture was heated gently until components were in solution.  
Colourless prisms suitable for X-ray diffraction were obtained after a few days via slow 
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evaporation of acetonitrile.  Mp: 99-101oC.  IR (KBr pellet): υ 3383, 3231, 1699, 1388, 1275, 
758 cm-1. 
3.2.1.6 Synthesis of 4-[(pyrazol-1-yl)methyl]benzamide : oxalic acid (2:1), 2f 
2 (0.0250g, 0.124mmol) and oxalic acid (0.0110g, 0.124mmol) were added to a test tube 
along with acetonitrile.  The mixture was heated gently until components were in solution.  
Colourless plates suitable for X-ray diffraction were obtained after a few days via slow 
evaporation of acetonitrile.  Mp: 143-145oC.  IR (KBr pellet): υ 3377, 3175, 1653, 1408, 1109, 
751 cm-1. 
3.2.1.7 Synthesis of 4-[(pyrazol-1-yl)methyl]benzamide : succinic acid (2:1), 2g 
2 (0.0250g, 0.124mmol) and succinic acid (0.0150g, 0.124mol) were added to a test tube 
along with acetonitrile.  The mixture was heated gently until components were in solution.  
Colourless prisms suitable for X-ray diffraction were obtained after a few days via slow 
evaporation of acetonitrile.  Mp: 146-149oC.  IR (KBr pellet): υ 3410, 3125, 1719, 1421, 1176, 
731 cm-1. 
3.2.1.8 Synthesis of 4-[(pyrazol-1-yl)methyl]benzamide : fumaric acid (2:1), 2h 
2 (0.0250g, 0.124mmol) and fumaric acid (0.0150g, 0.124mmol) were added to a test 
tube along with acetonitrile.  The mixture was heated gently until components were in solution.  
Colourless prisms suitable for X-ray diffraction were obtained after a few days via slow 
evaporation of acetonitrile.  Mp: 162-165oC.  IR (KBr pellet): υ 3297, 3138, 1706, 1414, 1169, 
758 cm-1. 
3.2.1.9 Synthesis of 4-[(3,5-dimethylpyrazol-1-yl)methyl]benzamide : 4-nitrobenzoic acid (1:1), 
4a 
4 (0.0250g, 0.109mmol) and 4-nitrobenzoic acid (0.0180g, 0.109mmol) were added to a 
test tube along with acetonitrile.  The mixture was heated gently until components were in 
solution.  Colourless plates suitable for X-ray diffraction were obtained after a few days via slow 
evaporation of acetonitrile.  Mp: 147-150oC.  IR (KBr pellet): υ 3390, 3170, 1706, 1516, 1419, 
1271, 717 cm-1. 
 47
3.2.1.10 Synthesis of 4-[(3,5-dimethylpyrazol-1-yl)methyl]benzamide : 4-hydroxybenzoic acid 
(1:1), 4b 
4 (0.0250g, 0.109mmol) and 4-hydroxybenzoic acid (0.0150g, 0.109mmol) were added to 
a test tube along with acetonitrile.  The mixture was heated gently until components were in 
solution.  Colourless prisms suitable for X-ray diffraction were obtained after a few days via 
slow evaporation of acetonitrile.  Mp: 144-147oC.  IR (KBr pellet): υ 3457, 3196, 2525, 1829, 
1696, 1429, 1265, 1148, 774 cm-1. 
3.2.1.11 Synthesis of 4-[(3,5-dimethylpyrazol-1-yl)methyl]benzamide : fumaric acid (2:1), 4c 
4 (0.0250g, 0.109mmol) and fumaric acid (0.0130g, 0.109mmol) were added to a test 
tube along with acetonitrile.  The mixture was heated gently until components were in solution.  
Colourless blocks suitable for X-ray diffraction were obtained after a few days via slow 
evaporation of acetonitrile.  Mp: 180-183oC.  IR (KBr pellet): υ 3397, 3191, 2482, 1912, 1706, 
1547, 1407, 1269, 977, 771 cm-1. 
3.2.1.12 Synthesis of 3-[(pyrazol-1-yl)methyl]benzamide : DL-malic acid (1:1), 8a 
8 (0.0200g, 0.0990mmol) and DL-malic acid (0.0130g, 0.0990mol) were added to a test 
tube along with ethanol.  The mixture was heated gently until components were in solution.  
Colourless plates suitable for X-ray diffraction were obtained after a few days via slow 
evaporation of acetonitrile.  Mp: 111-114oC.  IR (KBr pellet): υ 3457, 3149, 1696, 1400, 1046, 
769 cm-1. 
3.2.1.13 Synthesis of 3-[(pyrazol-1-yl)methyl]benzamide : 3,5-dinitrobenzoic acid (1:1), 8b 
8 (0.0200g, 0.0990mmol) and 3,5-dinitrobenzoic acid (0.0210g, 0.0990mol) were added 
to a test tube along with ethanol.  The mixture was heated gently until components were in 
solution.  Brown blocks suitable for X-ray diffraction were obtained after a few days via slow 
evaporation of acetonitrile.  Mp: 119-122oC.  IR (KBr pellet): υ 3413, 3093, 2678, 2541, 1967, 
1701, 1546, 1350, 732 cm-1. 
 
 
 
 
 48
3.3 Results 
All hydrogen bond geometries are listed in Table 3.1.  A summary of the crystallographic 
information for each compound is displayed in Tables A.7-A.19. 
 
Table 3.1 Hydrogen bond geometries for 2a-2h, 4a-4c and 8a-8b. 
Compound D-H•••A D-H / Å H•••A / Å D•••A / Å <(DHA) / o 
2ai 
N(27)-H(27B)...N(12)#1 
N(27)-H(27B)...N(12)#1 
N(27)-H(27B)...N(12)#1 
0.93(3) 
0.90(3) 
0.90(3) 
1.65(4) 
1.96(3) 
2.14(3) 
2.566(3) 
2.861(3) 
3.023(3) 
169(3) 
173(3) 
165(3) 
2bii 
O(31)-H(31)...O(27) 
N(27)-H(27A)...O(32) 
N(27)-H(27B)...N(12)#1 
0.95(2) 
0.922(18) 
0.888(17) 
1.63(2) 
2.007(18) 
2.171(18) 
2.5661(11) 
2.9224(13) 
3.0312(13) 
172.0(19) 
172.1(15) 
163.2(15) 
2ciii 
O(31)-H(31)...O(17) 
N(17)-H(17A)...O(32) 
N(17)-H(17B)...N(22)#1 
1.00(2) 
0.94(2) 
0.89(2 
1.55(2) 
1.95(2) 
2.12(2) 
2.5415(17) 
2.879(2) 
2.954(2) 
173.4(19) 
171.8(18) 
156.3(18) 
2div 
N311-H31A1...O721 
N311-H31B1...N124#1 
N411-H41A1...O821 
N411-H41B1...N224#2 
O711-H711...O311 
O811-H811...O411 
N312-H31A2...O722 
N312-H31B2...N123#1 
N412-H41A2...O822 
N412-H41B2...N223#2 
O712-H712...O312 
O812-H812...O412 
N313-H31A3...O723 
N313-H31B3...N122#1 
N413-H41A3...O823 
N413-H41B3...N222#2 
O713-H713...O313 
O813-H813...O413 
N314-H31A4...O724 
N314-H31B4...N121#1 
N414-H41A4...O824 
N414-H41B4...N221#2 
O714-H714...O314 
O814-H814...O414 
N315-H31A5...O725 
N315-H31B5...N125#3 
N415-H41A5...O825 
N415-H41B5...N225#4 
0.88 
0.88 
0.88 
0.88 
0.84 
0.84 
0.88 
0.88 
0.88 
0.88 
0.84 
0.84 
0.88 
0.88 
0.88 
0.88 
0.84 
0.84 
0.88 
0.88 
0.88 
0.88 
0.84 
0.84 
0.88 
0.88 
0.88 
0.88 
2.08 
2.12 
2.01 
2.14 
1.74 
1.71 
1.99 
2.15 
2.01 
2.16 
1.74 
1.73 
2.09 
2.15 
2.09 
2.15 
1.75 
1.73 
2.02 
2.12 
1.96 
2.16 
1.73 
1.74 
1.96 
2.14 
2.06 
2.13 
2.945(8) 
2.96(4) 
2.876(10) 
2.99(5) 
2.562(8) 
2.535(9) 
2.849(8) 
2.96(2) 
2.864(8) 
2.96(3) 
2.573(7) 
2.557(7) 
2.946(8) 
2.99(3) 
2.957(8) 
2.99(3) 
2.572(7) 
2.559(7) 
2.881(8) 
2.94(5) 
2.824(9) 
2.98(4) 
2.550(7) 
2.570(7) 
2.822(12) 
2.97(3) 
2.921(9) 
2.95(3) 
167.8 
158.7 
166.2 
161.2 
165.0 
167.7 
165.0 
151.8 
164.3 
151.2 
168.8 
167.4 
165.2 
158.9 
166.1 
159.3 
166.0 
166.7 
165.9 
153.2 
166.3 
155.0 
166.2 
167.5 
164.7 
156.0 
166.3 
155.3 
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O715-H715...O315 
O815-H815...O415 
0.84 
0.84 
1.72 
1.72 
2.549(9) 
2.540(8) 
171.1 
164.0 
2ev 
N(17)-H(17A)...O(32) 
N(17)-H(17B)...N(52)#1 
O(31)-H(31)...O(17) 
N(47)-H(47A)...O(62) 
N(47)-H(47B)...N(22)#1 
O(61)-H(61)...O(47) 
0.911(16) 
0.865(16) 
0.899(16) 
0.917(16) 
0.839(16) 
0.896(16) 
2.066(17) 
2.147(16) 
1.683(17) 
1.948(17) 
2.195(16) 
1.682(17) 
2.9740(15) 
2.9946(16) 
2.5692(13) 
2.8599(15) 
2.9840(15) 
2.5702(13) 
174.2(14) 
166.4(14) 
168.0(15) 
172.5(14) 
156.8(14) 
170.4(15) 
2fvi 
N(27)-H(27A)...O(32) 
O(31)-H(31)...O(27) 
0.91(3) 
0.89(3) 
2.05(3) 
1.63(3) 
2.932(3) 
2.515(2) 
164(3) 
171(3) 
2gvii 
N(17)-H(17A)...O(32) 
N(17)-H(17B)...N(22)#2 
O(31)-H(31)...O(17) 
0.89(2) 
0.94(2) 
0.88(3) 
1.99(3) 
2.06(2) 
1.71(3) 
2.868(2) 
2.978(2) 
2.586(2) 
166.9(18) 
162.6(18) 
172(2) 
2hviii 
N(17)-H(17A)...O(32) 
N(17)-H(17B)...N(22)#2 
O(31)-H(31)...O(17) 
0.933(18) 
0.887(17) 
0.932(18) 
1.942(18) 
2.118(18) 
1.644(19) 
2.8548(16) 
2.9713(17) 
2.5694(14) 
165.4(15) 
161.2(16) 
171.4(17) 
4aix 
N(17)-H(17A)...O(32) 
N(17)-H(17B)...N(22)#1 
O(31)-H(31)...O(17) 
0.91(2) 
0.96(2) 
1.05(2) 
1.98(2) 
2.12(2) 
1.54(2) 
2.871(2) 
3.066(2) 
2.5801(19) 
168(2) 
169(2) 
170(2) 
4bx 
N(17)-H(17A)...O(35) 
N(17)-H(17B)...O(32)#1 
O(31)-H(31)...N(22)#2 
O(34)-H(34)...O(17) 
0.879(19) 
0.87(2) 
0.94(2) 
0.911(19) 
2.01(2) 
2.16(2) 
1.67(2) 
1.685(19) 
2.8829(17) 
2.9978(17) 
2.5812(16) 
2.5906(15) 
171.5(17) 
162.1(17) 
162.0(17) 
172.5(18) 
4cxi 
N(17)-H(17A)...O(32) 
N(17)-H(17B)...O(34)#1 
O(31)-H(31)...O(17) 
O(34)-H(34)...N(22)#2 
0.831(17) 
0.871(17) 
0.915(17) 
0.874(15) 
2.012(18) 
2.476(18) 
1.725(17) 
1.830(16) 
2.8387(13) 
3.2960(14) 
2.6358(11) 
2.6966(12) 
172.6(16) 
157.2(14) 
173.2(16) 
170.9(14) 
8axii 
O(31)-H(31)...O(17A) 
O(31)-H(31)...O(17B) 
N(17A)-H(17A)...O(32) 
N(17B)-H(17C)...O(32) 
N(17A)-H(17B)...O(33)#1 
N(17B)-H(17D)...O(33)#1 
O(33)-H(33)...O(35)#2 
O(34)-H(34)...N(22)#3 
0.88(3) 
0.88(3) 
0.88 
0.88 
0.88 
0.88 
0.91(3) 
0.95(3) 
1.73(4) 
1.70(4) 
2.05 
2.07 
2.49 
2.40 
1.87(3) 
1.73(3) 
2.581(19) 
2.56(3) 
2.907(11) 
2.915(16) 
3.342(12) 
3.276(16) 
2.781(2) 
2.646(3) 
163(3) 
166(3) 
163.8 
162.1 
161.6 
173.1 
174(3) 
162(3) 
8bxiii 
O(31)-H(31)...O(11) 
O(41)-H(41)...N(22) 
N(11)-H(11A)...O(32) 
N(11)-H(11B)...O(42)#1 
1.00(2) 
0.86(2) 
0.84(2) 
0.90(3) 
1.54(2) 
1.71(2) 
2.09(3) 
2.00(3) 
2.538(2) 
2.574(2) 
2.920(3) 
2.871(3) 
173(2) 
176(3) 
171(2) 
162(2) 
i) #1 x+1/2,y+1/2,z ; (ii) #1 x,-y+1/2,z-1/2; (iii) #1 -x,-y,-z+1; (iv) #1 -x,-y+1,-z, #2 -x+1,-y,-
z+1, #3 -x,-y+1,-z+1, #4 -x+1,-y,-z+2; (v) #1 -x,-y,-z+1; (vi) #1 -x-1,-y,-z; (vii) #1 -x+2,-y+3,-z, 
#2 -x+3/2,y+1/2,-z+1/2; (viii) #1 -x+1,-y+2,-z, #2 -x+1/2,y+1/2,-z+1/2; (ix) #1 x+1,y,z; (x) #1 
x+1/2,-y+1/2,z+1/2, #2 -x+1,-y+1,-z+1; (xi) #1 -x+2,-y+2,-z+1, #2 x+1/2,-y+3/2,z+1/2; (xii) #1 -
x+1/2,-y+1/2,-z, #2 x,y-1,z, #3 x+1/2,y-1/2,z; (xiii) #1 -x+1,y,-z+3/2. 
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3.3.1 Crystal structure of 4-[(pyrazol-1-yl)methyl]benzamide : 4-nitrobenzoic acid (1:1), 2a 
The crystal structure of 2a shows the formation of a binary 1:1 supermolecule through an 
acid-amide heteromeric dimer via O-H•••O and N-H•••O hydrogen bonds (2.555(3) Å and 
2.852(3) Å respectively), Figure 3.8.  All hydrogen-bond donor and acceptors are satisfied since 
dimers are extended into a 1D chain via an N-H•••N hydrogen bonds (3.023(3) Å) between the 
anti amide hydrogen atom and the pyrazole nitrogen. 
 
Figure 3.8 Two 1:1 supermolecules observed in the crystal structure of 2a.  Dimers are 
extended into a 1D chain via secondary N-H•••N hydrogen bonds. 
3.3.2 Crystal structure of 4-[(pyrazol-1-ylmethyl)]benzamide : 3,5-dinitrobenzoic acid (1:1), 
2b 
Isostructural to 2a, 2b is a 1:1 supermolecule driven by the acid-amide synthon.  The acid 
interacts with the amide via O-H•••O and N-H•••O hydrogen bonds (2.5661(11) Å and 2.9224(13) 
Å respectively), Figure 3.9, leaving the pyrazole nitrogen to accept a secondary, N-H•••N 
hydrogen bond (3.0312(13) Å) from the anti amide hydrogen atom resulting in a 1D chain. 
 
Figure 3.9 Two 1:1 supermolecules observed in the crystal structure of 2b.  Dimers are 
extended into a 1D chain via secondary N-H•••N hydrogen bonds. 
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3.3.3 Crystal structure of 4-[(pyrazol-1-yl)methyl]benzamide : 2-fluorobenzoic acid (1:1), 2c 
Similar connectivity to 2a and 2b is observed in the 1:1 supermolecule 2c, with the acid-
amide heteromeric dimer forming via O-H•••O and N-H•••O hydrogen bonds (2.5145(17) Å and 
2.879(2) Å respectively), Figure 3.10.  The anti amide hydrogen atom interacts with the free 
pyrazole nitrogen, however in this case, instead of a 1D chain forming, two N-H•••N hydrogen 
bonds (2.954(2) Å) combine between two amide species producing a tetrameric species. 
 
Figure 3.10 Two 1:1 supermolecules observed in the crystal structure of 2c, which form a 
tetramer via two N-H•••N hydrogen bonds.  
3.3.4 Crystal structure of 4-[(pyrazol-1-yl)methyl]benzamide : 3-fluorobenzoic acid (1:1), 2d 
The 1:1 co-crystal, 2d, contains 10 inequivalent dimeric supermolecules each possessing 
an acid-amide heteromeric dimer (O-H•••O 2.535(9) Å and N-H•••O 2.876(10) Å; O-H•••O 
2.557(7) Å and N-H•••O 2.864(8) Å; O-H•••O 2.559(7) Å and N-H•••O 2.957(8) Å; O-H•••O 
2.570(7) Å and N-H•••O 2.824(9) Å; O-H•••O 2.540(8) Å and N-H•••O 2.921(9) Å; O-H•••O 
2.562(8) Å and N-H•••O 2.945(8) Å; O-H•••O 2.573(7) Å and N-H•••O 2.849(8) Å; O-H•••O 
2.572(7) Å and N-H•••O 2.946(8) Å; O-H•••O 2.550(7) Å and N-H•••O 2.881(8) Å; O-H•••O 
2.549(9) Å and N-H•••O 2.822 (12) Å), Figure 3.11.  The anti amide hydrogen atom in each case 
interacts with the pyrazole nitrogen of an adjacent dimer via a N-H•••N hydrogen bond (2.99(5) 
Å; 2.96(3) Å; 2.99(3) Å; 2.98(4) Å; 2.95(3) Å; 2.96(4) Å; 2.96(2) Å; 2.99(3) Å; 2.94(5) Å; 
2.97(3) Å) resulting in 10, discrete tetramers.  
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Figure 3.11 Two 1:1 supermolecules observed in the crystal structure of 2d, which form a 
tetramer via two N-H•••N hydrogen bonds. 
 
3.3.5 Crystal structure of 4-[(pyrazol-1-yl)methyl]benzamide : benzoic acid (1:1), 2e 
2e contains two inequivalent 1:1 binary supermolecules constructed from heteromeric 
acid-amide dimers (O-H•••O 2.5692(13) Å and N-H•••O 2.9740(15) Å; O-H•••O 2.5702(13) Å 
and N-H•••O 2.8599(15) Å), Figure 3.12.  Each co-crystal is linked to an adjacent symmetry 
related co-crystal through an N-H•••N interaction between the anti hydrogen atom of the amide 
and the free pyrazole nitrogen atom (N-H•••N 2.9946(16) Å and 2.9840(15) Å) resulting in two, 
discrete tetramers. 
 
Figure 3.12 Two 1:1 supermolecules observed in the crystal structure of 2e, which form a 
tetramer via two N-H•••N hydrogen bonds. 
3.3.6 Crystal structure of 4-[(pyrazol-1-yl)methyl]benzamide : oxalic acid (2:1), 2f 
The crystal structure of 2f shows a trimeric supermolecule constructed via two symmetry 
related acid-amide heteromeric dimers (O-H•••O 2.932(3) Å and N-H•••O 2.515(2) Å), Figure 
3.13. Adjacent trimers are organized through long N–H•••O contacts (ca. 3.26 Å) between the 
anti proton of the amide and an -OH moiety on a neighboring supermolecule. 
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Figure 3.13 Two 2:1 supermolecules observed in the crystal structure of 2f.  Trimers are 
extended into a 1D chain via long N-H•••O interactions. 
3.3.7 Crystal structure of 4-[(pyrazol-1-yl)methyl]benzamide : succinic acid (2:1), 2g 
Similar connectivity to 2f is observed in the 2:1 supermolecule 2g with the diacid 
forming two symmetry related acid-amide heteromeric dimers via O-H•••O and N-H•••O 
hydrogen bonds (2.586(2) Å and 2.868(2) Å, respectively) between two amide species, Figure 
3.14.  Adjacent supermolecules are interconnected through a secondary N-H•••N interaction 
between the anti proton of the amide and the free pyrazole nitrogen atom (N-H•••N 2.978(2) Å), 
and oriented perpendicular to each other. 
 
Figure 3.14 The 2:1 supermolecule observed in the crystal structure of 2g.  Trimers are 
extended into a 1D chain via N-H•••O hydrogen bonds. 
3.3.8 Crystal structure of 4-[(pyrazol-1-yl)methyl]benzamide : fumaric acid (2:1), 2h 
The crystal structure of 2h is isostructural with 2g with the diacid sandwiched between 
two amide species and interacting via O-H•••O and N-H•••O hydrogen bonds (2.5694(14) Å and 
2.8548(16) Å respectively), Figure 3.15.  Adjacent supermolecules are interconnected through a 
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secondary N-H•••N interaction between the anti proton of the amide and the free pyrazole 
nitrogen atom (N-H•••N 2.9713(17) Å), and oriented perpendicular to each other. 
 
Figure 3.15 The 2:1 supermolecule observed in the crystal structure of 2h.  Trimers are 
extended into a 1D chain via N-H•••O hydrogen bonds. 
3.3.9 Crystal structure of 4-[(3,5-dimethylpyrazol-1-yl)methyl]benzamide : 4-nitrobenzoic 
acid (1:1), 4a 
The crystal structure of 4a shows the formation of a binary 1:1 supermolecule through an 
acid-amide heteromeric dimer via O-H•••O and N-H•••O hydrogen bonds (2.5801(19) Å and 
2.871(2) Å, respectively), Figure 3.16.  The dimer is extended into a 1D chain via an N-H•••N 
hydrogen bonds (3.066(2) Å) between the anti amide hydrogen atom and the pyrazole nitrogen. 
 
Figure 3.16 Two binary 1:1 supermolecules observed in the crystal structure of 4a.  Dimers 
are extended into a 1D chain via secondary N-H•••N hydrogen bonds. 
3.3.10 Crystal structure of 4-[(3,5-dimethylpyrazol-1-yl)methyl]benzamide : 4-hydroxybenzoic 
acid (1:1), 4b 
A four component ring is observed in the 1:1 supermolecule, 4b.  The acid-amide 
heteromeric dimer is again the prevalent interaction via O-H•••O and N-H•••O hydrogen bonds 
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(2.6358(11) Å and 2.8387(13) Å, respectively), Figure 3.17.  The hydroxyl group of the acid 
forms an O-H•••N (2.6966(12) Å) hydrogen bond to the pyrazole nitrogen with the anti hydrogen 
atom of the amide binding to the hydroxyl oxygen, N-H•••O (ca. 3.29 Å) which results in the 
extension of the tetramers into a zigzag chain. 
 
Figure 3.17 Two 1:1 supermolecules observed in the crystal structure of 4b.  Dimers interact 
via secondary O-H•••N hydrogen bonds to form a tetramer. 
3.3.11 Crystal structure of 4-[(3,5-dimehtylpyrazol-1-yl)methyl]benzamide : fumaric acid 
(2:1), 4c 
4c is a 2:1 supermolecule with three hydrogen-bonding interactions present, Figure 3.18.  
The acid-amide heteromeric dimer is observed via O-H•••O and N-H•••O hydrogen bonds 
(2.5906(15) Å and 2.8829(17) Å, respectively) however, unlike the case of co-crystal 1h, the 
diacid does not form two symmetry related acid-amide dimers; the second acid moiety in fact 
forms an O-H•••N hydrogen bond (2.5812(16) Å) to the pyrazole nitrogen.  Two trimeric co-
crystals interact via N-H•••O hydrogen bonds (2.9978(17) Å) between the anti amide hydrogen 
atom and an adjacent acid carbonyl oxygen to produce a hexamer. 
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Figure 3.18 Two 2:1 supermolecules observed in the crystal structure of 4c.  Trimers interact 
via N-H•••O hydrogen bonds to form a hexamer. 
3.3.12 Crystal structure of 3-[(pyrazol-1-yl)methyl]benzamide : DL-malic acid (2:1), 8a 
The crystal structure of 8a shows a trimeric supermolecule similar to that observed in 4c, 
Figure 3.19.  The asymmetric diacid, forms an acid-amide heteromeric dimer via O-H•••O and N-
H•••O hydrogen bonds (2.581(19) Å and 2.907(11) Å respectively) with the second acid moiety 
forming an O-H•••N hydrogen bond (2.646(3) Å) to a pyrazole nitrogen acceptor.  The trimers 
are extended into layers via an O-H•••O hydrogen bond (2.781(2) Å) between the free hydroxyl 
groups of one acid and the carbonyl oxygen of an adjacent acid. 
 
Figure 3.19 Two 2:1 supermolecules observed in the crystal structure of 8a.  Trimers interact 
via O-H•••O hydrogen bonds forming layers. 
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3.3.13 Crystal structure of 3-[(pyrazol-1-yl)methyl]benzamide : 3,5-dinitrobenzoic acid (1:2), 
8b 
The crystal structure of 8b shows two carboxylic acids and one SR.  One of the 
carboxylic acids forms an acid-amide heteromeric dimer via O-H•••O and N-H•••O hydrogen 
bonds (2.538(2) Å and 2.920(3) Å, respectively) with the second carboxylic acid interacting with 
the pyrazole nitrogen acceptor via an O-H•••N hydrogen bond (2.574(2) Å). Two trimeric co-
crystals interact via N-H•••O hydrogen bonds (2.871(3) Å) between the anti amide hydrogen 
atom and an adjacent acid carbonyl oxygen to produce a hexamer, Figure 3.20. 
 
Figure 3.20 The 2:1 supermolecule observed in the crystal structure of 8b.  Trimers interact 
via N-H•••O hydrogen bonds to form a hexamer. 
3.4 Discussion 
3.4.1 Controlling the location of the carboxylic acid in binary co-crystals 
All three SR’s 2, 4 and 8, possess a heterocyclic nitrogen atom that is a poorer hydrogen-
bond acceptor (based on MEP surfaces) than the heterocyclic nitrogen atom in isonicotinamide.  
Structural analysis of 13 acid•••pyrazole benzamide co-crystals shows that the acid-amide 
heteromeric dimer appears in every single case, Figure 3.21.  This result demonstrates that it is 
possible, through simple covalent modifications (i.e. changing the heterocycle in the SR), to 
make the amide moiety the best hydrogen-bond acceptor, thus completely changing the binding 
preference between the incoming carboxylic acid and the SR. 
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Figure 3.21 Comparison of acid-pyrazole and acid-amide interactions. 
3.4.2 Assessing the competitive capability of the pyrazole functionality 
Although a supramolecular yield of 100% was obtained, it is pertinent to scrutinize the 
activity of the pyrazole as a hydrogen-bond acceptor.  In order to develop a hierarchy of 
interactions it is necessary to have more than one potential binding site in the system, and 
consequently it is essential to establish whether the pyrazole is active enough to partake in 
hydrogen bonding. 
In the case of 4-[(pyrazol-1-ylmethyl)]-benzamide (MEP=-236kJ/mol), the acid forms a 
heteromeric dimer with the amide moiety leaving the pyrazole nitrogen to interact with the anti 
amide hydrogen atom in 7 of 8 examples, Figure 3.22.  This demonstrates the pyrazole is 
‘active’, however it does not compete successfully with the amide for the incoming acid. 
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Figure 3.22 Secondary interactions in 4-[(pyrazol-1-ylmethyl)]-benzamide co-crystals. 
 
If the pyrazole is “boosted” with electron-donating substituents (e.g. methyl groups 
increases the MEP to -246kJ/mol) the N-heterocycle takes on a more important structural role.   
In the co-crystal incorporating a mono-carboxylic acid (4a), in order to satisfy all 
hydrogen bond possibilities, the secondary interaction again is an N-H•••N hydrogen bond 
between the pyrazole nitrogen and the anti amide hydrogen atom, Figure 3.23. 
However, when the carboxylic acid is more complex (4b and 4c) through the inclusion of 
a second donor group (i.e. a hydroxyl (4b) or second acid (4c) functionality), the pyrazole 
nitrogen forms an O-H•••N hydrogen bond with the much better ‘-OH’ hydrogen-bond donor 
instead of with the anti amide hydrogen atom, Figure 3.23. 
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Figure 3.23 Secondary interactions in 4-[(3,5-dimethylpyrazol-1-ylmethyl)]-benzamide co-
crystals. 
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3-[(pyrazol-1-ylmethyl)]-benzamide (MEP=-255kJ/mol), which, through a simple isomer 
change becomes an even better acceptor than both 4-[(pyrazol-1-ylmethyl)]-benzamide and 4-
[(3,5-dimethylpyrazol-1-ylmethyl)]-benzamide) (by -19kJ/mol and -11kJ/mol, respectively) is 
comparable to 4-[(3,5-dimethylpyrazol-1-ylmethyl)]-benzamide). 
In the di-acid co-crystal, 8a, the ever-present acid-amide heteromeric dimer is observed 
between the SR and the better of the two acid moieties8 (the two acid moieties in DL-malic are 
electronically different due to the hydroxyl group at the C2 position) with the second acid 
forming an O-H•••N hydrogen bond to the pyrazole nitrogen.  Similarly, in the co-crystal, 8b, the 
acid-amide heteromeric dimer is observed between the acid and the SR with a second carboxylic 
acid forming an O-H•••N hydrogen bond to the pyrazole nitrogen, Figure 3.24. 
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Figure 3.24 Secondary interaction in 3-[(pyrazol-1-ylmethyl)]-benzamide : diacid co-crystals. 
 
The synthesis and structural analysis of 13 co-crystals between pyrazole-benzamide SR’s 
and a carboxylic acid have now provided reliable answers to the questions presented at the 
beginning of this chapter. 
 
I. Can the hydrogen-bond acceptor ability (based on MEP surfaces) be lowered such that 
the incoming acid will form a heteromeric acid-amide heteromeric dimer via O-H•••O 
and N-H•••O hydrogen bonds? 
The MEP surface was lowered sufficiently to move the incoming carboxylic acid to the 
amide site in all 13 cases.  These results, in conjunction with those previously reported for 
isonicotinamide2 and benzimidazole-benzamides,6 validate MEP surface calculations as an 
effective tool in the control and prediction of hydrogen bonds in N-heterocycle/amide systems, 
Figure 3.25. 
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Figure 3.25 Hierarchical approach to controlling hydrogen bond interactions in N-
heterocycle/amide systems. 
 
II. Can the hydrogen-bond acceptor ability (based on MEP surfaces) be fine-tuned 
through minor covalent modifications to “turn up” the acceptor strength of the N-
heterocycle? 
Subtle covalent changes (adding methyl groups or changing the isomer) to the SR’s were 
enough to change the MEP surface (by -11kJ/mol and -19kJ/mol respectively).  
These changes activated the pyrazole nitrogen and were sufficient to compete with the 
amide for a secondary interaction, Figure 3.26. 
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Figure 3.26 Fine-tuning the acceptor strength of the N-heterocycle. 
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CHAPTER 4 - Ditopic Pyridine/Pyrazole and Pyridine/Indazole 
Supramolecular Reagents for Refining Co-crystal Synthesis 
 
4.1 Introduction 
Although reliable co-crystal synthesis has been demonstrated with isonicotinamide1 and 
pyrazol-1-yl benzamide SR’s,2 attention now needs to be turned toward SR’s that possess two 
chemically and geometrically similar sites with different hydrogen-bond acceptor abilities.  This 
will allow for a more stringent examination of an MEP-based description of charge, and its 
connection to hydrogen-bond ability.   
A suitable system should contain two heterocycles that offer different hydrogen-bond 
acceptors (based upon MEP, surfaces3) lacking self-complementarity. 
In addition, the two heterocycles should be uncoupled (e.g. by a methylene bridge), thus 
allowing for subtle fine-tuning of each individual heterocycle without affecting the other. 
When choosing which heterocycles to use, pyridine is a well-known hydrogen-bond 
acceptor1, 4 and therefore provides a good starting point, Figure 4.1. 
N
Het
 
Figure 4.1 Pyridine-based SR’s (Het= N-heterocycle). 
 
Previous studies have incorporated pyridine and benzimidazole5 into the SR, Figure 4.2, 
giving two binding sites with different hydrogen-bond acceptor strengths.   
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Figure 4.2 [Benzimidazol-1-yl)methyl]pyridine SR’s and MEP surface values (kJ/mol). 
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In 1:1 binary co-crystals, the incoming hydrogen-bond donor interacts with the 
benzimidazole in all cases.6  This agrees with MEP surface calculations that show the 
benzimidazole nitrogen with a more negative charge than pyridine and hence is the better 
hydrogen-bond acceptor.   
If an MEP-based approach is viable, it should be possible to move an acid to the pyridine 
if a significantly weaker but structurally similar five-membered heterocyclic hydrogen-bond 
acceptor is used instead of benzimidazole. 
In addition to this, benzimidazole also has a tendency to deprotonate a carboxylic acid.  
57% of all 1:1 two component crystal structures containing a [benzimidazol-1-
yl)methyl]pyridine SR and a carboxylic acid resulted in proton transfer from the carboxylic acid 
to the benzimidazole nitrogen atom.6  This severely hinders control of co-crystallisations and 
thus, replacing benzimidazole with a similar but weaker five-membered hydrogen-bond acceptor 
will allow for this issue to be addressed. 
Consequently, a new family of SR’s will be designed to answer two questions: 
 
I. Can the hydrogen-bond acceptor strength of the second N-heterocycle be lowered such 
that pyridine becomes the best acceptor? 
 
II. Can the hydrogen-bond acceptor strength of the second N-heterocycle be lowered 
(compared to benzimidazole) to prevent deprotonation of the incoming carboxylic acid? 
 
With this in mind, a family of SR’s have been developed in which pyridine is combined 
with a weaker (based on pKa and charge approximations7) but geometrically similar N-
heterocycle (pyrazole or indazole), Figure 4.3.  Through a series of co-crystallisations, the 
potential to form co-crystals (determined by infra-red spectroscopy) and a hierarchy of 
preferential binding (determined by single crystal X-ray diffraction) will be determined. 
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Figure 4.3 Pyridine/pyrazole and pyridine/indazole based SR’s with pKa values of the 
conjugate acids. 
4.2 Experimental 
4.2.1 Synthesis 
All chemicals were purchased from Aldrich and Fischer and used without further 
purification.  Melting points were determined on a Fisher-Johns melting point apparatus and are 
uncorrected. 
4.2.1.1 Synthesis of 4-[(pyrazol-1-yl)methyl]pyridine, 13 
N
N
N
40% NaOH, 40% TBA-OH
Benzene, Pyrazole, Reflux
N
Cl
.HCl  
To a round bottom flask, 4-picolylchloride hydrochloride (3.00g, 18.0mmol), pyrazole 
(1.20g, 18.0mmol), 40% NaOH(aq) (48mL), 40% tetrabutylammonium hydroxide (24 drops) and 
benzene (240mL) were added.  The biphasic solution was stirred at reflux for 8 hours, cooled to 
room temperature and stirred over night.  On completion of the stir, the benzene layer was 
extracted and the solvent removed under vacuum.  The crude product was flushed through a 
silica plug (ethyl acetate as eluent), to yield a brown oil, 13, (2.23g, 76.6%).  1H NMR (δH; 
400MHz, CDCl3): 5.32 (s 2H), 6.32 (t, J
 = 4.4Hz, 1H), 6.99 (d, J = 5.6Hz, 2H), 7.43 (d, J = 
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2.4Hz, 1H), 7.57 (d, J = 1.6Hz, 1H), 8.53 (dd, J1  = 4.4Hz, J2 = 1.6Hz, 2H), Figure B.13a;  13C 
NMR, (δC; 50MHz, CDCl3): 54.38, 106.50, 121.82, 129.93, 140.22, 146.14, 149.94, Figure 
B.13b. 
4.2.1.2 Synthesis of 3-[(pyrazol-1-yl)methyl]pyridine, 14 
N
N
N
40% NaOH, 40% TBA-OH
Benzene, Pyrazole, Reflux
N
Cl
.HCl  
To a round bottom flask, 3-picolylchloride hydrochloride (0.500g, 2.94mmol), pyrazole 
(0.200g, 2.94mmol), 40% NaOH(aq) (8mL), 40% tetrabutylammonium hydroxide (4 drops) and 
benzene (40mL) were added.  The biphasic solution was stirred at reflux for 8 hours, cooled to 
room temperature and stirred over night.  On completion of the stir, the benzene layer was 
extracted and the solvent removed under vacuum.  The crude product was flushed through a 
silica plug (ethyl acetate as eluent), to yield a brown oil, 14, (0.303g, 64.8%).  1H NMR (δH; 
400MHz, CDCl3): 5.25 (s, 2H), 6.22 (t, J
 = 4.4Hz, 1H), 7.17 (dd, J1 = 8Hz, J2=4Hz, 1H), 7.35 (d, 
J = 2.4Hz, 1H), 7.41-7.43 (m, 1H), 8.43 (s, 1H), 8.46 (d, J = 4Hz, 1H), Figure B.14a;  13C NMR, 
(δC; 50MHz, CDCl3): 53.16, 106.34, 123.68, 129.40, 132.43, 135.29, 139.97, 148.71, 149.30, 
Figure B.14b. 
4.2.1.3 Synthesis of 4-[(indazol-1-yl)methyl]pyridine, 15 and 4-[(indazole-2-yl)methyl]pyridine, 
16 
N
N
N
40% NaOH, 40% TBA-OH
Benzene, indazole, Reflux
N
Cl
N
N
N
.HCl
15
16  
To a round bottom flask, 4-picolylchloride hydrochloride (0.500g, 3.04mmol), indazole 
(0.390g, 3.04mmol), 40% NaOH(aq) (8mL), 40% tetrabutylammonium hydroxide (4 drops) and 
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benzene (40mL) were added.  The biphasic solution was stirred at reflux for 8 hours, cooled to 
room temperature and stirred over night.  On completion of the stir, the benzene layer was 
extracted and the solvent removed under vacuum.  The two product isomers were separated by 
column chromatography (hexanes:ethyl acetate; 20:1  hexanes:ethyl acetate; 1:1), to yield a 
pale yellow solid 15, (0.249g, 39.0%).  Mp: 83-85oC. 1H NMR (δH; 400MHz, CDCl3): 5.48 (s, 
2H), 6.90 (d, J = 12Hz, 1H), 7.09 (q, J = 16Hz, 2H) 7.20-7.30 (m, 1H), 7.67 (d, J = 16Hz, 2H), 
7.98 (s, 1H), 8.41 (d, J = 8Hz, 1H), Figure B.15a;  13C NMR, (δC; 50MHz, CDCl3): 51.54, 
108.82, 121.02, 121.34, 121.68, 124.34, 126.80, 134.07, 139.64, 145.79, 150.17, Figure B.15b; 
and a brown oil, 16, (0.151g, 23.6%).  1H NMR (δH; 400MHz, CDCl3): 5.62 (s, 2H), 7.08 (d, J
 = 
12Hz, 2H), 7.14 (d, J = 16Hz, 1H), 7.32 (t, J = 16Hz, 1H), 7.70 (dd, J1 = 28Hz, J2 = 16Hz, 1H), 
7.99 (s, 1H), 8.57 (d, J = 12Hz, 2H), Figure B.16a; 13C NMR, (δC; 50MHz, CDCl3): 55.47, 
117.31, 120.32, 121.76, 121.90, 121.93, 123.77, 126.23, 144.98, 149.04, 149.84, Figure B.16b. 
4.2.1.4 Synthesis of 3-[(indazol-1-yl)methyl]pyridine, 17 and 3-[(indazole-2-yl)methyl]pyridine, 
18 
N
N
N
40% NaOH, 40% TBA-OH
Benzene, indazole, Reflux
N
Cl
N
N
N
.HCl
17
18  
To a round bottom flask, 3-picolylchloride hydrochloride (0.500g, 3.04mmol), indazole 
(0.390g, 3.04mmol), 40% NaOH(aq) (8mL), 40% tetrabutylammonium hydroxide (4 drops) and 
benzene (40 mL) were added.  The biphasic solution was stirred at reflux for 8 hours, cooled to 
room temperature and stirred over night.  On completion of the stir, the benzene layer was 
extracted and the solvent removed under vacuum.  The two product isomers were separated by 
column chromatography (hexanes:ethyl acetate; 20:1  hexanes:ethyl acetate; 1:1), to yield an 
off white solid 17, (0.146g, 23.0%).  Mp: 73-76oC. 1H NMR (δH; 400MHz, CDCl3): 5.38 (s, 2H), 
7.11-7.19 (m, 2H), 7.34 (d, J = 4Hz, 2H), 7.44 (d, J = 16Hz, 1H), 7.74 (dt, J1 = 16Hz, J2 = 4Hz, 
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1H), 8.05 (s, 1H), 8.49 (dd, J1 = 8Hz, J2 = 4Hz, 1H), 8.56 (d, J = 4Hz, 1H), Figure B.17a;  13C 
NMR, (δC; 50MHz, CDCl3): 50.16, 108.83, 120.83, 121.20, 123.50, 124.31, 126.60, 132.37, 
133.77, 134.81, 139.35, 148.60, 149.20, Figure B.17b; and a brown oil, 18, (0.0989g, 16.0%).  
1H NMR (δH; 400MHz, CDCl3): 5.55 (s, 2H), 7.03-7.11 (m, 1H), 7.18-7.32 (m, 2H), 7.51-7.55 
(m, 1H), 7.60-7.64 (m, 1H), 7.69-7.74 (m, 1H), 7.90 (s, 1H) 8.53 (dd, J1 = 8Hz, J2 = 4Hz, 1H), 
8.57 (d, J = 4Hz, 1H), Figure B.18a; 13C NMR, (δC; 50MHz, CDCl3): 54.33, 117.28, 120.25, 
121.77, 121.93, 123.11, 123.51, 126.08, 131.57, 135.25, 148.73, 148.95, 149.33, Figure B.18b. 
4.2.1.5 Synthesis of 4-[(indazol-1-yl)methyl]pyridine : 4-nitrobenzoic acid (1:1), 15a 
15 (0.015g, 0.72mmol) and 4-nitrobenzoic acid (0.012g, 0.72mmol) were added to a test 
tube along with acetonitrile.  The mixture was heated gently until components were in solution.  
Colourless prisms suitable for X-ray diffraction were obtained after a few days via slow 
evaporation of acetonitrile.  Mp: 159-162oC.  IR (KBr pellet): υ 3443, 2449, 1879, 1700, 1520, 
1282, 765, 718 cm-1. 
4.2.1.6 Synthesis of 4-[(indazol-1-yl)methyl]pyridine : 3,5-dinitrobenzoic acid (1:1), 15b 
15 (0.015g, 0.72mmol) and 3,5-dinitrobenzoic acid (0.015g, 0.72mmol) were added to a 
test tube along with acetonitrile.  The mixture was heated gently until components were in 
solution.  Yellow prisms suitable for X-ray diffraction were obtained after a few days via slow 
evaporation of acetonitrile.  Mp: 132-135oC.  IR (KBr pellet): υ 3408, 3098, 2469, 1905, 1700, 
1542, 1350, 732 cm-1. 
4.2.1.7 Synthesis of 4-[(indazol-1-yl)methyl]pyridine : succinic acid (1:1), 15c 
15 (0.015g, 0.72mmol) and succinic acid (0.009g, 0.7mmol) were added to a test tube 
along with acetonitrile.  The mixture was heated gently until components were in solution.  
Colourless prisms suitable for X-ray diffraction were obtained after a few days via slow 
evaporation of acetonitrile.  Mp: 120-123oC. IR (KBr pellet): υ 3442, 2918, 2546, 1926, 1711, 
1609, 1184, 750 cm-1. 
4.2.1.8 Synthesis of 3-[(indazol-1-yl)methyl]pyridine : 4-nitrobenzoic acid (1:2), 17a 
17 (0.015g, 0.72mmol) and 4-nitrobenzoic acid (0.012g, 0.72mmol) were added to a test 
tube along with acetonitrile.  The mixture was heated gently until components were in solution.  
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Colourless prisms suitable for X-ray diffraction were obtained after a few days via slow 
evaporation of acetonitrile.  Mp: 164-167oC.  IR (KBr pellet): υ 3458, 2429, 1878, 1700, 1510, 
1346, 1273, 762 cm-1. 
4.2.1.9 Synthesis of 3-[(indazol-1-yl)methyl]pyridine : 3,5-dinitrobenzoic acid (1:1), 17b 
17 (0.015g, 0.72mmol) and 3,5-dinitrobenzoic acid (0.015g, 0.72mmol) were added to a 
test tube along with acetonitrile.  The mixture was heated gently until components were in 
solution.  Yellow prisms suitable for X-ray diffraction were obtained after a few days via slow 
evaporation of acetonitrile.  Mp: 130-132oC.  IR (KBr pellet): υ 3397, 2502, 1938, 1710, 1534, 
1350, 1046, 731 cm-1. 
4.3 Results 
All hydrogen bond geometries are listed in Table 4.1.  A summary of the crystallographic 
information for each compound is displayed in Tables A.20-A.24. 
 
Table 4.1 Hydrogen bond geometries for 15a-15c and 17a-17c. 
Compound D-H•••A D-H / Å H•••A / Å D•••A / Å <(DHA) / o 
15a O(31)-H(31)...N(21) 0.980(18) 1.633(17) 2.6107(14) 175.3(16) 
15b O(31)-H(31)...N(21) 1.15(2) 1.39(2) 2.5409(16) 177.5(18) 
15ci 
O(31)-H(31)...N(12) 
O(41)-H(41)...N(21) 
0.90(3) 
1.01(3) 
1.81(3) 
1.64(3) 
2.705(2) 
2.611(2) 
171(2) 
160(2) 
17a 
O(31)-H(31)...N(13) 
O(41)-H(41)...N(21) 
0.959(14) 
1.012(14) 
1.688(14) 
1.585(14) 
2.6378(11) 
2.5840(11) 
170.1(14) 
168.4(13) 
17b 
O(51)-H(51)...N(21) 
O(61)-H(61)...N(41) 
0.84 
0.84 
1.74 
1.68 
2.579(6) 
2.518(6) 
178.3 
177.1 
(i) #1 -x+1,y,-z+1/2, #2 -x+1/2,-y-1/2,-z. 
 
4.3.1 MEP surface calculations 
In order to rank the hydrogen-bonding capability of the N-heterocyclic compounds 
included in this study, we calculated molecular electrostatic potential (MEP) surfaces for all 
compounds,8 Table 4.2 and Figure 4.4.  It has previously been shown3 that such an approach is 
feasible even if the calculations are performed at a relatively low level of theory (AM1), which 
makes this a versatile and readily accessible tool. 
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Table 4.2 Molecular electrostatic surface potential calculations. 
Ligand E(NPy) kJ mol
-1 E(NPz or Iz) kJ mol
-1 
13 -270 -238 
14 -279 -244 
15 -282 -222 
16 -265 -238 
17 -264 -224 
18 -258 -238 
 
 
13          14 
 
                        15         17 
 
16         18 
Figure 4.4 Molecular electrostatic potential surfaces for (pyrazol-1-yl)methylpyridine and 
(indazol-1-yl)methylpyridine SR’s. 
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4.3.2 Crystal structure of 4-(indazol-1-yl)methylpyridine : 4-nitrobenzoic acid (1:1), 15a 
The crystal structure of 15a shows a 1:1 binary co-crystal with the carboxylic acid and 
the pyridyl moiety interacting via an acid-pyridyl O-H•••N hydrogen bond (2.6107(14) Å), 
Figure 4.5.  There are no other significant hydrogen bonds present, as the indazole nitrogen is not 
participating in any hydrogen bonding. 
 
Figure 4.5 The 1:1 binary supermolecule observed in the crystal structure of 15a. 
4.3.3 Crystal structure of 4-(indazol-1-yl)methylpyridine : 3,5-dinitrobenzoic acid (1:1), 15b 
Similar to 15a, 15b is a 1:1 binary co-crystal with the carboxylic acid and the pyridyl 
moiety interacting via an O-H•••N hydrogen bond (2.5409(16) Å), Figure 4.6.  The indazole 
nitrogen atom is not participating in any hydrogen bonding. 
 
Figure 4.6 The 1:1 binary supermolecule observed in the crystal structure of 15b. 
4.3.4 Crystal structure of 4-(indazol-1-yl)methylpyridine : succinic acid (1:1), 15c 
Both the pyridine and the indazole nitrogen atoms participate in hydrogen bonding in co-
crystal 15c.  The diacid forms two symmetry related O-H•••N hydrogen bonds (2.611(2) Å) 
between succinic acid and two pyridyl nitrogen atoms on separate SR’s, Figure 4.7.  Similarly, 
 72
the diacid also forms a sandwich between two indazole moieties via two symmetry related O-
H•••N hydrogen bonds (2.705(2) Å) producing a 1-D chain. 
 
Figure 4.7 A section of the 1-D chain observed in the crystal structure of 15c. 
4.3.5 Crystal structure of 3-(indazol-1-yl)methylpyridine : 4-nitrobenzoic acid (1:2), 17a 
17a consists of two carboxylic acids and one SR interacting via two independent O-H•••N 
hydrogen bonds between one acid and the pyridine nitrogen atom (2.5840(11) Å) and a second 
acid and the indazole nitrogen atom (2.6378(11) Å), Figure 4.8. 
 
Figure 4.8 The 1:1 binary supermolecule observed in the crystal structure of 17a. 
4.3.6 Crystal structure of 3-(indazol-1-yl)methylpyridine : 3,5-dinitrobenzoic acid (1:1), 17b 
The crystal structure of 17b shows two similar 1:1 binary co-crystals with the two 
carboxylic acids and two SR’s interacting via O-H•••N hydrogen bonds (2.579(6) Å and 2.518(6) 
Å respectively), Figure 4.9. 
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Figure 4.9 The 1:1 binary supermolecule observed in the crystal structure of 17b. 
4.3.7 Determining co-crystal formation by infra-red (IR) spectroscopy 
Along with the five crystal structures reported, IR spectroscopy was carried out on a 
number of co-crystallisation reactions.9  Although it is not possible to determine specific 
connectivity and stoichiometry within a co-crystal via this method, IR spectroscopy is still a 
highly effective tool for the identification of co-crystals.  Distinct stretches at ~2500 cm-1 and 
~1900 cm-1 are indicative of O-H•••N hydrogen bonds between the two individual components, 
Figure 4.10, and allows for a large number of co-crystallisation reactions to be carried out and 
monitored, Table 4.3. 
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Figure 4.10 IR spectrum of 15a displaying the O-H•••N stretches (circled). 
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Table 4.3 IR data. 
SR Carboxylic Acid O-H•••N stretches / cm-1 
4-Nitrobenzoic Acid 2528 & 2051 
3,5-Dinitrobenzoic Acid 2500 & 2100 
4-Fluorobenzoic Acid   
3-Cyanobenzoic Acid 2502 & 1912 
Succinic Acid 2588 & 1991 
Fumaric Acid 2469 & 1898 
N
N
N
 
13 
Oxalic Acid 2575 & 1931 
4-Nitrobenzoic Acid 2502 & 1951 
3,5-Dinitrobenzoic Acid 2482 & 1955 
3-Cyanobenzoic Acid 2422 & 1965 
Succinic Acid   
Fumaric Acid 2535 & 1905 
Oxalic Acid 2594 & 2100 
N
N
N
 
14 
3,5-Difluorobenzoic Acid 2531 & 1918 
4-Nitrobenzoic Acidi 2449 & 1879 
3,5-Dinitrobenzoic Acidi 2469 & 1905 
Succinic Acidi 2546 & 1926 
4-Fluorobenzoic Acid 2462 & 1918 
N
N
N
 
15 Fumaric Acid 2482 & 1925 
4-Nitrobenzoic Acidi 2429 & 1878 
3,5-Dinitrobenzoic Acidi 2502 & 1938 
3-Cyanobenzoic Acid 2515 & 1898 
3,5-Difluorobenzoic Acid 2455 & 1965 
N
N
N
 
17 Fumaric Acid 2535 & 1859 
(i) Crystal structure determined 
4.4 Discussion 
4.4.1 Determining the best hydrogen-bond acceptor site in the ditopic SR 
O-H•••N hydrogen-bond stretches were observed in the IR spectra of 22 of the 24 (92%) 
co-crystallisations.   
Single crystal data confirms that O-H•••N hydrogen bonds between the incoming 
carboxylic acid and the pyridine of the SR was present in all cases, Figure 4.11.  
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Figure 4.11 Co-crystals of (a) 4-(indazol-1-yl)methylpyridine and (b) 3-(indazol-1-
yl)methylpyridine with carboxylic acids. 
 
All co-crystallisations were set up in a 1:1 ratio however, 17a contains two molecules of 
4-nitrobenzoic acid interacting at both pyridine and indazole nitrogen atoms of one SR, Figure 
4.12a. Also, 15c shows the indazole nitrogen is able to accept a hydrogen bond, Figure 4.12b.  
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Figure 4.12 Acceptor ability of indazole nitrogen in co-crystals of (a) 4-(indazol-1-
yl)methylpyridine and (b) 3-(indazol-1-yl)methylpyridine with carboxylic acids. 
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Although hydrogen-bond interactions are observed between a carboxylic acid and the 
indazole nitrogen atom of the SR’s, it is clear that indazole is the second-best acceptor.  This is 
evidenced by (a) the lack of 1:1 co-crystals composed solely of O-H•••N hydrogen bonds 
between the acid and the indazole moiety and (b) the shorter acid-pyridine O-H•••N hydrogen-
bond lengths compared to acid-indazole, Table 4.4. 
 
Table 4.4 Acid-pyridine O-H•••N hydrogen-bond lengths compared to acid-indazole O-
H•••N hydrogen-bond lengths. 
Co-crystal 
Acid-pyridine O-H•••N 
hydrogen-bond lengths / Å 
Acid-indazole O-H•••N 
hydrogen-bond lengths / Å 
15c 2.611(2) 2.705(2) 
17a 2.5840(11) 2.6378(11) 
  
The structural analysis of five co-crystals between  (indazol-1-yl)methylpyridine SR’s 
and a carboxylic acid have provided reliable answers to the questions addressed at the beginning 
of this chapter. 
 
I. Can the hydrogen-bond acceptor strength of the second N-heterocycle be lowered such 
that pyridine becomes the best acceptor? 
The MEP of the second N-heterocycle was lowered sufficiently to move the incoming 
carboxylic acid to the pyridine moiety.  MEP surface calculations provide practical guidelines for 
identifying best and second-best acceptor sites in ditopic SR’s, Figure 4.13. 
N
N N
N
N
N
H
O
R
O
H O
R
O
100% supramolecular yield 
for an acid-pyridine
interaction via an O-H...N 
hydrogen-bond.
100% supramolecular yield 
for an acid-benzimidazole
interaction via an O-H...N 
hydrogen-bond.  
Figure 4.13 Hierarchical approach to controlling hydrogen-bond interactions in pyridine/N-
heterocycle SR’s. 
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II. Can the hydrogen-bond acceptor strength of the second N-heterocycle be lowered 
(compared to benzimidazole) to prevent deprotonation of the incoming carboxylic acid? 
Replacing benzimidazole with indazole reduced the hydrogen-bond acceptor strength 
from ~-300 kJ/mol to ~-223kJ/mol.  This decrease was significant enough to change the 
frequency of deprotonation from ~50% in benzimidazole systems to 0% in indazole systems, 
Figure 4.14. 
N
N N
N
N
N H O
R
O
53% supramolecular yield 
for deprotonation of the 
carboxylic acid by benzimidazole.
0% supramolecular yield 
for deprotonation of the 
carboxylic acid by indazole.
H
O R
O
 
Figure 4.14 Ability to fine-tune the acceptor strength of the N-heterocycle to prevent 
deprotonation of the incoming carboxylic acid. 
 
This adds substance to the results previously obtained for benzimidazole-pyridine ditopic 
systems5 validating MEP surface calculations as a tool for predicting a hierarchy of hydrogen-
bond acceptors in ditopic heterocycle SR’s. 
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the electrostatic potential surface (0.002 e/au isosurface) determined using a positive point 
charge in the vacuum as a probe. 
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CHAPTER 5 - Employing Ditopic Pyrimidine/Bis-Pyrazole 
Supramolecular Reagents to Construct Co-crystals and Inorganic-
Organic Hybrid Materials 
 
5.1 Introduction 
Pyrazole is a good hydrogen-bond acceptor,1 however, in SR’s when pyrazole is coupled 
to a hydrogen-bond acceptor such as an amide moiety2 or a pyridyl functionality,3 the ability to 
act as a hydrogen-bond acceptor is relatively poor. 
In order to assess the hydrogen-bond acceptor ability of pyrazole in a ditopic SR, a 
system needs to be designed in which pyrazole is the best hydrogen-bond acceptor.  This can be 
achieved by pairing pyrazole with a considerably poorer hydrogen-bond acceptor (based on 
approximated pKa values of the conjugate acids).  Furthermore, the acceptor strength of the 
pyrazole nitrogen atom can be fine-tuned through simple covalent modifications to the ring (e.g. 
by adding electron donating methyl groups) allowing for a range of acceptor strengths to be 
obtained. 
When choosing the second weaker hydrogen-bond acceptor, pyrimidine, Figure 5.1, is a 
good candidate. 
N N
pKa = ~1.1
N
N
pKa = ~2.5
R
 
Figure 5.1 Pyrimidine and pyrazole with pKa values of the conjugate acids. 
 
The conjugate acid of pyrimidine has a significantly lower pKa than pyrazole (1.1 cf: 
2.5)4 and coupled with the limited number of co-crystals in the CSD5 (there are only three 1:1 co-
crystals between a carboxylic acid and pyrimidine6), makes it a suitable target for such a study.   
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Additionally, pyrimidine-pyrazole4, 7 systems have been exploited in coordination 
chemistry as chelating ligands, Figure 5.2.  It makes sense then to have a structurally similar 
backbone that can be implemented to examine a MEP-based approach to co-crystal predictability 
as well as to provide control over metal coordination. 
N N
N
N
N N
N
N
M M
N
N
M
 
Figure 5.2 Pyrimidine-pyrazole as a chelating ligand. 
 
This chapter will address two questions: 
 
I. Is pyrazole a better hydrogen-bond acceptor than pyrimidine? 
 
II. Can pyrimidine/pyrazole ligands be used successfully as chelating ligands to construct 
reliable coordination complexes? 
 
With this in mind, a family of SR’s has been targeted in which pyrimidine is appended 
with two pyrazole arms, Figure 5.3.  This makes pyrazole the better hydrogen-bond acceptor 
(based on pKa and charge approximations4) compared to pyrimidine. 
N N
N N
N N
R
R1
R R
R1
R
1) R=H, R1=H
2) R=Me, R1=H
3) R=Me, R1=Br
4) R=H, R1=Br
5) R=H, R1=I  
Figure 5.3 Target pyrimidine/bis-pyrazole SR’s. 
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Through a series of co-crystallisations, the potential to form co-crystals (determined by 
infra-red spectroscopy) and a hierarchy of preferential binding, Figure 5.4,  (determined by 
single crystal X-ray diffraction) will be established. 
N N
N N
N N
R
R1
R R
R1
R
1) R=H, R1=H
2) R=Me, R1=H
3) R=Me, R1=Br
4) R=H, R1=Br
5) R=H, R1=I
~2.5
~1.1
Co-crystallisation with 
carboxylic acid
N N
N N
N N
R
R1
R R
R1
R
O
O
H
or
N N
N N
N N
R
R1
R R
R1
R
O
O
H
(a)
(b)  
Figure 5.4 Target pyrimidine/bis-pyrazole SR’s with pKa numbers and the potential co-
crystallisation products.  The pKa values for the conjugate acids indicate the pyrazole nitrogen 
atom is the better acceptor and consequently co-crystallisation product (a) is expected. 
 
Additionally, the direct N-C coupling between pyrazole and pyrimidine creates a suitable 
bidentate chelate ligand, Figure 5.5, for the construction of extended metal-containing 
architectures. 
N N
N N
N N
R
R1
R R
R1
R
M M
N N
N N
N N
R
R1
R R
R1
R
1) R=H, R1=H
2) R=Me, R1=H
3) R=Me, R1=Br
4) R=H, R1=Br
5) R=H, R1=I
Coordination reactions
 
Figure 5.5 Target pyrimidine/bis-pyrazole ligands and the potential inorganic-organic hydrid 
materials. 
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5.2 Experimental 
5.2.1 Synthesis  
All chemicals were purchased from Aldrich and Fischer and used without further 
purification.  4-Bromo-3,5-dimethylpyrazole and 4-iodopyrazole were synthesised via previously 
published procedures.8,9  Melting points were determined on a Fisher-Johns melting point 
apparatus and are uncorrected. 
5.2.1.1 Synthesis of 4,6-bis(pyrazol-1-yl)pyrimidine, 19 
N
H
N
4,6-Dichloropyrimidine
Aliquat 336, KOtBu
N N
N N
N N  
To a round bottom flask, pyrazole (0.500g, 7.35mmol), Aliquat® 336 
(trioctylmethylammonium chloride) (0.196g, 0.490mmol) and potassium tert-butoxide (1.47g, 
13.1mmol) were added and stirred for 30min at 120oC.  4,6-Dichloropyrimidine (1.64g, 11mmol) 
was added to the reaction and stirred overnight.  The reaction was cooled and methylene chloride 
(25mL) was added.  The organics were washed with water (3x25mL), dried over MgSO4 and 
reduced to a white solid.  The solid was purified by column chromatography (hexanes  30:1 
hexanes:ethyl acetate) to yield 19 as a white solid, (0.200g, 25%).  Mp: 120-123oC.  1H NMR 
(δH; 200MHz, CDCl3): 6.53 (t, J = 2Hz, 2H), 7.82 (d, J = 1.4Hz, 2H), 7.98 (d, J = 0.6Hz, 1H), 
8.57 (d, J = 4Hz, 2H), 8.80 (s, 1H), Figure B.19a;  13C NMR, (δC; 50MHz, CDCl3): 95.68, 
109.01, 127.79, 143.93, 158.00, 158.79, Figure B.19b. 
5.2.1.2 Synthesis of 4,6-bis(3,5-dimethylpyrazol-1-yl)pyrimidine, 20 
N
H
N
4,6-Dichloropyrimidine
Aliquat 336, KOtBu
N N
N N
N N
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To a round bottom flask, 3,5-dimethylpyrazole (0.500g, 5.2mmol), Aliquat® 336 (0.139g, 
0.343mmol) and potassium tert-butoxide (1.04g, 9.27mmol) were added and stirred for 30min at 
120oC.  4,6-Dichloropyrimidine (1.63g, 10.9mmol) was added to the reaction and stirred 
overnight.  The reaction was cooled and methylene chloride (25mL) was added.  The organics 
were washed with water (3x25mL), dried over MgSO4 and reduced to a white solid.  The solid 
was purified by column chromatography (hexanes  30:1 hexanes:ethyl acetate) to yield 20 as a 
white solid, (0.260g, 37.3%).  Mp: 127-130oC.  1H NMR (δH; 200MHz, CDCl3): 2.31 (s, 3H), 
2.72 (s, 3H), 6.02 (s, 2H), 8.38 (d, J = 1.2Hz, 1H), 8.75 (d, J = 1.2Hz, 1H), Figure B.20a; 13C 
NMR, (δC; 50MHz, CDCl3): 13.75, 15.36, 99.43, 110.65, 142.79, 151.59, 156.80, 160.57, Figure 
B.20b. 
5.2.1.3 Synthesis of 4,6-bis(4-bromo-3,5-dimethylpyrazol-1-yl)pyrimidine, 21 
N
H
N
4,6-Dichloropyrimidine
Aliquat 336, KOtBu
N N
N N
N NBr
BrBr
 
To a round bottom flask, 4-bromo-3,5-dimethylpyrazole (0.500g, 2.86mmol), Aliquat® 
336 (0.0760g, 0.189mmol) and potassium tert-butoxide (0.570g, 5.09mmol) were added and 
stirred for 30min at 120oC.  4,6-Dichloropyrimidine (0.200g, 1.36mmol) was added to the 
reaction and stirred overnight.  The reaction was cooled and methylene chloride (25mL) was 
added.  The organics were washed with water (3x25mL), dried over MgSO4 and reduced to a 
white solid.  The solid was purified by column chromatography (hexanes  30:1 hexanes:ethyl 
acetate) to yield 21 as a white solid, (0.157g, 27.1%).  Mp: 247-250oC.  1H NMR (δH; 200MHz, 
CDCl3): 2.31 (s, 3H), 2.74 (s, 3H), 7.97 (s, 1H), 8.78 (s, 1H), Figure B.21a;  
13C NMR, (δC; 
50MHz, CDCl3): 12.74, 14.46, 98.94, 100.94, 140.32, 150.49, 156.91, 160.49, Figure B.21b. 
5.2.1.4 Synthesis of 4,6-bis(4-bromopyrazol-1-yl)pyrimidine, 22 
N
H
N
4,6-Dichloropyrimidine
Aliquat 336, KOtBu
N N
N N
N NBr
BrBr
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To a round bottom flask, 4-bromopyrazole (0.500g, 3.40mmol), Aliquat® 336 (0.0910g, 
0.225mmol) and potassium tert-butoxide (0.680g, 6.05mmol) were added and stirred for 30min 
at 120oC.  4,6-Dichloropyrimidine (0.241g, 1.62mmol) was added to the reaction and stirred 
overnight.  The reaction was cooled and methylene chloride (25mL) was added.  The organics 
were washed with water (3x25mL), dried over MgSO4 and reduced to a white solid.  The solid 
was purified by column chromatography (hexanes  30:1 hexanes:ethyl acetate) to yield 22 as a 
white solid, (0.222g, 35.2%).  Mp: 212-215oC.  1H NMR (δH; 200MHz, CDCl3): 7.76 (d, J = 
0.8Hz, 2H), 8.40 (d, J = 1Hz, 1H), 8.61 (d, J = 0.8Hz, 2H), 8.79 (d, J = 1Hz, 1H), Figure B.22a;  
13C NMR, (δC; 100MHz, CDCl3): 94.94, 98.17, 127.93, 144.55, 158.14, 158.24, Figure B.22b. 
5.2.1.5 Synthesis of 4,6-bis(4-iodoopyrazol-1-yl)pyrimidine, 23 
N
H
N
4,6-Dichloropyrimidine
Aliquat 336, KOtBu
N N
N N
N NI
II
 
To a round bottom flask, 4-iodopyrazole (1.00g, 5.16mmol), Aliquat® 336 (0.138g, 
0.341mmol) and potassium tert-butoxide (1.03g, 9.18mmol) were added and stirred for 30min at 
120oC.  4,6-Dichloropyrimidine (0.370g, 2.46mmol) was added to the reaction and stirred 
overnight.  The reaction was cooled and methylene chloride (50mL) was added.  The organics 
were washed with water (3x50mL), dried over MgSO4 and reduced to a white solid.  The solid 
was purified by column chromatography (hexanes  30:1 hexanes:ethyl acetate) to yield 23 as a 
white solid, (0.430g, 37.4%).  Mp: 220-222oC.  1H NMR (δH; 200MHz, CDCl3): 7.80 (s, 2H), 
8.40 (d, J = 1Hz, 1H), 8.66 (d, J = 0.6Hz, 2H), 8.78 (d, J = 1Hz, 1H), Figure B.23a;  13C NMR, 
(δC; 50MHz, CDCl3): 94.98, 108.47, 132.41, 148.66, 158.09, 158.41, Figure B.23b. 
5.2.1.6 Synthesis of 4,6-bis(pyrazol-1-yl)pyrimidine : 3,5-dinitrobenzoic acid (1:1), 19a 
19 (0.0250g, 0.118mmol) and 3,5-dinitrobenzoic acid (0.0250g, 0.118mmol) were added 
to a test tube along with acetonitrile.  The mixture was heated gently until components were in 
solution.  Colourless prisms suitable for X-ray diffraction were obtained after a few days via 
slow evaporation of acetonitrile.  Mp: 123-126oC.  IR (KBr pellet): υ 3432, 3135, 3094, 2500, 
1865, 1696, 1055, 1350, 733 cm-1. 
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5.2.1.7 Synthesis of 4,6-bis(pyrazol-1-yl)pyrimidine : 4-nitrobenzoic acid (1:1), 19b 
19 (0.0250g, 0.118mmol) and 4-nitrobenzoic acid (0.0200g, 0.118mmol) were added to a 
test tube along with acetonitrile.  The mixture was heated gently until components were in 
solution.  Colourless plates suitable for X-ray diffraction were obtained after a few days via slow 
evaporation of acetonitrile.  Mp: 164-167oC.  IR (KBr pellet): υ 3450, 3138, 2475, 1905, 1719, 
1593, 1527, 1388, 712 cm-1. 
5.2.1.8 Synthesis of 4,6-[bis(3,5-dimethylpyrazol-1-yl)pyrimidine]copper(II) dichloride, 20a 
20 (0.0150g, 0.0560mmol) was dissolved in acetonitrile and combined with an 
acetonitrile solution of CuCl2 (0.00300g, 0.00187mmol).  Blue needles suitable for X-ray 
diffraction were obtained after a few days via slow evaporation of acetonitrile.  Mp: 270-273oC 
(dec).  IR (KBr pellet): υ 2925, 1603, 1475, 1317, 1035, 723 cm-1. 
5.3 Results 
All hydrogen bond geometries for 19a and 19b are listed in Table 5.1.  A summary of the 
crystallographic information for each compound is displayed in Tables A.25-A.28. 
 
Table 5.1 Hydrogen bond geometries for 19a-19b 
Compound D-H…A D-H / Å H…A / Å D…A / Å <(DHA) / o 
19a 
O411-H411...N221 
O412-H412...N222 
O413-H413...N223 
0.93(3) 
0.92(3) 
0.93(3) 
1.70(3) 
1.73(3) 
1.73(3) 
2.625(3) 
2.656(3) 
2.656(3) 
174(3) 
175(2) 
178(2) 
19b O(41)-H(41)...N(22) 0.90(2) 1.79(2) 2.6917(18) 172.8(17) 
 
5.3.1 MEP calculations 
In order to rank the hydrogen-bonding capability of the N-heterocyclic compounds 
included in this study, we calculated molecular electrostatic potential (MEP) surfaces for all 
compounds,10 Table 5.2 and Figure 5.6.  It has previously been shown11 that such an approach is 
feasible even if the calculations are performed at a relatively low level of theory (AM1), which 
makes this a versatile and readily accessible tool. 
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Table 5.2 Molecular electrostatic potential surface calculations. 
 
 
 
 
 
 
 
 
 
 
 
 
         19    20           21 
 
    22        23 
Figure 5.6 Molecular electrostatic potential surfaces for 4,6-bis(pyrazol-1-yl)pyrimidine 
SR’s. 
 
 
 
 
Ligand 
E(NPym) 
kJ mol-1 
E(NPz) 
kJ mol-1 
19 -208 -219 
20 -163 -230 
21 -146 -211 
22 -185 -186 
23 -175 -191 
N N
N N
N N
R
R1
R R
R1
R
19) R=H, R1=H
20) R=Me, R1=H
21) R=Me, R1=Br
22) R=H, R1=Br
23) R=H, R1=I
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5.3.2 Crystal structure of 4,6-bis(3,5-dimethylpyrazol-1-yl)pyrimidine, 20 
The crystal structure of 20 shows both pyrazole arms located in the trans orientation with 
respect to pyrimidine and pyrazole nitrogen atoms, Figure 5.7. 
 
Figure 5.7 One molecule of 20 observed in the crystal structure showing trans orientation. 
5.3.3 Crystal structure of 4,6-bis(pyrazol-1-yl)pyrimidine : 3,5-dinitrobenzoic acid (1:1), 19a 
The crystal structure of 19a shows three structurally similar dimeric supermolecules with 
the incoming carboxylic acid and one of the trans pyrazole moieties interacting via an O-H•••N 
hydrogen bond (2.625(3) Å, 2.656(3) Å, 2.656(3) Å respectively), Figure 5.8.  Neither 
pyrimidine nitrogen atom is participating in any hydrogen bonding. 
 
Figure 5.8 One of the three 1:1 binary supermolecule observed in the crystal structure of 19a. 
5.3.4 Crystal structure of 4,6-bis(pyrazol-1-yl)pyrimidine : 4-nitrobenzoic acid (1:1), 19b 
Similar to 19a, 19b is a 1:1 binary co-crystal with the carboxylic acid and one of the 
trans pyrazole moieties interacting via an O-H•••N hydrogen bond (2.6917(18) Å), Figure 5.9. 
Neither pyrimidine nitrogen atom is participating in any hydrogen bonding. 
N N
N N
N N
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Figure 5.9 The 1:1 binary supermolecule observed in the crystal structure of 19b.  
5.3.5 Crystal structure of 4,6-[bis(3,5-dimethylpyrazol-1-yl)pyrimidine]copper(II) dichloride, 
20a 
The coordination complex 20a shows 20 chelating to a five-coordinate copper centre 
(Cu-N 2.031(2) Å and 2.047(2) Å, respectively).  A dinuclear ion is produced via two Cu-Cl-Cu 
bridges (Cu-Cl 2.3156(7) Å, 2.6656(8) Å, 2.3156(7) Å and 2.6657(8) Å respectively) to a 
symmetry related copper centre giving a Cu-Cu distance of ~3.640 Å, Figure 5.10a.  The fifth 
coordination site of each copper ion is occupied by a terminal chloride ion (Cu-Cl 2.2434(8) Å). 
A second copper ion is also observed with 20 chelating to a tetrahedral copper centre (Cu-N 
2.015(2) Å and 2.043(2) Å, respectively), Figure 5.10b.  The two remaining sites on the copper 
ion are occupied by terminal chloride ions (Cu-Cl 2.2131(8) Å and 2.2427(8) Å respectively). 
  
(a)         (b) 
Figure 5.10 Two different complex ions observed in the crystal structure 20a showing: (a) two 
symmetry related five-coordinate copper(II) ions interconnected by two Cu-Cl-Cu bridges and 
(b) tetrahedral copper(II) ion with two terminal chloride ions. 
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5.3.6 Determining co-crystal formation by infra-red (IR) spectroscopy 
Along with the two crystal structures reported, IR spectroscopy was carried out on a 
number of co-crystallisation reactions.12  Although it is not possible to determine specific 
connectivity and stoichiometry within a co-crystal via this method, IR spectroscopy is still a 
highly effective tool for the identification of co-crystals.  Distinct stretches at ~2500 cm-1 and 
~1900 cm-1 are indicative of O-H•••N hydrogen bonds between the two individual components, 
Figure 5.11, and allows for a large number of co-crystallisation reactions to be analysed, Table 
5.3. 
 
Figure 5.11 IR spectrum of 19a displaying the O-H•••N stretches (circled). 
 
Table 5.3 IR data. 
SR Carboxylic Acid O-H•••N stretches / cm-1 
3,5-Dinitrobenzoic Acid i 2500 & 1865 
4-Nitrobenzoic Acid i 2475 & 1905 
2-Fluorobenzoic Acid   
Benzoic Acid   
Fumaric Acid 2523 & 1898 
Succinic Acid  2546 & 1993 
N N
N N
N N  
19 
Oxalic Acid 2541 & 1977 
3,5-Dinitrobenzoic Acid 2522 & 1938 
4-Nitrobenzoic Acid 2555 & 1958 
2-Fluorobenzoic Acid   
3-Cyanobenzoic Acid 2555 & 1925 
Benzoic Acid 2455 & 1918 
Fumaric Acid  2535 & 1916 
Succinic Acid 2548 & 1945 
N N
N N
N N
 
20 
Oxalic Acid 2508 & 1938 
(i) Crystal structure determined 
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5.4 Discussion 
5.4.1 Assessing potential orientations of 4,6-bis(pyrazol-1-yl)pyrimidine SR’s 
Based on single crystal data the trans orientation is favoured in the SR (20) and in co-
crystals (19a and 19b), Figure 5.9.  The cis orientation however, is observed in the presence of 
metal ions due to the preference for a metal-chelate, Figure 5.12. 
Coordination
complex
N N
N N
N N
N N
N N
N
N
R
R
R
R
M
H
O
O
R2
N N
N N
N N
trans orientation 
favoured 
in co-crystals
trans orientation 
favoured in SR
cis orientation 
favoured in 
inorganic-organic 
hybrid materials
R
R1
R R
R
R1 R1
R1R
R1
RR
R
R1
Co-crystal
 
Figure 5.12 Favoured orientations of  4,6-bis(pyrazol-1-yl)pyrimidine SR’s. 
5.4.2 Determining the best hydrogen-bond acceptor site in the ditopic SR 
O-H•••N hydrogen-bond stretches were observed in the IR spectra of 12 of the 15 (80%) 
co-crystallisations. 
Based on single crystal data for 19a and 19b, it was established that the co-crystal was 
formed via an O-H•••N hydrogen bond between the carboxylic acid and the pyrazole nitrogen, 
Figure 5.13. 
N N
N N
N N
2/2 form O-H...N to pyrazole (1:1 co-crystal)
-219
-208 N N
N N
N N
H
O
O
R  
Figure 5.13 Co-crystals of 4,6-bis(pyrazol-1-yl)pyrimidine and carboxylic acids. 
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5.4.3 Addressing reliability of 4,6-bis(pyrazol-1-yl)pyrimidine as a chelating ligand 
The crystal structure of 20a shows the pyrimidine-pyrazole chelating to two different 
copper ions, Figure 5.14.   
N N
N
N
N
N
N N
N N
N N
M
Cl
Cl
Cl
M
Cl
Cl
M
Cl
N
N
N
N
N
N
N
N
N
N
N
N
orForms metal chelate
 
Figure 5.14 Metal coordination complexes of 4,6-bis(3,5-methylpyrazol-1-yl)pyrimidine. 
 
This crystal structure when paired with ~40 pyrimidine-pyrazole coordination complexes 
previously synthesised,4, 7 Figure 5.15, supports the idea that pyrimidine-pyrazole can be used as 
a reliable chelating ligand. 
N
N
N
N
N
N
Ru
PPh3
Cl
PPh3
Cl
N
N
N
N
N
N
Pd
C6F5
C6F5
 
Figure 5.15 Two examples of previously synthesised pyrimidine-pyrazole coordination 
complexes.7b, 7c 
 
The structural analysis of the two co-crystals 19a and 19b between 4,6-bis(pyrazol-1-
yl)pyrimidine and a carboxylic acid and the inorganic-organic hybrid, 20a, have provided 
answers to the questions addressed at the beginning of this chapter. 
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I. Is pyrazole a better hydrogen-bond acceptor than pyrimidine? 
The MEP surface calculations confirm that pyrazole is more electrostatic than 
pyrimidine.  This directly translates into hydrogen-bond acceptor strength with the two co-
crystals showing hydrogen-bond interactions at the pyrazole nitrogen atom and no interactions at 
both pyrimidine nitrogen atoms, Figure 5.16.  This adds weight to MEP surface calculations as a 
tool for predicting a hierarchy of hydrogen-bond acceptors in ditopic heterocycle SR’s. 
N N
N N
N N
H
O
O
R
100% supramolecular yield 
for an acid-pyrazole
interaction via an O-H...N 
hydrogen-bond.
 
Figure 5.16 Hydrogen-bond preference in co-crystals between pyrazole/pyrimidine SR’s and 
carboxylic acids. 
 
II. Can pyrimidine/pyrazole ligands be used successfully as chelating ligands to 
construct reliable coordination complexes? 
The family of pyrimidine/pyrazole ligands can be employed to construct hybrid materials 
with the ability of pyrimidine/pyrazole to act as a chelating ligand shown in 20a, Figure 5.17.  
Backed up by structurally similar pyrimidine/pyrazole complexes previously synthesised,4, 7 
these chelating ligands offer a reliable approach to constructing predictable coordination 
complexes. 
N N
N N
N
N
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Figure 5.17 Pyrazole/pyrimidine chelating ligands. 
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CHAPTER 6 - Using [(pyrazol-1-yl)methyl]benzamide SR’s to 
construct 1-D inorganic-organic hybrid materials 
 
6.1 Introduction 
The construction of inorganic-organic hybrid materials with the overall goal of 
developing systems with specific properties e.g. magnetic,1 catalytic,2 and storage3 via 
supramolecular synthesis is a rapidly growing field within crystal engineering focused on (i) 
ligand-metal interactions to yield coordination polymers4 and (ii) ligand-metal interactions paired 
with non-covalent interactions.5 
A significant level of control is required for a specific design to be applied reliably and 
the introduction of non-covalent interactions (e.g. hydrogen bonding) may allow for easier, 
flexible dimensionality control and improved solubility of coordination networks.  However, the 
reliability of such architectures is likely to be affected by the introduction of competitive forces, 
which can cause structural interference from the numerous undesired hydrogen bonds that can 
potentially form between the ligand and solvent molecules or counter ions.  Consequently a 
robust supramolecular motif is necessary in order to prevent a high level of unpredictability. 
The amide-amide self-complementary homomeric dimer lends itself well to such a study 
as it was demonstrated to be a fairly robust synthon (69% supramolecular yield) in the presence 
of competitive forces such as a N-heterocycle.6   
In order to be able to assess the ability of such ligands to achieve the desired metal-
containing extended structural motif in the absence of potentially disruptive counter-ions, a set of 
neutral coordination complexes were targeted, Figure 6.1.  In addition, by using chelating 
ligands, the number of possible geometries that each metal ion could adopt will be restricted, 
thereby simplifying the assembly process further. 
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Figure 6.1 (a) Bidentate acetylacetonate (acac) and (b) acetate “paddle-wheel” complexes. 
 
The supramolecular target in each case presented in this study is first of all an infinite 1-
D chain, Figure 6.2.  Therefore, each metal complex is required to have exactly two available 
binding sites that could be occupied by N-heterocycle/amide ligands. 
Amide-Amide 
heteromeric 
dimer
Ligand-Metal
Coordination
 
Figure 6.2 Representation of supramolecular 1-D chain via both metal coordination and 
amide-amide hydrogen bonding. 
 
Bidentate acetylacetonate (acac) and acetate “paddle-wheel” complexes are particularly 
useful in this context as they both produce neutral complexes (with M(II) metal ions) that present 
two open binding sites suitable for heterocycle coordination, Figure 6.1.   
Isonicotinamide,7 and (benzimidazol-1-yl)benzamides,8 Figure 6.3, have both previously 
been used to construct 1-D chains through coordination to Ag(I), Figure 6.4a and 
isonicotinamide has also been used effectively with acac and “paddle-wheel” complexes5d, 9 to 
construct 1-D chains, Figure 6.4b.  However, an extensive survey of the effectiveness of a series 
of N-heterocycle/amide ligands to direct the assembly of neutral coordination complexes into 
infinite 1-D chains has never been addressed. 
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        (a)         (b) 
Figure 6.3 (a) Isonicotinamide; (b) (benzimidazol-1-yl)benzamides 
 
 
(a) 
 
(b) 
Figure 6.4 1-D chains constructed from (a) isonicotinamide and Ag(OTf);7a and (b) 
isonicotinamide and Cu(OAc)2.
9a 
 
Consequently, the goal of this study is to establish the robustness of a supramolecular 
synthetic strategy based upon a ligand comprising an N-heterocycle (for binding to the metal 
ion), and an amide (for providing intermolecular amide•••amide synthons). 
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A series of hybrid materials will be constructed between [(pyrazol-1-
yl)methyl]benzamide ligands, Figure 6.5 and acac or “paddle-wheel” type coordination 
complexes.  Subsequent analysis of single crystal X-ray structures will allow for the robustness 
of such systems to be addressed. 
N
N
2
NH2
O NH2O
N
N
8  
Figure 6.5 [(Pyrazol-1-yl)methyl]benzamide ligands. 
6.2 Experimental 
6.2.1 Synthesis 
All chemicals were purchased from Aldrich and Fischer and used without further 
purification.  Synthesis of the [(pyrazol-1-yl)methyl]benzamide ligands is reported in chapter 2.  
Melting points were determined on a Fisher-Johns melting point apparatus and are uncorrected.   
6.2.1.1 Synthesis of [4-(pyrazol-1-yl)methyl]benzamide : bis-(hexafluoroacetylacetonato) 
copper(II), 2i 
2 (0.0250g, 0.124mmol) and bis-(hexafluoroacetylacetonato)copper(II) (0.0300g, 
0.0545mmol) were added to a vial along with chloroform.  The solution was heated gently to 
dissolve the components and allowed to stand under ambient conditions.  Green prisms, 2i, 
suitable for X-ray diffraction were formed after a few days.  Mp  132-135˚C.  IR (KBr pellet): υ 
3477, 3368, 1679, 1647, 1469, 1256, 1211, 1131 cm-1. 
6.2.1.2 Synthesis of [4-(pyrazol-1-yl)methyl]benzamide : bis-(dibenzoylmethanato)nickel(II), 2j 
2 (0.0200g, 0.099mmol) and bis-(dibenzoylmethanato)nickel(II) (0.0240g, 0.0498mmol) 
were added to a vial along with ethanol.  The solution was heated gently to dissolve the 
components and allowed to stand under ambient conditions.  Yellow blocks, 2j, suitable for X-
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ray diffraction were formed after a few days.  Mp  152-155˚C.  IR (KBr pellet): υ 3443, 1665, 
1597, 1553, 1473, 1415, 720 cm-1. 
6.2.1.3 Synthesis of [3-(pyrazol-1-yl)methyl]benzamide : bis-(hexafluoroacetylacetonato) 
copper(II), 8c 
8 (0.0250g, 0.124mmol) and bis-(hexafluoroacetylacetonato)copper(II) (0.0300g, 
0.0545mmol) were added to a vial along with chloroform.  The solution was heated gently to 
dissolve the components and allowed to stand under ambient conditions.  Green prisms, 8b, 
suitable for X-ray diffraction were formed after a few days.  Mp  137-140˚C.  IR (KBr pellet): υ 
3498, 3391, 1666, 1643, 1558, 1256, 1202 cm-1. 
6.2.1.4 Synthesis of tetrakis(µ-2-fluorobenzoato-O,O’)-bis(4-(pyrazol-1-yl)methylbenzamide)-
dicopper(II), 2k 
2 (0.0150g, 0.0750mmol) and copper 2-fluorobenzoate (0.0147g, 0.0430mmol) were 
added to a beaker and dissolved in acetonitrile.  A few drops of acetic acid were added to make 
the solution transparent and the solution was allowed to stand under ambient conditions.    Aqua 
prisms, 2k, suitable for X-ray diffraction were formed after a few days.  Mp  208-211˚C.  IR 
(KBr pellet): υ 3428, 1682, 1632, 1402, 760 cm-1. 
6.2.1.5 Synthesis of tetrakis(µ-acetato-O,O’)-bis(4-(pyrazol-1-yl)methylbenzamide)-
dicopper(II), 2l 
 2 (0.015g, 0.075mmol) and copper acetate (0.0082g, 0.045mmol) were added to a beaker 
and dissolved in acetonitrile.  A few drops of acetic acid were added to make the solution 
transparent and the solution was allowed to stand under ambient conditions.  Green prisms, 2l, 
suitable for X-ray diffraction were formed after a few days.  Mp  149-151˚C.  IR (KBr pellet): υ 
3416, 3278, 1614, 1440, 692 cm-1. 
6.2.1.6 Synthesis of tetrakis(µ-acetato-O,O’)-bis(3-(pyrazol-1-yl)methylbenzamide)-
dicopper(II), 8d 
8 (0.015g, 0.082mmol) and copper acetate (0.0082g, 0.045mmol) were added to a beaker 
and dissolved in acetonitrile.  A few drops of acetic acid were added to make the solution 
transparent and the solution was allowed to stand under ambient conditions.  Green blocks, 8c, 
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suitable for X-ray diffraction were formed after a few days.  Mp  188-190˚C.  IR (KBr pellet): υ 
3453, 1677, 1447, 1427, 1403, 1366 cm-1. 
6.3 Results 
All hydrogen bond geometries are listed in Table 6.1.  A summary of the crystallographic 
information for each compound is displayed in Tables A.29-A.34. 
 
Table 6.1 Hydrogen bond geometries for 2i-2l and 8c-8d 
Compound D-H•••A D-H / Å H•••A / Å D•••A / Å <(DHA) / o 
2ii 
N(47)-H(47A)...O(24)#1 
N(47)-H(47B)...O(12)#2 
0.87(2) 
0.82(2) 
2.21(2) 
2.27(2) 
2.9963(19) 
3.0105(18) 
150.5(18) 
150(2) 
2jii N(87)-H(87A)...O(41)#3 0.88 2.27 2.943(2) 133.4 
8ciii 
N(47)-H(47A)...O(14) 
N(47)-H(47B)...O(12)#2 
0.82(2) 
0.85(2) 
2.61(2) 
2.38(2) 
3.2986(19) 
3.1466(18) 
143.2(19) 
150.0(19) 
2kiv 
N(27)-H(27A)...O(27)#2 
N(27)-H(27B)...O(48)#3 
0.88 
0.88 
1.99 
2.43 
2.859(3) 
3.098(3) 
168.8 
132.9 
2lv 
N(17)-H(17A)...O(31)#2 
N(17)-H(17B)...N(1S) 
0.87(4) 
0.80(4) 
2.24(4) 
2.26(4) 
3.086(3) 
3.045(4) 
164(3) 
167(4) 
8dvi 
N(27)-H(27A)...O(27)#2 
N(27)-H(27B)...O(31)#3 
0.78(2) 
0.81(2) 
2.16(2) 
2.47(2) 
2.9359(18) 
3.1634(18) 
172(2) 
144(2) 
(i) #1 -x+1,-y+1,-z+1, #2 x-1,y,z; (ii) #1 -x+1,-y+1,-z+1, #2 -x+2,-y,-z, #3 x,y+1,z; (iii) #1 -
x+1,-y+1,-z+1, #2 x,-y+3/2,z-1/2; (iv) #1 -x+1,-y+1,-z+1, #2 -x+1,-y,-z+1, #3 -x+1/2,y-1/2,-
z+1/2; (v) #1 -x+1,-y+2,-z, #2 -x+1,-y+1,-z+1; (vi) #1 -x+1,-y,-z, #2 -x,-y+2,-z+1, #3 -x+1,-
y+1,-z+1. 
6.3.1 Crystal structure of [4-(pyrazol-1-yl)methylbenzamide]bis-(hexafluoroacetyl 
acetonato)copper(II), 2i 
The complex ion in the crystal structure of 2i has a combination of both pyrazole N 
coordination to two copper ions (Cu-N, 2.0320(13) Å) as well as carbonyl O coordintion (Cu-O, 
2.2297(12) Å) from two 4-[(pyrazol-1-yl)methyl]benzamide ligands, 2.  This results in a 
metallocycle with a Cu•••Cu distance of approximately 10.3 Å, Figure 6.6.  Similarly, both syn 
and anti amide hydrogen atoms form hydrogen bonds to oxygen atoms of two hfacac ligands (N-
H•••O, 2.9963(19) and 3.0105(18) Å respectively). 
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Figure 6.6 Metallacycle observed in the crystal structure of 2i. 
6.3.2 Crystal structure of [4-(pyrazol-1-yl)methylbenzamide]bis-(dibenzoylmethanato) 
nickel(II), 2j 
The coordination complex, 2j, contains two different nickel(II) centres.  Two 4-[(pyrazol-
1-yl)methyl]benzamide ligands, 2, occupy the available axial positions via coordination through 
the pyrazole nitrogen (Ni-N 2.006(12) Å).  However, the amide does not form a self-
complementary homomeric hydrogen-bond dimer but instead an O-H•••O hydrogen bond (ca. 
2.733 Å) forms between the amide carbonyl and the ethanol hydroxyl group.  The syn-hydrogen 
atom of the amide forms a N-H•••O hydrogen bond (2.943(2) Å) to an acac oxygen atom, Figure 
6.7.  Ni•••Ni distances are approximately 10.5 Å. 
 
Figure 6.7 Part of the 1-D chain in the crystal structure of  2j. 
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6.3.3 Crystal structure of [3-(pyrazol-1-yl)methylbenzamide]bis-(hexafluoroacetylacetonato) 
copper(II), 8c 
The inorganic-organic hybrid species, 8c, is isostructural to 2i and comprises two hfacac 
ligands and two 3-[(pyrazol-1-yl)methyl]benzamide ligands, 8.  The hfacac ligands occupy three 
equatorial sites and one axial site of the octahedral copper(II) ion with  two 3-[(pyrazol-1-
yl)methyl]benzamide ligands occupying the two remaining coordination sites via pyrazole 
nitrogen coordination (Cu-N, 2.0040(13) Å) and amide carbonyl coordination (Cu-O, 1.9725(12) 
Å).    The amide carbonyl oxygen present on the pyrazole coordinating ligand and the pyrazole N 
on the amide coordinating ligand occupy the two free sites on a second copper(II) centre 
resulting in the formation of a metallocycle, Figure 6.8.  Additionally, both the syn and anti-
amide hydrogen atoms form hydrogen bonds to oxygen atom of the hfacac ligand (N-H•••O, 
3.2986(19) and 3.1466(18) Å repectively).  The two copper(II) ions present in the metallocycle 
are approximately  9.1 Å apart. 
 
Figure 6.8 Metallacycle observed in the crystal structure of 8c.  
6.3.4 Crystal structure of tetrakis(µ-2-fluorobenzoato-O,O’)-bis(4-(pyrazol-1-yl)methyl 
benzamide)-dicopper(II), 2k 
The inorganic-organic hybrid species, 2k, is comprised of two 4-[(pyrazol-1-
yl)methyl]benzamide ligands, 2, coordinating to the free axial sites of a copper(II) 2-
fluorobenzoate “paddle wheel” unit (Cu-N,  2.165(2) Å).  1-dimensional chains are produced 
through self-complementary homomeric amide-amide dimers via N-H•••O hydrogen bonds 
(2.859(3) Å) between the syn-hydrogen atom and the carbonyl oxygen of another amide, Figure 
6.9.  Additionally, the anti-hydrogen atom of the amide moiety interacts with a 2-fluoro benzoate 
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oxygen atom via a N-H•••O hydrogen bond (3.098(3) Å) and the Cu•••Cu distance within the 
“paddle wheel” unit is 2.6480(5) Å. 
 
Figure 6.9 Part of the 1-D chain observed in the crystal structure of 2k. 
6.3.5 Crystal structure of tetrakis(µ-acetato-O,O’)-bis(4-(pyrazol-1-yl)methylbenzamide)-
dicopper(II), 2l 
The complex ion in the crystal structure 2l contains two 4-[(pyrazol-1-
yl)methyl]benzamide ligands, 2, coordinating to the free axial sites of a copper(II) acetate 
“paddle wheel” unit (Cu-N,  2.191(2) Å).  The 1-dimensional chain is disrupted in this case, by 
the syn-hydrogen atom interacting with an acetate oxygen atom via a N-H•••N hydrogen bond 
(3.086(3) Å), Figure 6.10.  Acetonitrile is also present in the crystal structure, interacting with 
the anti-hydrogen atom of the amide moiety via a N-H•••N hydrogen bond (3.045(4) Å).  Cu•••Cu 
distance within the “paddle wheel” unit is 2.6282(5) Å. 
 
Figure 6.10 Primary non-covalent interactions observed in the crystal structure of 2l. 
6.3.6 Crystal structure of tetrakis(µ-acetato-O,O’)-bis(3-(pyrazol-1-yl)methylbenzamide)-
dicopper(II), 8d 
The coordination complex, 8d, consists of two 3-[(pyrazol-1-yl)methyl]benzamide 
ligands, 8, coordinating to the available axial positions of a copper(II) acetate “paddle wheel” 
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unit via the pyrazole nitrogen, (Cu-N,  2.1908(12) Å).  The complex is extended into 1-
dimensional chains through self complementary homomeric amide-amide dimers via N-H•••O 
hydrogen bonds (2.9359(18) Å) between the syn-hydrogen atom and the carbonyl oxygen of 
another amide, Figure 6.11.  Additionally, the anti-hydrogen atom of the amide moiety interacts 
with an acetate oxygen atom via a N-H•••O hydrogen bond (3.1634(18) Å) and the Cu•••Cu 
distance within the “paddle wheel” unit is 2.6596(3) Å. 
 
Figure 6.11 Part of the 1-D chain observed in the crystal structure of 8d. 
6.4 Discussion 
The connectivity observed in the six structures presented herein, indicate that a degree of 
control can be established, for the construction of 1-D chains.  However, complementing our 
results with existing crystallographic information will allow for a more thorough structural study 
to be carried out. 
These structures are accompanied by two acac coordination complexes obtained utilising 
4-[(2-methylbenzimidazol-1-yl)methyl]benzamide,10 Figure 6.12.  In addition, a CSD11 search of 
isonicotinamide and nicotinamide (a search of imidazole and pyrazole amide ligands yielded no 
hits) in the presence of an acac or “paddle wheel” metal complex, Table 6.3, gives a total of 25 
structures. 
 
 (a) 
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(b) 
Figure 6.12 Coordination complexes between 4-[(2-methylbenzimidazol-1-
yl)methyl]benzamide and (a) Co(DBM)2; (b) Ni(DBM)2.
10 
 
Table 6.2 Acac- and “paddle-wheel” coordination complexes of isonicotinamide and 
nicotinamide (CSD codes in bold in parentheses). 
Metal complex Desired metal 
coordination 
Amide-amide dimer 
yielding 1-D chain 
Isonicotinamide+Co(DBM)2+CHCl3 
(HAJPOY) 5d 
    
Isonicotinamide+Ni(DBM)2+PhBr 
(HAJPUE) 5d 
    
Isonicotinamide+Co(DBM)2+DMF 
(HAJQAL) 5d 
    
Isonicotinamide+Ni(DBM)2+CHCl3+THF 
(HAJQEP) 5d 
    
Isonicotinamide+Rh(OAc)2+(CH3)2O 
(BEDHEY) 9a 
    
Isonicotinamide+Cu(OAc)2+MeCN 
(EMAWAQ) 9b 
    
Isonicotinamide+Cu(OAc)2 
(TALKEX) 9c 
    
Nicotinamide+Rh(OAc)2+(CH3)2O 
(BEDHIC) 9c 
    
Nicotinamide+Cu(OAc)2 
(BENQEQ) 9d 
    
Nicotinamide+Cu(OAc)2 
(BENQAM) 9d 
    
Nicotinamide+Cu(OAc)2+H2O 
(BEXNOH01) 9e 
    
Nicotinamide+Zn(OAc)2+H2O 
(TAYFIJ) 9f 
    
Nicotinamide+Cu(OPr)2 
(VORWUV) 9g 
    
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Nicotinamide+Cu(OVal)2 
(GETQEC) 9h 
    
Nicotinamide+Cu(OHep)2 
(CAYHIT01) 9i 
    
Nicotinamide+Cu(OHep)2 
(CAYHIT) 9i 
    
Nicotinamide+Cu(ONon)2 
(CAYHUF) 9i 
    
4-[(2-methylbenzimidazol-1-yl) 
methyl]benzamide + Co(DBM)2+THF
10 
    
4-[(2-methylbenzimidazol-1-yl) 
methyl]benzamide + Ni(DBM)2+THF
10 
    
2i     
2j     
8c     
2k     
2l     
8d     
 
Analysis of the 25 data points gives a supramolecular yield of 88% for the desired 
coordination chemistry and geometry and a 68% supramolecular yield for the formation of an 
infinite 1-D chain, Figure 6.13.   
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Figure 6.13 Formation of desired 1-D architectures. 
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The nine structures that do not form the desirable architectures can be rationalised using 
three disruptive factors: 
 
I. The ability of the amide to coordinate to the metal  
Three structures in which the desired coordination chemistry was not attained (2i, 8c and 
BENQAM), demonstrate the issue associated with the amide binding directly to the metal ion 
via its C=O moiety, Figure 6.14.  Even though this is a potential interaction, the fact it only 
occurs in 12% of cases demonstrates the effectiveness of the supramolecular design.  
N N M
3/25 have undesired 
coordination chemistry 
and geometry
NH2
O O
H2N N
O
H2N  
Figure 6.14 Amide coordination to metal centre. 
 
II. The ability of the amide to hydrogen bond to the chelating ligands 
The amide•••amide interaction is disrupted in three cases (2l, TALKEX, and CAYHIT) 
due to an oxygen atom from an acetate ligand (as part of the ‘paddle-wheel’ complex) 
successfully competing for the attention of the syn-amide hydrogen atom, which prevents the 
formation of a 1-D chain, Figure 6.15. 
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Figure 6.15 Amide-acetate N-H•••O hydrogen bonding. 
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III. The ability of the amide to hydrogen bond to solvent molecules 
The presence of potentially disruptive solvent molecules is another factor shown to 
disrupt the desired architecture.  Many such compounds are capable of acting as hydrogen-bond 
donors/acceptors as well as coordinating to the metal.  Three cases discussed, 2j, (ethanol as a 
ligand), BEXNOH1, and TAYFIJ (both with non-coordinating H2O), all possess potential 
hydrogen bonding solvent molecules and in all three cases the amide•••amide synthon is 
disrupted, Figure 6.16.  This being said, the use of solvents that cannot partake in hydrogen 
bonding is feasible with nine of the structures presented in this study possessing the desired 1-D 
motif in the presence of solvents such as chloroform, acetonitrile, DMF, bromobenzene, acetone 
and THF. 
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Figure 6.16 Disruptive effect of (a) ethanol as a solvent and (b) water as a solvent. 
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CHAPTER 7 - Functionalised Bis-pyrazole Ligands: A Tool for 
Construction of Inorganic-organic Hybrid Materials 
 
7.1 Introduction 
Chelating ligands provide an avenue towards reliable assembly coordination networks.  
The use of ligands that can bind to a metal ion via two or more coordination sites has been 
exploited1 and offers an advantage for controlling and predicting coordination complexes.  
Figure 7.1 shows three examples within a diverse range of chelating ligands available. 
N N
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N N
N N
N N
H M
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H
R
O O
R
H
R
O
M(II)
 
    (a)                 (b)             (c) 
Figure 7.1 Examples of chelating ligands; (a) 2,2’-bipyridine;2 (b) trispyrazolylborate;3 (c) 
acetylacetonate.4 
 
2,2’-Bipyridine,2 trispyrazolylborate3 and acetylacetonate (acac)4 ligands have been 
utilised to ‘block off’ coordination sites of transition metals allowing for control over metal 
coordination, geometry and network dimensionality. 
It is clear then in order to gain an additional level of predictability, chelating ligands 
should be employed. 
1,3-Bis-benzylpyrazole, Figure 7.2a, is a potential chelating ligand as the flexible 
benzylpyrazole arms could allow a metal ion to “sit” between the two pyrazole rings.  1,3-Bis-
benzylpyrazole has been used to construct coordination polymers,5 however its use as a chelating 
ligand has been limited to organometallic compounds6 in which the C-H bond is replaced with a 
direct C-M bond, ‘locking’ the bis-pyrazole arms into position, Figure 7.2b. 
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   (a)           (b) 
Figure 7.2 1,3-Bis-benzylpyrazole as a chelating ligand in (a) coordination complexes and 
(b) organometallic compounds. 
 
2,6-Bis[(pyrazol-1-yl)methyl]pyridine,7 Figure 7.3, is an effective tridentate chelating 
ligand so it is feasible that 1,3-bisbenzylpyrazole can act as a bidentate chelating ligand. 
N
N N
N N
N
N N
N N
M
 
Figure 7.3 2,6-Bis[(pyrazol-1-yl)methyl]pyridine as a chelating ligand. 
 
If 1,3-bis-benzylpyrazole can be reliably used to coordinate a metal ion, appending a 
second functionality capable of either (i) coordination to a second metal or (ii) forming self-
complementary hydrogen bonds, Figure 7.4, would make construction of bimetallic systems and 
extended supramolecular coordination complexes possible. 
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Figure 7.4 Functionalised 1,3-bis-benzylpyrazole systems. 
  
With this in mind, a new family of SR’s will be designed to answer the following 
questions: 
 
I. Can functionalised 1,3-bis-benzylpyrazole ligands be employed as chelating ligands? 
 
Consequently, a family of ligands has been targeted in which 1,3-bis-benzylpyrazole is 
paired with a pyridyl or pyrazole functionality, Figure 7.5.  Through a series of metal-
coordination and organometallic reactions, the potential of 1,3-bis-benzylpyrazole as a chelating 
ligand (determined by single crystal X-ray diffraction and NMR) will be addressed. 
N N
N N
R
R R
R
R1
N N
NH2
NHN N
R1 =
R  = H or Me  
Figure 7.5  Target 1,3-bis-pyrazole SR’s.  
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7.2 Experimental 
7.2.1 Synthesis 
All chemicals were purchased from Aldrich and Fischer and used without further 
purification.  4-Iodopyrazole was synthesised via a previously published procedure.8  Melting 
points were determined on a Fisher-Johns melting point apparatus and are uncorrected. 
7.2.1.1 Synthesis of 1-bromo-3,5-bis(bromomethyl)benzene, 24 
Br Br
Br Br
NBS, AIBN, CCl4
 
To a round bottom flask, 1-bromo-3,5-dimethylbenzene (10.0g, 54.0mmol), N-
bromosuccinimide (NBS) (20.6g, 114mmol), azobisisobutyronitrile (AIBN) (0.460g, 2.80mmol) 
and CCl4 (150mL) were added and stirred at reflux for 3 hours.  The reaction was cooled to room 
temperature and the solution filtered to remove the succinimide.  The CCl4 filtrate was 
concentrated in vacuum and the resulting orange solid recrystallised from ethanol to give a white 
solid, 24, (5.38g, 30.0%). Mp: 84-86oC. 1H NMR (δH; 400MHz, CDCl3): 4.42 (s, 4H), 7.35 (s, 
1H), 7.48 (d, J = 2.8Hz, 2H), Figure B.24. 
7.2.1.2 Synthesis of 1-bromo-3,5-bis[(pyrazol-1-yl)methyl]benzene, 25 
Br
N N
N N
NaOH, THF, pyrazole
Br
Br Br
 
To a round bottom flask, pyrazole (5.40g, 79.0mmol) and THF (150mL) were added.  To 
this solution, NaOH pellets (32.0g, 790mmol) were added and the reaction was stirred at room 
temperature for 2 hours.  On completion, 24 (10.9g, 32.0mmol) in THF (150mL) was added and 
the reaction mixture stirred at room temperature for 2 days.  On completion, water was added to 
dissolve any excess NaOH, the organic layer was separated, dried over MgSO4 and the solvent 
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removed under vacuum to yield 25 as a white solid (8.73g, 86.6%).  Mp: 67-70oC.  1H NMR (δH; 
200MHz, CDCl3): 5.21 (s, 4H), 6.27 (t, J = 2.2Hz, 2H), 6.91 (s, 1H), 7.19 (s, 2H), 7.38 (d, J = 
2.2Hz, 2H), 7.54 (d, J = 1.8Hz, 2H), Figure B.25. 
7.2.1.3 Synthesis of 1-bromo-3,5-bis[(3,5-dimethylpyrazol-1-yl)methyl]benzene, 26 
Br
N N
N N
NaOH, THF
3,5-dimethylpyrazole
Br
Br Br
 
To a round bottom flask, 3,5-dimethylpyrazole (3.60g, 10.9mmol) and THF (75mL) were 
added.  To this solution, NaOH pellets (8.32g, 208mmol) were added and the reaction was stirred 
at room temperature for 2 hours.  On completion, 24 (1.20g, 20.8mmol) in THF (75mL) was 
added and the reaction mixture stirred at room temperature for 2 days.  On completion, water 
was added to dissolve any excess NaOH, the organic layer was separated, dried over MgSO4 and 
the solvent removed under vacuum to yield 26 as a white solid (3.86g, 95.0%).  Mp: 68-70oC.  
1H NMR (δH; 200MHz, CDCl3): 2.10 (s, 6H), 2.23 (s, 6H), 5.11 (s, 4H), 5.84 (s, 2H), 6.61 (s, 
1H), 7.06 (s, 2H), Figure B.26. 
7.2.1.4 Synthesis of 1-trimethylsilanylethynyl-3,5-bis[(pyrazol-1-yl)methyl]benzene, 27 
Br
N N
N N
N N
N N
TMS
TMSA, CuI, PPh3, NEt3
PdCl2(PPh3)2, THF, Reflux
 
THF (30mL) and NEt3 (30mL) were added to a round bottom flask and nitrogen bubbled 
through the solution for 10 minutes.  To this, 25 (2.0g, 6.3mmol), trimethylsilylacetylene 
(TMSA) (0.88g, 9.0mmol), CuI (0.036g, 0.19mmol), PPh3 (0.13g, 0.50mmol) and PdCl2(PPh3)2 
(0.13g, 0.19mmol) were added and the solution stirred at 75oC for 24 hours at which point more 
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trimethylsilylacetylene (0.88g, 9.0mmol), CuI (0.036g, 0.19mmol),  PPh3(0.13g, 0.50mmol) and 
PdCl2(PPh3)2 (0.13g, 0.19mmol) were added and stirred for a further 24 hours.  Upon 
completion, the solution was diluted with ethyl acetate and washed with water (3x25mL) and 
NaCl(aq) (25mL).  The ethyl acetate layer was separated, dried over MgSO4 and reduced to a 
brown oil.  The residue was purified by column chromatography (hexanes  hexanes:ethyl 
acetate; 1:1), to yield 27 as a brown oil, (2.00g, 92%).  1H NMR (δH; 200MHz, CDCl3): 0.21 (s, 
9H), 5.16 (s, 4H), 6.23 (t, J = 2Hz, 2H), 6.94 (s, 1H), 7.21 (s, 2H), 7.33 (d, J = 2.2Hz, 2H), 7.50 
(d, J = 1.4Hz, 2H), Figure B.27. 
7.2.1.5 Synthesis of 1-trimethylsilanylethynyl-3,5-bis[(3,5-dimethylpyrazol-1-
yl)methyl]benzene, 28 
TMSA, CuI, PPh3, NEt3
PdCl2(PPh3)2, THF, Reflux
Br
N N
N N
N N
N N
TMS
 
THF (30mL) and NEt3(30mL) were added to a round bottom flask and nitrogen bubbled 
through the solution for 10 minutes.  To this, 26 (2.00g, 5.35mmol), trimethylsilylacetylene 
(0.680g, 6.89mmol), CuI (0.0390g, 0.203mmol), PPh3 (0.110g, 0.422mmol) and PdCl2(PPh3)2 
(0.110g, 0.158mmol) were added and the solution stirred at 75oC for 24 hours at which point 
more trimethylsilylacetylene (0.680g, 6.89mmol) was added and stirred for a further 24 hours.  
Upon completion, the solution was diluted with ethyl acetate and washed with water (3x25mL) 
and NaCl(aq) (25mL).  The ethyl acetate layer was separated, dried over MgSO4 and reduced to a 
brown oil.  The residue was purified by column chromatography (hexanes  hexanes:ethyl 
acetate; 1:1), to yield 28 as a brown oil, (1.67g, 79.6%).  1H NMR (δH; 200MHz, CDCl3): 0.22 
(s, 9H), 2.08 (s, 6H), 2.23 (s, 6H), 5.11 (s, 4H), 5.83 (s, 2H), 6.61 (s, 1H), 7.09 (d, J = 0.6Hz, 
2H), Figure B.28. 
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7.2.1.6 Synthesis of 1-ethynyl-3,5-bis[(pyrazol-1-yl)methyl]benzene, 29 
N N
N N
H
N N
N N
TMS
K2CO3, MeOH
 
To a round bottom flask, 27 (1.74g, 5.18mmol), K2CO3 (0.716g, 5.18mmol) and 
methanol (40mL) were added and stirred at room temperature over night.  The solution was 
diluted with diethyl ether and washed with water (4x25mL).  The diethyl ether was separated, 
dried over MgSO4 and reduced to a white solid.  The solid was purified by column 
chromatography (hexanes  hexanes:ethyl acetate; 1:1), to yield 29 as a white solid, (1.02g, 
76.0%). Mp: 92-95oC. 1H NMR (δH; 200MHz, CDCl3): 3.05 (s, 1H), 5.24 (s, 4H), 6.29 (t, J = 
2.2Hz, 2H), 6.99 (s, 1H), 7.21 (s, 2H), 7.37 (d, J = 1.8Hz, 2H), 7.54 (d, J = 1.8Hz, 2H), Figure 
B.29. 
7.2.1.7 Synthesis of 1-ethynyl-3,5-bis[(3,5-dimethylpyrazol-1-yl)methyl]benzene, 30 
N N
N N
H
N N
N N
TMS
K2CO3, MeOH
 
To a round bottom flask, 28 (1.67g, 4.23mmol), K2CO3 (0.584g, 4.23mmol) and 
methanol (40mL) were added and stirred at room temperature over night.  The solution was 
diluted with diethyl ether and washed with water (4x25mL).  The diethyl ether was separated, 
dried over MgSO4 and reduced to a white solid.  The solid was purified by column 
chromatography (hexanes  hexanes:ethyl acetate; 1:1), to yield 30 as a white solid, (1.16g, 
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85.0%). Mp: 67-70oC. 1H NMR (δH; 200MHz, CDCl3): 2.08 (s, 6H), 2.22 (s, 6H), 3.05 (s, 1H), 
5.11 (s, 4H), 5.82 (s, 2H), 6.69 (s, 1H), 7.06 (s, 2H), Figure B.30. 
7.2.1.8 Synthesis of 1-[3,5-bis(pyrazol-1-ylmethyl)phenyl]-2-[pyridin-3-yl]ethyne, 31 
N N
N N
H
3-Iodopyridine, CuI, PPh3, NEt3
PdCl2(PPh3)2, THF, Reflux
N N
N N
N
 
THF (10mL) and NEt3(10mL) were added to a round bottom flask and nitrogen bubbled 
through the solution for 10 minutes.  To this, 29 (0.25g, 0.95mmol), 3-iodopyridine (0.16g, 
0.79mmol), CuI (0.0060g, 0.030mmol), PPh3 (0.016g, 0.063mmol) and PdCl2(PPh3)2 (0.016g, 
0.023mmol) were added and the solution stirred at 75oC for 24 hours.  Upon completion, the 
solution was diluted with ethyl acetate and washed with water (3x25mL) and NaCl(aq) (25mL).  
The ethyl acetate layer was separated, dried over MgSO4 and reduced to a brown oil.  The 
residue was purified by column chromatography (hexanes  hexanes:ethyl acetate; 1:1), to yield 
a yellow solid.  Recrystallisation from ethanol yielded 31 as a white solid (0.23g, 85%).  Mp: 54-
56oC.  1H NMR (δH; 200MHz, CDCl3): 5.30 (s, 4H), 6.31 (t, J = 2.2Hz, 2H), 7.03 (s, 1H), 7.21-
7.31 (m, 3H), 7.42 (d, J = 1.4Hz, 2H), 7.57 (d, J = 1.4Hz, 2H), 7.76 (dt, J1 = 8Hz, J2 = 1.8Hz, 
1H), 8.54 (dd, J1 = 5.0Hz, J2 = 1.6Hz, 1H), 8.72 (d, J = 2.2Hz, 1H), Figure B.31a; 13C NMR, (δC; 
50MHz, CDCl3): 55.22, 86.80, 91.67, 106.29, 123.06, 123.75, 126.93, 129.47, 130.18, 130.80, 
137.89, 138.49, 139.97, 148.76,152.22, Figure B.31b. 
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7.2.1.9 Synthesis of 1-[3,5-bis(3,5-dimethylpyrazol-1-ylmethyl)phenyl]-2-[pyridin-3-yl]ethyne, 
32 
N N
N N
H
3-Iodopyridine, CuI, PPh3, NEt3
PdCl2(PPh3)2, THF, Reflux
N N
N N
N
 
THF (10mL) and NEt3(10mL) were added to a round bottom flask and nitrogen bubbled 
through the solution for 10 minutes.  To this, 30 (0.25g, 0.79mmol), 3-iodopyridine (0.13g, 
0.66mmol), CuI (0.0050g, 0.0025mmol), PPh3 (0.014g, 0.052mmol) and PdCl2(PPh3)2 (0.014g, 
0.019mmol) were added and the solution stirred at 75oC for 24 hours.  Upon completion, the 
solution was diluted with ethyl acetate and washed with water (3x25mL) and NaCl(aq) (25mL).  
The ethyl acetate layer was separated, dried over MgSO4 and reduced to a brown oil.  The 
residue was purified by column chromatography (hexanes  hexanes:ethyl acetate; 1:1), to yield 
32 as a yellow solid, (0.19g, 57 %).  Mp: 75-78oC.  1H NMR (δH; 200MHz, CDCl3): 2.13 (s, 6H), 
2.25 (s, 6H), 5.16 (s, 4H), 5.86 (s, 2H), 6.73 (s, 1H), 7.13 (d, J = 1.6Hz, 2H), 7.26 (dd, J1 = 
7.6Hz, J2 = 2.6Hz, 1H), 7.78 (dt, J1 = 7.6Hz, J2 = 2.0Hz, 1H), 8.53 (d, J = 3.6Hz, 1H), 8.73 (d, J = 
1.4Hz, 2H), Figure B.32a;  13C NMR, (δC; 100MHz, CDCl3): 11.10, 13.53, 51.89, 86.43, 92.09, 
105.75, 120.16, 123.05, 123.41, 125.28, 128.79, 138.46, 138.50, 139.26, 147.88, 148.62, 152.15, 
Figure B.32b. 
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7.2.1.10 Synthesis of 1-[3,5-bis(pyrazol-1-ylmethyl)phenyl]-2-[2-aminopyridin-5-yl]ethyne, 33 
N N
N N
H
N N
N N
N
2-Amino-5-iodopyridine, CuI, PPh3,
NEt3, PdCl2(PPh3)2, THF, Reflux
NH2
 
THF (25mL) and NEt3(25mL) were added to a round bottom flask and nitrogen bubbled 
through the solution for 10 minutes.  To this, 29 (0.50g, 1.90mmol), 2-amino-5-iodopyridine 
(0.35g, 1.6mmol), CuI (0.012g, 0.060mmol), PPh3 (0.033g, 0.13mmol) and PdCl2(PPh3)2 
(0.033g, 0.047mmol) were added and the solution stirred at 75oC for 24 hours.  Upon 
completion, the solution was diluted with ethyl acetate and washed with water (3x50mL) and 
NaCl(aq) (50mL).  The ethyl acetate layer was separated, dried over MgSO4 and reduced to a 
brown oil.  The residue was purified by column chromatography (hexanes  hexanes:ethyl 
acetate; 1:1), to yield 33 as a yellow solid, (0.30g, 53%).  Mp: 148-151oC.  1H NMR (δH; 
200MHz, CDCl3): 4.72 (s, 2H), 5.28 (s, 4H), 6.30 (t, J = 2.0Hz, 2H), 6.45 (d, J = 8.6Hz, 1H), 
6.98 (s, 1H), 7.25 (d, J = 1.2Hz, 2H), 7.40 (d, J = 2.2Hz, 2H), 7.48 (d, J = 2.6Hz, 1H), 7.53 (d, J 
= 2.6Hz, 1H), 7.56 (d, J = 2.0Hz, 1H), 8.22 (d, J = 2.2Hz, 1H), Figure B.33a; 13C NMR, (δC; 
50MHz, CDCl3): 55.28, 89.00, 106.21, 107.99, 109.28, 124.59, 126.20, 129.41, 129.88, 130.76, 
137.65, 139.84, 140.37, 151.34, 157.57, Figure B.33b. 
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7.2.1.11 Synthesis of 1-[3,5-bis(3,5-dimethylpyrazol-1-ylmethyl)phenyl]-2-[2-aminopyridin-5-
yl]ethyne, 34 
N N
N N
H
2-Amino-5-iodopyridine, CuI, PPh3,
NEt3, PdCl2(PPh3)2, THF, Reflux
N N
N N
N
NH2
 
THF (10mL) and NEt3(10mL) were added to a round bottom flask and nitrogen bubbled 
through the solution for 10 minutes.  To this, 30 (0.25g, 7.9mmol), 2-amino-5-iodopyridine 
(0.14g, 0.66mmol), CuI (0.0050g, 0.025mmol), PPh3 (0.014g, 0.052mmol) and PdCl2(PPh3)2 
(0.014g, 0.019mmol) were added and the solution stirred at 75oC for 24 hours.  Upon 
completion, the solution was diluted with ethyl acetate and washed with water (3x50mL) and 
NaCl(aq) (50mL).  The ethyl acetate layer was separated, dried over MgSO4 and reduced to a 
brown oil.  The residue was purified by column chromatography (hexanes  hexanes:ethyl 
acetate; 1:1), to yield 34 as a yellow solid, (0.18g, 67%).  Mp: 122-125oC.  1H NMR (δH; 
200MHz, CDCl3): 2.12 (s, 6H), 2.24 (s, 6H), 5.15 (s, 4H), 5.85 (s, 2H), 6.44 (dd, J
1 = 8.6Hz, J2 = 
0.8Hz, 1H), 6.66 (s, 1H), 7.07 (s, 2H), 7.51 (dd, J1 = 8.6Hz, J2 = 2.2Hz, 1H), 8.15 (d, J = 2.8Hz, 
1H), Figure B.34a;  13C NMR, (δC; 100MHz, DMSO-d
6): 10.38, 13.11, 50.76, 104.90, 107.48, 
123.88, 124.95, 127.89, 128.48, 131.22, 133.98, 138.66, 139.19, 146.04, 150.34, 151.06, 159.10, 
Figure B.34b. 
7.2.1.12 Synthesis of 1-(1-butoxyethyl)-4-iodopyrazole, 35 
N NH
I
N N
I
O
Butyl vinyl ether
conc. HCl, benzene
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To a round bottom flask, 4-iodopyrazole (0.250g, 1.29mmol), butyl vinyl ether (0.34g, 
3.38mmol), conc. HCl (1 drop) and benzene (10mL) were added and the reaction stirred at 35oC 
for 2 hours.  NaHCO3 and K2CO3 added to the reaction and the benzene extracted, dried over 
MgSO4 and reduced to yield 35 as a colourless oil, (0.349g, 92.1%).  
1H NMR (δH; 200MHz, 
CDCl3): 0.86 (t, J = 7.4Hz, 3H), 1.25-1.56 (m, 4H), 1.62 (d, J = 6.2Hz, 3H), 3.20-3.46 (m, 2H), 
5.48 (q, J = 6.2Hz, 1H), 7.50 (s, 1H), 7.63 (s, 1H), Figure B.35. 
7.2.1.13 Synthesis of 1-[3,5-bis(pyrazol-1-ylmethyl)phenyl]-2-[1-(1-butoxyethyl)-pyrazol-4-
yl]ethyne, 36 
N N
N N
H
NN
NN
25, CuI, PPh3,NEt3, 
PdCl2(PPh3)2, THF, Reflux
N N
O
 
THF (25mL) and NEt3(25mL) were added to a round bottom flask and nitrogen bubbled 
through the solution for 10 minutes.  To this, 29 (0.50g, 1.9mmol), 35 (0.48g, 1.6mmol), CuI 
(0.012g, 0.060mmol), PPh3 (0.033g, 0.13mmol) and PdCl2(PPh3)2 (0.033g, 0.047mmol) were 
added and the solution stirred at 75oC for 24 hours.  Upon completion, the solution was diluted 
with ethyl acetate and washed with water (3x50mL) and NaCl(aq) (50mL).  The ethyl acetate 
layer was separated, dried over MgSO4 and reduced to a brown oil.  The residue was purified by 
column chromatography (hexanes  hexanes:ethyl acetate; 1:1), to yield 36 as a yellow oil, 
(0.36g, 51%).  1H NMR (δH; 200MHz, CDCl3): 0.87 (t, J = 7.2Hz, 3H), 1.22-1.54 (m, 4H), 1.64 
(d, J = 6.2Hz, 3H), 3.21-3.46 (m, 2H), 5.27 (s, 4H), 5.48 (q, J = 6.2Hz, 1H), 6.29 (t, J = 2.0Hz, 
2H), 6.98 (s, 1H), 7.22 (s, 2H), 7.39 (s, 2H), 7.55 (d, J = 1.8Hz, 2H), 7.63 (s, 1H), 7.75 (s, 1H), 
Figure B.36. 
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7.2.1.14 Synthesis of 1-[3,5-bis(3,5-dimethylpyrazol-1-ylmethyl)phenyl]-2-[1-(1-butoxyethyl)-
pyrazol-4-yl]ethyne, 37 
N N
N N
H
N N
N N
N N
O
25, CuI, PPh3,NEt3, 
PdCl2(PPh3)2, THF, Reflux
 
THF (25mL) and NEt3(25mL) were added to a round bottom flask and nitrogen bubbled 
through the solution for 10 minutes.  To this, 30 (0.53g, 1.7mmol), 35 (0.41g, 1.4mmol), CuI 
(0.010g, 0.053mmol), PPh3 (0.029g, 0.11mmol) and PdCl2(PPh3)2 (0.029g, 0.041mmol) were 
added and the solution stirred at 75oC for 24 hours.  Upon completion, the solution was diluted 
with ethyl acetate and washed with water (3x50mL) and NaCl(aq) (50mL).  The ethyl acetate 
layer was separated, dried over MgSO4 and reduced to a brown oil.  The residue was purified by 
column chromatography (hexanes  hexanes:ethyl acetate; 1:1), to yield 37 as a yellow oil, 
(0.21g, 30%).  1H NMR (δH; 200MHz, CDCl3): 0.87 (t, J = 7.4Hz, 3H), 1.25-1.58 (m, 4H), 1.64 
(d, J = 5.8Hz, 3H), 2.12 (s, 3H), 2.24 (s, 3H), 3.21-3.46 (m, 2H), 5.14 (s, 4H), 5.48 (q, J = 6.2Hz, 
1H), 5.84 (s, 2H), 6.68 (s, 1H), 7.07 (d, J = 2.4Hz, 2H), 7.51 (s, 1H), 7.63 (s, 1H), Figure B.37. 
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7.2.1.15 Synthesis of 1-[3,5-bis(pyrazol-1-ylmethyl)phenyl]-2-[pyrazol-4-yl]ethyne, 38 
N N
N N
N NH
N N
N N
N N
O
conc. HCl, MEOH
 
To a round bottom flask, 36 (0.36, 0.84mmol), chloroform (50mL), water (12.5mL) and 
conc. HCl (2.5mL) were added and stirred at room temperature overnight.  The solution was 
neutralized with NaHCO3 and the organic layer separated.  The aqueous layer was washed with 
chloroform, the organic extracts combined, dried over MgSO4 and reduced to yield 38 as a 
yellow solid, (0.25g, 90%).  Mp: 76-79oC. 1H NMR (δH; 200MHz, CDCl3): 5.27 (s, 4H), 6.30 (t, 
J = 2.2Hz, 2H), 6.96 (s, 1H), 7.22 (d, J = 1.4Hz, 2H), 7.41 (d, J = 2.6Hz, 2H), 7.57 (d, J = 1.4Hz, 
2H), 7.70 (s, 2H), Figure B.38a; 13C NMR, (δC; 100MHz, CDCl3): 55.30, 106.25, 124.65, 126.23, 
128.47, 128.58, 129.92, 131.97, 132.06, 132.16, 137.67, 139.91, Figure B.38b. 
7.2.1.16 Synthesis of 1-[3,5-bis(3,5-dimethylpyrazol-1-ylmethyl)phenyl]-2-[pyrazol-4-
yl]ethyne, 39 
conc. HCl, MEOH
N N
N N
N NH
N N
N N
N N
O
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To a round bottom flask, 37 (0.21, 0.55mmol), chloroform (33mL), water (8.2mL) and 
conc. HCl (1.65mL) were added and stirred at room temperature for 2 days.  The solution was 
neutralized with NaHCO3 and the organic layer separated.  The aqueous layer was washed with 
chloroform, the organic extracts combined, dried over MgSO4 and reduced to yield 39 as a white 
solid, (0.12g, 69%).  Mp: 195-198oC. 1H NMR (δH; 200MHz, CDCl3): 2.11 (s, 3H), 2.24 (s, 3H), 
5.13 (s, 4H), 5.85 (s, 2H), 6.65 (s, 1H), 7.05 (s, 2H), 7.68 (s, 2H), Figure B.39a; 13C NMR, (δC; 
50MHz, CDCl3): 11.07, 13.49, 51.93, 89.27, 105.70, 124.29, 124.57, 128.42, 128.66, 131.92, 
132.11, 138.14, 139.33, 147.78, Figure B.39b. 
7.2.1.17 Synthesis of 1-iodo-3,5-bis(bromomethyl)benzene, 40 
I I
Br Br
NIS, AIBN, Benzene
 
To a round bottom flask, 1-iodo-3,5-dimethylbenzene (1.068g, 6.93mmol), N-
iodosuccinimide (NIS) (2.70g, 15.2mmol), AIBN (0.230g, 1.39mmol) and benzene (50mL) were 
added and stirred at reflux for 3 hours.  The reaction was cooled to room temperature and the 
solution filtered to remove the succinimide.  The benzene filtrate was removed in vacuum and 
the resulting red solid was recrystallised from ethanol.  The resulting white solid was collected 
by filtration to yield 40, (0.962g, 35.5%). Mp: 93-96oC. 1H NMR (δH; 400MHz, CDCl3): 4.38 (s, 
4H), 7.38 (s, 1H), 7.67 (s, 2H), Figure B.40. 
7.2.1.18 Synthesis of 1-iodo-3,5-bis[(pyrazol-1-yl)methyl]benzene, 41 
I
N N
N N
NaOH, THF, pyrazole
I
Br Br
 
To a round bottom flask, pyrazole (0.183g, 2.69mmol) and THF (25mL) were added.  To 
this solution, NaOH pellets (1.08g, 26.9mmol) were added and the reaction was stirred at room 
temperature for 2 hours.  On completion, 40 (0.486g, 1.25mmol) in THF (25mL) was added and 
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the reaction mixture stirred at room temperature for 2 days.  On completion, water was added to 
dissolve any excess NaOH, the organic layer was separated, dried over MgSO4 and the solvent 
removed under vacuum to yield 41 as a white solid (0.390g, 85.7%).  Mp: 58-61oC.  1H NMR 
(δH; 200MHz, CDCl3): 5.19 (s, 4H), 6.27 (t, J = 2.2Hz, 2H), 6.94 (s, 1H), 7.36 (d, J = 2.2Hz, 
2H), 7.41 (d, J = 1.4Hz, 2H), 7.53 (d, J = 1.0Hz, 2H), Figure B.41. 
7.2.1.19 Synthesis of [1-(pyridin-3-yl)-3,5-bis(pyrazol-1-ylmethyl)phenyl], 42 
N N
N N
I
N N
N N
3-pyridylboronic acid,
Pd(PPh3)2Cl2,
Na2CO3, MeCN, H2O
N
 
MeCN (15mL) and water (15mL) were added to a round bottom flask and nitrogen 
bubbled through the solution for 10 minutes.  To this, 41 (0.390g, 1.07mmol), 3-pyridylboronic 
acid (0.189g, 1.54mmol), Na2CO3 (0.246g, 2.32mmol) and PdCl2(PPh3)2 (0.0186g, 0.0265mmol) 
were added and the solution stirred at 75oC for 48 hours.  Upon completion, the solution was 
diluted with ethyl acetate and washed with water (3x50mL) and NaCl(aq) (50mL).  The ethyl 
acetate layer was separated, dried over MgSO4 and reduced to a brown oil.  The residue was 
purified by column chromatography (hexanes  hexanes:ethyl acetate; 1:1), to yield 42 as a 
yellow solid, (0.217g, 64.4%).  Mp: 40-43oC.  1H NMR (δH; 200MHz, CDCl3): 5.36 (s, 4H), 6.29 
(t, J = 2.2Hz, 2H), 7.07 (s, 1H), 7.29 (s, 2H), 7.35 (dd, J1 = 4.4Hz, J2 = 2.4Hz, 1H), 7.44 (d, J = 
2.2Hz, 2H), 7.56 (d, J = 2.2Hz, 2H), 7.79 (dt, J1 = 8.2Hz, J2 = 2.0Hz, 1H), 8.56 (d, J = 4.8Hz, 
1H), 8.74 (d, J = 1.8Hz, 1H), Figure B.42a; 13C NMR, (δC; 50MHz, CDCl3): 55.33, 106.22, 
123.73, 125.79, 126.26, 129.57, 134.84, 135.85, 138.45, 138.76, 139.82, 147.61, 148.23, Figure 
B.42b. 
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7.2.1.20 Synthesis of chloro[4-(pyridin-3-yl)-2,6-bis[(pyrazol-1-yl-αN2methyl)phenyl-αC]-
palladium(II)], 43 
N N
N N
1) Pd(OAc)2, AcOH
N
N N
N N
N
Pd
Cl
2) Acetone/H2O, LiCl
 
 
To a round bottom flask, 42 (0.031g, 0.099mmol), Pd(OAc)2 (0.027g, 0.12mmol) and 
acetic acid (5mL) were added and stirred at reflux for 2 days.  Upon completion, the solution was 
reduced under vacuum to give a brown solid.  The solid was redissolved in acetone/water 
(3mL/2mL) and stirred in the presence of LiCl (0.025g, 0.59mmol) at room temperature for 2 
days.  Upon completion, the solution was filtered to yield 43 as a brown solid (0.045g, 100%). 
Mp: >300oC. 1H NMR (δH; 200MHz, CDCl3): 5.55 (s, 4H), 6.47 (s, 2H), 7.50 (s, 3H), 7.94 (s, 
2H), 8.06 (d, 8Hz, 1H), 8.20 (s, 2H), 8.58 (s, 1H), 8.88 (s, 1H), Figure B.43. 
7.2.1.21 Synthesis of 1-[3,5-bis(pyrazol-1-ylmethyl)phenyl]-2-[pyridin-3-yl]ethyne cobalt(II) 
dichloride, 31a 
20 (0.025mg, 0.074mmol) and CoCl2 (0.0060mg, 0.025mmol) were added to a beaker 
and dissolved in acetonitrile.  Blue plates suitable for X-ray diffraction were obtained after a few 
days. Mp: >300oC.  IR (KBr pellet): υ 3112, 2919, 2217, 1627, 1414, 1275, 1070, 765. 
7.2.1.22 Synthesis of 1-[3,5-bis(pyrazol-1-ylmethyl)phenyl]-2-[2-aminopyridin-5-yl]ethyne 
silver(I) hexafluorophosphate, 33a 
22 (0.010g, 0.028mmol) and AgPF6 (0.0071mg, 0.028mmol) were added to a beaker and 
dissolved in acetonitrile.  Colourless rods suitable for X-ray diffraction were obtained after a few 
days. Mp: 245-248oC (dec).  IR (KBr pellet): υ 3426, 3192, 2914, 2213, 1634, 1511, 1296, 1137, 
840. 
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7.3 Results 
All hydrogen-bond geometries for 33 are listed in Table 7.1.  A summary of the 
crystallographic information for each compound is displayed in Tables A35-A37. 
 
Table 7.1 Hydrogen-bond geometries for 33. 
Compound D-H•••A D-H / Å H•••A / Å D•••A / Å <(DHA) / o 
33i 
N(36)-H(36A)...N(31)#1 
N(36)-H(36B)...N(52)#2 
0.945(18) 
0.901(18) 
2.047(18) 
2.335(17) 
2.9875(16) 
3.0192(16) 
173.1(14) 
132.8(14) 
(i) #1 -x,-y,-z+2, #2 -x+1,-y,-z+1. 
7.3.1 Crystal structure of 1-[3,5-bis(pyrazol-1-ylmethyl)phenyl]-2-[2-aminopyridin-5-
yl]ethyne, 33 
The crystal structure of 33 shows two symmetry related N-H•••N hydrogen bonds 
(3.0192(16) Å) between the anti hydrogen atom of the amino group and the pyrazole nitrogen 
atom resulting in a )28(R22 motif, Figure 7.6.   The homomeric aminopyridine )8(R
2
2 dimer also 
forms via two symmetry related N-H•••N hydrogen bonds (2.9875(16) Å) which extends the 
network. 
 
Figure 7.6 Section of the extended network observed in the crystal structure of 33 via N-
H•••N hydrogen bonds ( )28(R22 motifs are highlighted). 
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7.3.2 Crystal structure of [1-[3,5-bis(pyrazol-1-ylmethyl)phenyl]-2-[pyridin-3-
yl]ethyne]cobalt(II) dichloride, 31a 
The complex ion in the crystal structure of 31a has a combination of both pyrazole N and 
pyridine N coordination to two symmetry related tetrahedral cobalt(II) ions (Co-N, 2.033(3) Å 
and 2.022(3) Å respectively).  Coordination from two 1-[3,5-bis(pyrazol-1-ylmethyl)phenyl]-2-
[pyridin-3-yl]ethyne ligands, 31, results in a metallacycle with a Co•••Co distance of 
approximately 11.5 Å, Figure 7.7.  The two remaining sites on the cobalt ion are occupied by 
chloride ions (Co-Cl, 2.2253(14) Å and 2.2468(12) Å, respectively). 
 
Figure 7.7 Metallacycle observed in the crystal structure of 31a. 
7.3.3 Crystal structure of [1-[3,5-bis(pyrazol-1-ylmethyl)phenyl]-2-[2-aminopyridin-5-
yl]ethyne]silver(I) hexafluorophosphate, 33a 
The complex ion in the crystal structure of 33a has a combination of both pyrazole N and 
pyridine N coordination to two symmetry related tetrahedral silver(I) ions (Ag-N, 2.331(8) Å and 
2.273(7) Å respectively).  Coordination from two 1-[3,5-bis(pyrazol-1-ylmethyl)phenyl]-2-[2-
aminopyridin-5-yl]ethyne ligands, 33, results in a metallacycle with an Ag•••Ag distance of 
approximately 11.5 Å, Figure. 7.8.  The two remaining sites on the silver ion are occupied by an 
acetonitrile solvent molecule (Ag-N, 2.474(11) Å) and a pyrazole N from a third 1-[3,5-
bis(pyrazol-1-ylmethyl)phenyl]-2-[2-aminopyridin-5-yl]ethyne, 33, ligand (Ag-N, 2.306(7) Å) 
which results in a 1D chain of metallacycles. 
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Figure 7.8 Extended metallacycle observed in the crystal structure of 33a (hydrogen atoms 
and acetonitrile molecules have been removed for clarity). 
7.4 Discussion 
7.4.1 Assessing 1,3-bis-benzylpyrazole as a potential chelating ligand 
In the two coordination complexes presented, a metallacycle is formed between two 
tetrahedral metal ions and two bis-pyrazole ligands, Figure 7.9a.  The observed cyclic 
arrangement is consistent with the structure observed for ligand 33, Figure 7.9b. 
R  = H or NH2
N
N
N
N
N
N
N
N
N
N
M R
R M
 
       (a)                (b) 
Figure 7.9 (a) Metallacycle observed in the crystal structures of 31a and 33a; (b) 
)28(R22 motif observed in the crystal structure of 33. 
N
H
N
N
N
N
N
N
N
N
N
N
N
H
H
H
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The coordination complexes 31a and 33a show that 1,3-bis-benzylpyrazole based species 
cannot act as chelating ligands in coordination complexes, which is supported by the 
coordination polymers previously constructed.5  The metallacycle products observed are 
attributed to (i) the competitive coordination of the pyridyl moiety and (ii) the steric bulk of the 
aromatic C(4)-H group located between the methylene bridges, which forces the pyrazole arms 
into an anti-parallel fashion, Figure 7.10. 
   
       (a)         (b)  
Figure 7.10 Steric bulk of aromatic C-H group; (a) ligand 31 from crystal structure of 31a and 
(b) ligand 33 observed in crystal structure. 
 
When compared to the structurally similar 2,6-bis[(pyrazol-1-yl)methyl]pyridine,7 it is 
clear the C(4)-H group plays a major role in controlling coordination complexes with 2,6-
bis[(pyrazol-1-yl)methyl]pyridine able to act as a chelating ligand and 1,3-bis-benzylpyrazole 
not, Figure 7.11. 
N
N N
N N
M N N
N N
H
M M
 
 (a)               (b) 
Figure 7.11 2,6-bis[(pyrazol-1-yl)methyl]pyridine (a) compared to 1,3-bis-benzylpyrazole (b). 
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7.4.2 ‘Locking’ the 1,3-bis-benzylpyrazole arms 
In order to utilise 1,3-bis-benzylpyrazole as a chelating ligand, the pyrazole arms were 
locked into place by formation of the organometallic product. 
However, in ligands containing an ethynyl spacer, the desired organometallic product 
was not formed, due to coordination of the ethynyl group, Figure 7.12. 
N
N
N
NN
Pd
 
Figure 7.12 Undesirable side product of organometallic reaction. 
 
Consequently, ligand 42 was designed and synthesised, which removed the competition 
of the ethynyl group allowing for successful M-C bond formation while retaining the pyridyl 
coordination site, Figure 7.13.   
N N
N N
1) Pd(OAc)2, AcOH
N
N N
N N
N
Pd
Cl
2) Acetone/H2O, LiCl
42 43  
Figure 7.13 Formation of the ‘locked’ chelate organometallic system. 
 
Analysis of the 1H NMR spectra of 42 and 43 confirms the formation of the 
organometallic species due to the disappearance of the C(4)-H peak at 7.07ppm, Figure 7.14.  
Also, minimal shifts in the pyridyl protons at 8.56 and 8.74ppm confirm that the pyridine is not 
coordinating to the palladium. 
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Figure 7.14 1H NMR spectra of (a) 42 and (b) 43. 
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Structural analysis of two coordination complexes 31a and 33a and NMR analysis of 43 
paired with previous studies of bis-benzylpyrazole ligands have provided an answer to the 
question addressed at the beginning of this chapter. 
 
I. Can functionalised 1,3-bis-benzylpyrazole ligands be employed as chelating ligands? 
1,3-Bis-benzylpyrazole does not act as chelating ligand in coordination complexes due to 
steric hindrance from C(4)-H.  In cases when no second metal coordination site is present5 the 
product of the reaction with a metal ion is a coordination polymer, Figure 7.14a, however it 
seems when a second coordination site is available (i.e. a pyridyl functionality) the most 
favorable arrangement is a metallacycle, Figure 7.14b. 
1,3-Bis-benzylpyrazole is successfully employed as a chelating ligand by forming the 
neutral organometallic species,6 Figure 7.14c.  By forming a Pd-C, the steric interference of the 
C(4)-H group is removed and the pyrazole arms are locked into position, leaving the second 
coordination site free. 
N N
N N
Metal coordintion 
reaction
N N
N N
M NN
NN
MM
 
(a) 
R  = H or NH2
N N
N N
N
R
R  = H or NH2
Metal coordintion reaction
Metallacycle forms in all cases
N
N
N
N
N
N
N
N
N
N
M R
R M
(b) 
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N N
N N
N
N N
N N
N
Pd
Cl
Organometallic reaction
Organometallic compex 
locks chelate into position
Pyridyl free to 
coordinate to 
a second metal
 
(c) 
Figure 7.15 1,3-Bis-benzylpyrazole based ligands in (a) coordination polymers, (b) 
coordination complexes and (c) organometallic species. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 137
                                                                                                                                                             
References 
 
1. A search in Sci-Finder of the term “chelate” gave 51995 hits.  Some elegant examples of 
chelating ligands: (a) M. Fujita, J. Yazaki and K. Ogura, J. Am. Chem. Soc., 1990, 112, 5645; 
(b) M. Fujita, D. Oguro, M. Miyazawa, H. Oka, K. Yamaguchi, and K. Ogura, Nature, 1995, 
378, 469; (c) J. A. Casares, P. Espinet, K. Soulantica, I. Pascual and G. A. Orpen, Inorg. 
Chem., 1997, 36, 5251; (d) M. Chas, D. Abella, V. Blanco, E. Pia, G. Blanco, A. Fernandez, 
C. Plata-Iglesias, C. Peinador and J. M. Carlos, Chem.-Eur. J., 2007, 13, 8572; (e) V. Carlos, 
M. Chas, D. Abella, C. Peinador, J. M. Quintela, J. Am. Chem. Soc., 2007, 129, 13978; (f) M. 
Yoshizawa, M. Tamura and M. Fujita, Angew. Chem. Int. Ed., 2007, 46, 3874; (g) Y. 
Nishioka, T. Yamaguchi, M. Yoshizawa and M. Fujita, J. Am. Chem. Soc., 2007, 129, 7000; 
(h) T. M. Fyles and C. C. Tong, New J. Chem., 2007, 31, 655; (i) D. K. Chand, K. Birhada, 
M. Kawano, S. Sakamoto, Y. Shigeru, K. Yamaguchi and M. Fujita, Chem. Asian J., 2006, 1, 
82; (j) R. Mukherjee, Coord. Chem. Rev., 2000, 203, 151 and references therein; (k) M. 
Heller and U. S. Schubert, Eur. J. Org. Chem., 2003, 947 and references therein; (l) J. I. van 
der Vlugt, S. Demeshko, S. Dechert and F. Meyer, Inorg. Chem., 2008, 47, 1576; (m) S. 
Vargas-Matinez, S. Ortega-Hernandez, R. A. Toscano, D. Salazar-Mendoza and J. Valdés-
Martínez, CrystEngComm., 2008, 10, 86; (n) J. P. Sauvage and C. O. Dietrick-Buchecker, 
Chem. Rev., 1987, 87, 795; (o) J. P. Sauvage, Acc. Chem. Res., 1998, 31, 611; (p) M. Fujita, 
M. Aoyagi, F. Ibukuro, K. Ogura and K. Yamaguchi, J. Am. Chem. Soc., 1998, 120, 611.  
2. (a) R. E. Marsh, M. Kapon, S. Hu, F. H. Herbstein, Acta Crystallogr., Sect.B, 2002, 58, 62; 
(b) J. A. Smith, J. –R. Galan-Mascaros, R. Clerac, J. –S. Sun, X. Ouyang, K. R. Dunbar, 
Polyhedron, 2001, 20, 1727; (c) Y. Rodriguez-Martin, J. Gonzalez-Platas, C. Ruiz-Perez, 
Acta Crystallogr., Sect.C, 1999, 55, 1087; (d) D. J. Chesnut, R. C. Haushalter, J. Zubieta, 
Inorg. Chim. Acta, 1999, 292, 41; (e) Z. Qin, M. C. Jennings, R. J. Puddephatt, Inorg. Chem., 
2001, 40, 6220; (f) M. Yoshizawa, T. Kusukawa, M. Kawano, T. Ohhara, I. Tanaka, K. 
Kurihara, N. Niimura, M. Fujita, J. Am. Chem. Soc., 2005, 127, 2798; (g) J. A. R. Navarro, 
M. A. Romero and J. M. Salas, J. Chem. Soc., Dalton Trans., 1997, 1001; (h) J. A. R. 
Navarro, M. A. Romero, J. M. Salas and M. Quiros, Inorg. Chem., 1997, 36, 3277. 
 138
                                                                                                                                                             
3. (a) K. Uehara, S. Hikichi, A. Inagaki, M. Akita, Chem.-Eur. J., 2005, 11, 2788; (b) J. 
Campora, P. Palma, D. del Rio, J. A. Lopez, P. Valerga, Chem.Commun., 2004, 1490; (c) A. 
J. Canty, H. Jin, A. S. Roberts, B. W. Skelton, P. R. Traill, A. H. White, Organometallics, 
1995, 14, 199; (d) M. A. Halcrow, L. M. L. Chia, X. Liu, E. J. L. McInnes, L. J. Yellowlees, 
F. E. Mabbs, I. J. Scowen, M. McPartlin, J. E. Davies, J. Chem. Soc., Dalton Trans., 1999, 
1753; (e) C. A. Kilner, E. J. L.McInnes, M. A. Leech, G. S. Beddard, J. A. K. Howard, F. E. 
Mabbs, D. Collison, A. J. Bridgeman, M. A. Halcrow, Dalton Trans., 2004, 236; (f) K. 
Uehara, S. Hikichi, M. Akita, J. Chem. Soc., Dalton Trans., 2002, 3529. 
4. For a discussion on acac chelating ligands, see Chapter 6 and (a) C. B. Aakeröy; J. Desper 
and J. Valdés-Martínez, CrystEngComm., 2004, 6, 413; (b) J. K. Bera, T. –T. Vo, R. A. 
Walton and K. R. Dunbar, Polyhedra, 2003, 22, 3009; (c) C. B. Aakeröy, N. Schultheiss and 
J. Desper, Inorg. Chem., 2005, 44, 4983;  
5. (a) R. Gupta and R. Mukherjee, Polyhedron, 2000, 19, 719; (b) V. Balamurugan and R. 
Mukherjee, Inorg. Chimica Acta, 2006, 359, 1376. 
6. (a) H. P. Dijkstra, M. D. Meijer, J. Patel, R. Kreiter, G. P. M. van Klink, M. Lutz, A. L. Spek, 
A. J. Canty and G. van Koten, Organometallics, 2001, 20, 3159; (b) A. J. Canty, J. Patel, B. 
W. Skelton and A. H. White, J. Organomet. Chem, 2000, 607, 194; (c) A. J. Canty, J. Patel, 
B. W. Skelton and A. H. White, J. Organomet. Chem, 2000, 599, 194; (d) C. M. Hartshorn 
and P. J. Steel, Organometallics, 1998, 17, 3487; (e) A. J. Canty, R. T. Honeyman, B. W. 
Skelton and A. H. White, J. Organomet. Chem, 1990, 389, 277. 
7. (a) D. L. Reger, R. F. Semeniuc and M. D. Smith, Cryst. Growth Des., 2005, 5, 1181; (b) P. 
Manikandan, M. Subramoni, B. Varghese and P. T. Manoharan, J. Chem. Soc. Dalton Trans., 
1998, 3219; (c) Z. Shirin, R. Mukherjee, J. F. Richardson and R. M. Buchanan, J. Chem. Soc. 
Dalton Trans., 1994, 465; (d) S. Mahapatra and R. Mukherjee, J. Chem. Soc. Dalton Trans., 
1992, 2337. 
8. S. F. Vasilevsky, S. V. Klyatskaya, E. V. Tretyakov and J. Elguero, Heterocycles, 2003, 60, 
879. 
 
 139
CHAPTER 8 - Using Supramolecular Synthons to Construct 
Bimetallic Nanoparticle Assemblies 
 
8.1 Introduction 
We have previously shown that supramolecular synthons1 can be used to construct 
discrete two or three component co-crystals2 and 1-D inorganic-organic chains,3 even in the 
presence of potentially disruptive forces.  It is pertinent however to test the influence of 
supramolecular synthons further, by studying the effect of incorporating hydrogen-bond 
functionalities onto larger architectures. 
Nanoparticles, which are substantially larger, Figure 8.1, provide a suitable system for 
such a study. 
 
Figure 8.1 Relative volumes of nanoparticles compared to molecules and coordination 
complexes (the volume for coordination complexes is taken as one repeat unit in the 1-D chain). 
 
One of the first known examples of nanoparticles is in the Lycurgus cup.  Made in ~4th 
century AD4 from dichroic glass, containing colloidal gold, the cup appears red in transmitted 
light and green in reflected light.  Colloidal gold was first reported in 1618 by Antoli,5 however 
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it was over 200 years later in 1857 when Faraday6 first described the reduction of ionic gold to 
give particles “very minute in their dimensions”,6 which, when diffused “produced a beautiful 
ruby fluid”.6 
Since Faraday’s report,6 nanoparticles (particularly gold nanoparticles) have been studied 
extensively within materials science7 due to their inherent physical properties (e.g. catalytic,8 
therapeutic,9 and optical10).  
Nanoparticles are stabilised with long chain ligands (~10 carbon atoms) possessing 
functional groups capable of binding to the metal (e.g. amines and thiols) at one end and 
(generally) an ‘inert’ functionality (e.g. methyl group) at the other.7d, 11  In assemblies of this 
nature, the nanoparticles can come within close proximity, dictated by interdigitation of the 
ligands and the van der Waals radii, Figure 8.2a, of the atoms to form an ordered superlattice, 
Figure 8.2b.11   
   
Au
Au
Au
Au
Au
Au
 
(a)            (b) 
Figure 8.2 (a) Arrangement of nanoparticles observed in dodecanethiol functionalised gold 
nanoparticles.  Interdigitation of aliphatic chains results in (b) an ordered monodisperse 
superlattice.11e 
 
If however, suitable thio- or amino-based ligands, terminated with functionalities capable 
of forming reliable and predictable hydrogen bonds, were utilised to “decorate” nanoparticles, 
the interparticle distance and hence the arrangement of the nanoparticles could be manipulated, 
Figure 8.3 and consequently, the properties could be tailored.  Furthermore, if the 
complementary ligands are appended to different types of nanoparticles, the construction of 
bimetallic nanoparticle assemblies is possible. 
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Figure 8.3 From interdigitation to tip-to-tip interactions, the effect of hydrogen bonding on 
nanoparticle assembly. 
 
Ligands terminated with hydrogen-bonding moieties have been used to functionalise 
nanoparticles.12  A good example is 1-(8-11-mercaptooctyl)thymine and 8-(4,6-
diamino[1,3,5]triazin-2-yl)octane-1-thiol, Figure 8.4a.12a  Hydrogen bonding between 
nanoparticles in this case however is limited due to (i) the potential to form only one type of 
heteromeric hydrogen-bond motif and (ii) the difficulties surrounding identification of the 
heteromeric motif versus the homomeric motif, Figure 8.4b. 
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Figure 8.4 (a) Heteromeric interaction between 1-(8-11-mercaptooctyl)thymine and 8-(4,6-
diamino[1,3,5]triazin-2-yl)octane-1-thiol and (b) homomeric interaction between two 4,6-
diamino[1,3,5]triazin-2-yl)octane-1-thiol ligands. 
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With this in mind, a versatile heteromeric synthon needs to be chosen which can be (i) 
subject to covalent modifications in order to fine-tune hydrogen-bond strength and (ii) identified 
by a straightforward procedure. 
O-H•••N hydrogen bonds are reliable interactions2, 13 that can be fine-tuned by altering 
either the strength of the hydrogen-bond acceptor (by changing or modifying the N-heterocycle) 
or the hydrogen-bond donor (by using different carboxylic acids, alcohols etc.).  Also, O-H•••N 
hydrogen bonds can be identified by infrared (IR) spectroscopy and therefore are an ideal target.   
Consequently, suitable ligands should contain: 
 
I. A long (~10 carbon atoms) aliphatic chain anchored with a sulfur functionality (thiol or 
disulfide) 
 
II. A hydrogen-bond acceptor or donor moiety 
 
Although pyridine is a good hydrogen-bond acceptor, 2a, 2b, 13 imidazole is even better 
(based on MEP surface calculations14), Figure 8.5. 
 
(a)         (b) 
Figure 8.5 MEP surface calculations of (a) N-methylimidazole and (b) pyridine. 
 
Data in the CSD15 has shown O-H•••N hydrogen bonds between imidazole and (i) 
alcohols (11 structures),16 Figure 8.6a, (ii) carboxylic acids (10 structures),16c, 17 Figure 8.6b as 
well as N+-H•••O- interactions between an imidazolium cation and a carboxylate anion (44 
structures),17e, 18 Figure 8.6c. 
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           (a)                     (b)                (c) 
Figure 8.6 Imidazole as a hydrogen-bond acceptor. 
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Consequently, an imidazole based disulfide ligand (which is more synthetically viable 
than an imidazole based thiol), Figure 8.7a, will be synthesised to provide a hydrogen-bond 
acceptor for 11-mercaptoundecanoic acid, Figure 8.7b and 11-mercaptoundecan-1-ol, Figure 
8.7c. 
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      (a)     (b)    (c) 
Figure 8.7 Target ligands; (a) bis(8-imidazol-1-yloctyl)disulfide; (b) 11-mercaptoundecanoic 
acid and (c) 11-mercaptoundecan-1-ol. 
 
Gold nanoparticles (AuNP’s) and silver nanoparticles (AgNP’s) will be synthesised via 
the inverse micelle method.11a-e  The metal salt is dissolved in a solution of 
didodecyldimethylammonium bromide (DDAB), reduced with NaBH4 and functionalised with 
dodecylamine (gold) and dodecanethiol (silver).19  Ligand exchange will then be performed in 
order to append the desired, hydrogen-bond functionalised ligands to the nanoparticles, Figure 
8.8. 
Au
= dodecylamine
= dodecanethiol
AuCl3 Au
0gold reduced nanoparticles
stabilised
Au
    (i)   11-Mercaptoundecanoic acid
=  (ii)  11-Mercaptoundecan-1-ol
    (iii) 8-(bisimidazol-1-yloctyl)
           disulfide
Ligand exchange
AgAgNO3 Ag
0silver reduced nanoparticles
stabilised
Ligand exchange
Ag
    (i)   11-Mercaptoundecanoic acid
=  (ii)  11-Mercaptoundecan-1-ol
    (iii) 8-(bisimidazol-1-yloctyl)
           disulfide  
Figure 8.8 Target nanoparticles. 
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Transmission electron microscopy (TEM) and IR analysis of homomeric and heteromeric 
nanoparticle assemblies will allow for the following three questions to be answered: 
 
I. Can nanoparticles be synthesised with hydrogen-bond functionalised ligands? 
 
II. Do hydrogen bonds form between nanoparticles? 
 
III. Can supramolecular synthons be used to manipulate nanoparticle assemblies? 
8.2 Experimental 
8.2.1 Synthesis 
All chemicals were purchased from Aldrich and Fischer and used without further 
purification.  Glassware for nanoparticle synthesis was cleaned with (i) soap and water, (ii) aqua 
regia (3:1 HCl:HNO3), (iii) conc. H2SO4, (iv) KOH base bath and (v) a water rinse followed by 
oven drying.  Melting points were determined on a Fisher-Johns melting point apparatus and are 
uncorrected.  TEM were performed on a Siemens CM100 transmission electron microscope.  
TEM samples were prepared by placing a drop of the colloidal solution onto a carbon-coated 
Formvar copper grid.  The grids were allowed to dry under ambient conditions (for toluene 
solutions) and dried using a heat gun for DMSO solutions.  
8.2.1.1 Synthesis of 1-bromooctan-8-ol, 44  
HO OH Br OH
47% HBr
8 8Cyclohexane  
To a round bottom flask, 1,8-octanediol, (5.87g, 40.2mmol) and cyclohexane (106mL) 
were added.  Once in solution, 47% HBr (27mL) was added and the solution stirred at reflux for 
6 hours.  Upon completion, the reaction mixture was diluted with hexanes and the aqueous layer 
separated.  The organic layer was then washed with NaHCO3(aq) (4 x 50mL) and NaCl(aq) (1 x 
50mL), dried over MgSO4 and reduced to a colourless oil, 44, (5.55g, 66.1%).  
1H NMR (δH; 
200MHz, CDCl3): 1.33-1.47 (m, 8H), 1.55 (quin, J = 6.6Hz, 2H), 1.86 (quin, J = 7.2Hz, 2H), 
2.83 (s, 1H), 3.41 (t, J = 6.8Hz, 2H), 3.56 (t, J = 6.6Hz, 2H), Figure B.44. 
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8.2.1.2 Synthesis of 1-mercaptooctan-8-ol, 45 
Br OH HS OH
Thiourea
Ethanol8 8  
To a round bottom flask, 44 (5.55g, 26.6mmol) and ethanol (150mL) were added.  Once 
in solution, thiourea (4.19g, 55.1mmol) was added and the reaction refluxed for 3 hours, at which 
point, 10% NaOH (75mL) was added and the reaction refluxed for a further 2 hours.  The 
reaction was then cooled to room temperature and the pH adjusted to 2-3 with 2N HCl.  The 
acidic solution was then washed with dichloromethane (3 x 100mL) and the organic layer 
separated, dried over MgSO4 and reduced to a white solid/colourless oil, 45, (4.20g, 97.3%).  
1H 
NMR (δH; 200MHz, CDCl3): 1.32-1.40 (m, 8H), 1.52-1.64 (m, 4H), 1.90 (s, 1H), 2.52 (q, J = 
3.6Hz, 2H), 3.61 (t, J = 3.2Hz, 2H), Figure B.45. 
8.2.1.3 Synthesis of bis(8-hydroxyoctyl)disulfide, 46 
HS OH Methanol
I2
S OH
S OH
8
8
8  
To a round bottom flask, 45, (2.01g, 12.4mmol) and methanol (10mL) were added.  Once 
in solution, a 0.5M methanolic solution of iodine (~20mL) was added dropwise until the solution 
remained yellow.  The reaction was then quenched with 10% NaHSO3 (50mL) and 
dichloromethane (50mL).  The organic layer was extracted and the aqueous layer was washed 
with dichloromethane (2 x 50mL).  All organic extracts were combined, dried over MgSO4 and 
reduced to a white solid, 46, (1.94g, 94.4%).  Mp: 32-35oC.  1H NMR (δH; 200MHz, CDCl3): 
1.34 (s, 16H), 1.54-1.71 (m, 8H), 2.68 (t, J = 7.2Hz, 4H), 3.64 (t, J = 6.6Hz, 4H), Figure B.46. 
8.2.1.4 Synthesis of bis(8-bromooctyl)disulfide, 47  
S OH
S OH
S Br
S Br
48% HBr
Cyclohexane
8
8
8
8  
To a round bottom flask, 45 (3.08g, 9.55mmol) and cyclohexane (80mL) were added.  
Once in solution, 47% HBr (80mL) was added and the reaction refluxed for 24 hours, at which 
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point a second portion of 47% HBr (80mL) was added and the reaction refluxed for an additional 
24 hours.  Upon completion, the reaction was diluted with hexanes (100mL) and the aqueous 
layer extracted.  The organic layer was then washed with NaHCO3(aq) (4 x 100mL) and NaCl(aq) 
(1 x 100mL), separated, dried over MgSO4 and reduced to a yellow liquid, 47, (3.63g, 84.8%).  
1H NMR, (δC; 200MHz, CDCl3): 1.32-1.42 (m, 16H), 1.67 (quin, J = 3.6Hz, 4H), 1.85 (quin, J = 
3.8Hz, 4H), 2.67 (t, J = 3.6Hz, 4H), 3.39 (t, J = 3.6Hz, 4H), Figure B.47. 
8.2.1.5 Synthesis of bis(8-imidazol-1-yloctyl)disulfide, 48 
S Br
S Br
S Im
S Im
Imidazole
NaOH, THF
8
8
8
8  
To a round bottom flask, imidazole (1.10g, 16.2mmol) and dry THF (50mL) were added.  
Once in solution, NaOH pellets (1.62g, 40.5mmol) were added and the reaction stirred for 2 
hours.  Upon completion, 47 (1.815g, 4.05mmol) in dry THF (50mL) was added and the reaction 
stirred for 4 days.  H2O was added to dissolve NaBr and excess NaOH pellets and the aqueous 
layer was saturated with NaCl.  The THF layer was extracted, dried over MgSO4 and reduced to 
a yellow oil.  The oil was then dissolved in ethyl acetate (50mL) and washed with 1M NaOH 
until excess imidazole was removed.  The organic layer was extracted, dried over MgSO4 and 
reduced to a yellow oil, 48, (0.972g, 56.9%).  1H NMR (δH; 200MHz, CDCl3): 1.30-1.43 (m, 
16H), 1.58-1.82 (m, 8H), 2.66 (t, J = 7.2Hz, 4H), 3.91 (t, J = 7Hz, 4H), 6.91 (d, J = 1.2Hz, 2H), 
7.03 (d, J = 1.2Hz, 2H), 7.45 (s, 2H), Figure B.48a; 13C NMR, (δC; 50MHz, CDCl3): 26.32, 
28.20, 28.82, 28.90, 28.97, 30.93, 38.80, 46.87, 118.73, 129.06, 136.90, Figure B.48b. 
8.2.1.6 Synthesis of dodecylamine functionalised gold nanoparticles, 49 
Didodecyldimethylammonium bromide (DDAB) (1.62g, 3.50mmol) was dissolved in dry 
toluene (10mL) in a clean, dry, 50ml Erlenmeyer flask.  AuCl3 (0.0340g, 0.112mmol) was added 
to the mixture and the resulting yellow solution was sonicated until AuCl3 was dissolved.  The 
gold ions were then reduced with NaBH4 (0.04ml of a 9.4M(aq) soln.) resulting in a colour change 
from yellow to deep purple.  The purple solution was stirred for a further 15min to ensure 
complete reduction before being transferred into a clean, dry, 40ml vial.  Dodecylamine (0.81g, 
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4.37mmol) was then added to the vial and shaken vigorously.  The purple solution was diluted 
with absolute ethanol (28mL) and shaken to initiate precipitation.  The particles were allowed to 
settle overnight, the ethanol/toluene mix was carefully removed from the vial using a Pasteur 
pipette and the particles were dried at room temperature under vacuum for ~1 hour. 
8.2.1.7 Ligand exchange of gold nanoparticles, 50-52 
The dried particles, 49, were redissolved in dry toluene (15mL) to give a purple solution.  
The exchange ligand (11-mercaptoundecanoic acid 0.195g, 0.893mmol; 11-mercaptoundecan-1-
ol 0.183g, 0.893mmol; bis(8-imidazol-1-yloctyl)disulfide 0.377g, 0.893mmol) was added to the 
solution and shaken resulting in immediate precipitation.  The particles were allowed to settle 
and the toluene carefully removed using a Pasteur pipette.  The particles were then washed with 
toluene (2x15mL) followed by dissolution in DMSO via sonication and heating. 
8.2.1.8 Synthesis of dodecanethiol functionalised silver nanoparticles, 53 
DDAB (1.62g, 3.50mmol) was dissolved in dry toluene (10mL) in a clean, dry, 50ml 
Erlenmeyer flask.  AgNO3 (0.0250g, 0.145mmol) was added and the colourless solution was 
sonicated to dissolve the AgNO3.  The silver ions were then reduced with NaBH4 (0.04ml of 
9.4M soln.) resulting in a colour change from colourless to brown.  The brown solution was 
stirred for a further 15min to ensure complete reduction before being transferred into a clean, 
dry, 40ml vial.  Dodecanethiol (0.85g, 4.20mmol) was then added to the vial and shaken 
vigorously.  The brown solution was diluted with absolute ethanol (28mL) and shaken, resulting 
in precipitation.  The particles were centrifuged, the ethanol/toluene mix was decanted and the 
particles were dried at room temperature under vacuum for ~1 hour. 
8.2.1.9 Ligand exchange of silver nanoparticles, 54-55 
The dried particles, 53, were redissolved in dry toluene (15mL) to give a straw coloured 
solution.  The exchange ligand (11-mercaptoundecanoic acid 0.195g, 0.893mmol; 11-
mercaptoundecan-1-ol 0.189g, 0.893mmol) was added to the solution and shaken.  Precipitation 
occurred overnight, the particles were allowed to settle and the toluene was carefully removed 
using a Pasteur pipette.  The particles were then washed with toluene (3x15mL) followed by 
dissolution in DMSO. 
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8.3 Results 
8.3.1 TEM image of dodecylamine functionalised AuNP’s 
The TEM image of dodecylamine functionalised AuNP’s shows a monodisperse 
superlattice of AuNPs, Figure 8.9.  The size of the particles ~8-9nm and the interparticle distance 
is ~1.5nm. 
    
(a)       (b) 
Figure 8.9 TEM image showing monodisperse dodecylamine functionalised AuNP’s; (a) 
magnification = 130000x; scale = 100nm (b) magnification = 180000x; scale = 20nm. 
8.3.2 TEM image of 11-mercaptoundecanoic acid functionalised AuNP’s 
The TEM image of 11-mercaptoundecanoic acid functionalised gold nanoparticles shows 
a fractal network of monodisperse nanoparticles ~8-9nm in size, with an interparticle distance of 
~3nm, Figure 8.10. 
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(a)       (b) 
Figure 8.10 TEM image showing network of monodisperse 11-mercaptoundecanoic acid 
functionalised AuNP’s; (a) magnification = 46000x; scale = 100nm; (b) magnification = 
130000x; scale = 100nm. 
8.3.3 TEM image of 11-mercaptoundecan-1-ol functionalised AuNP’s 
The TEM image of 11-mercaptoundecan-1-ol functionalised gold nanoparticles shows 
monodisperse nanoparticles ~8-9nm in size, with an interparticle distance is ~2.3nm, Figure 
8.11. 
    
(a)       (b) 
Figure 8.11 TEM image showing monodisperse 11-mercaptoundecan-1-ol functionalised 
AuNP’s; (a) magnification = 46000x; scale = 100nm; (b) magnification = 130000x; scale = 
100nm. 
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8.3.4 TEM image of bis(8-imidazol-1-yloctyl)disulfide functionalised AuNP’s 
The TEM image of bis(8-imidazol-1-yloctyl)disulfide functionalised gold nanoparticles 
shows a monodisperse cluster of nanoparticles ~8-9nm in size with an interparticle distance of 
~1.5nm, Figure 8.12. 
    
(a)       (b) 
Figure 8.12 TEM image showing bis(8-imidazol-1-yloctyl)disulfide functionalised AuNP’s; 
(a) magnification = 46000x; scale = 100nm; (b) magnification = 130000x; scale = 100nm. 
8.3.5 TEM image of dodecaethiol functionalised AgNP’s 
The TEM image of dodecanethiol functionalised AgNP’s shows monodisperse AgNPs, 
Figure 8.13.  The size of the particles is ~6-7nm and the interparticle distance is ~1.8nm. 
    
(a)       (b) 
Figure 8.13 TEM image showing monodisperse dodecanethiol functionalised AgNP’s; (a) 
magnification = 64000x; scale = 100nm; (b) magnification = 92000x; scale = 100nm. 
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8.3.6 TEM image of 11-mercaptoundecanoic acid functionalised AgNP’s 
Similar to the TEM image of 11-mercaptoundecanoic acid functionalised gold 
nanoparticles, silver 11-mercaptoundecanoic acid nanoparticles show a fractal network of 
monodisperse nanoparticles ~6-7nm in size with an interparticle distance of ~2.4nm, Figure 8.14.   
    
(a)       (b) 
Figure 8.14 TEM image showing network of monodisperse 11-mercaptoundecanoic acid 
functionalised AgNP’s; (a) magnification = 34000x; scale = 100nm; (b) magnification = 92000x; 
scale = 100nm. 
8.3.7 TEM image of 11-mercaptoundecan-1-ol functionalised AgNP’s 
Similar to the TEM image of 11-mercaptoundecan-1-ol functionalised gold nanoparticles, 
the TEM image of silver 11-mercaptoundecan-1-ol nanoparticles shows monodisperse 
nanoparticles ~6-7nm in size with an interparticle distance of ~2.4nm, Figure 8.15. 
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(a)       (b) 
Figure 8.15 TEM image showing monodisperse 11-mercaptoundecan-1-ol functionalised 
AgNP’s; (a) magnification = 92000x; scale = 100nm; (b) magnification = 130000x; scale = 
100nm.  
8.3.8 TEM image of 11-mercaptoundecanoic acid functionalised AuNP’s + bis(8-imidazol-1-
yloctyl)disulfide functionalised AuNP’s 
Dramatically different from the homomeric nanoparticle assemblies, the TEM image of 
11-mercaptoundecanoic acid functionalised gold nanoparticles + bis(8-imidazol-1-
yloctyl)disulfide functionalised gold nanoparticles shows a network of monodisperse particles 
~8-9nm in size, Figure 8.16. 
    
(a)       (b) 
Figure 8.16 Network of 11-mercaptoundecanoic acid functionalised AuNP’s + bis(8-imidazol-
1-yloctyl)disulfide functionalised AuNP’s observed in the TEM image; (a) magnification = 
64000x; scale = 100nm; (b) magnification = 130000x; scale = 100nm. 
 153
8.3.9 TEM image of 11-mercaptoundecan-1-ol functionalised AuNP’s + bis(8-imidazol-1-
yloctyl)disulfide functionalised AuNP’s 
Significantly different from the homomeric nanoparticle assemblies, the TEM image of 
11-mercaptoundecan-1-ol functionalised gold nanoparticles + bis(8-imidazol-1-yloctyl)disulfide 
functionalised gold nanoparticles shows monodisperse particles ~8-9nm in size forming a dense 
network, Figure 8.17. 
   
(a)       (b) 
Figure 8.17 Network of 11-mercaptoundecan-1-ol functionalised AuNP’s + bis(8-imidazol-1-
yloctyl)disulfide functionalised AuNP’s observed in the TEM image; (a) magnification = 
25000x; scale = 500nm; (b) magnification = 64000x; scale = 100nm. 
8.3.10 TEM image of 11-mercaptoundecanoic acid functionalised AgNP’s + bis(8-imidazol-
1-yloctyl)disulfide functionalised AuNP’s 
Dramatically different from the homomeric nanoparticle assemblies, the TEM image of 
11-mercaptoundecanoic acid functionalised silver nanoparticles + bis(8-imidazol-1-
yloctyl)disulfide functionalised gold nanoparticles shows a cluster of monodisperse particles ~8-
9nm in size, Figure 8.18. 
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(a)       (b) 
Figure 8.18 Cluster of 11-mercaptoundecanoic acid functionalised AgNP’s + bis(8-imidazol-
1-yloctyl)disulfide functionalised AuNP’s observed in the TEM image; (a) magnification = 
46000x; scale = 100nm; (b) magnification = 130000x; scale = 100nm. 
8.3.11 TEM image of 11-mercaptoundecan-1-ol functionalised AgNP’s + bis(8-imidazol-1-
yloctyl)disulfide functionalised AuNP’s 
Similar to the TEM image observed for 11-mercaptoundecanoic acid functionalised silver 
nanoparticles + bis(8-imidazol-1-yloctyl)disulfide functionalised gold nanoparticles and different 
from the homomeric nanoparticle assemblies, the TEM image of 11-mercaptoundecan-1-ol 
functionalised silver nanoparticles + bis(8-imidazol-1-yloctyl)disulfide functionalised gold 
nanoparticles shows a cluster of ~8-9nm nanoparticles, Figure 8.19.  
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(a)       (b) 
Figure 8.19 Network of 11-mercaptoundecan-1-ol functionalised AgNP’s + bis(8-imidazol-1-
yloctyl)disulfide functionalised AuNP’s observed in the TEM image; (a) magnification = 
46000x; scale = 100nm; (b) magnification = 130000x; scale = 100nm. 
8.3.12 Determining nanoparticle “communication” by infra-red (IR) spectroscopy 
IR spectroscopy was carried out on heteromeric nanoparticle assemblies.20  Although it is 
not possible to determine the exact number of hydrogen-bond interactions between particles via 
this method, IR spectroscopy is still effective for identifying O-H•••N hydrogen bonds.  Broad 
bands at ~2500 cm-1 and ~1900 cm-1 are indicative of O-H•••N hydrogen bonds and although 
only the stretch at ~1900 cm-1 is visible, Figure 8.20, it still allows for identification of hydrogen 
bonding in nanoparticles, Table 8.1. 
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Figure 8.20 IR spectrum of 11-mercaptoundecanoic acid functionalised AuNP’s + bis(8-
imidazol-1-yloctyl)disulfide functionalised AuNP’s showing the 1900 cm-1 O-H•••N stretch 
(circled). 
 
Table 8.1 IR data of heteromeric nanoparticle assemblies. 
Ligand 1 (metal) Ligand 2 (metal) O-H•••N stretches / cm-1 
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8.3.13 Estimating extent of ligand exchange by elemental analysis 
Elemental analysis was carried out to estimate the extent of ligand exchange.  The ratio of 
sulfur : nitrogen was calculated for 11-mercaptoundecanoic acid and 11-mercaptoundecan-1-ol 
AuNP’s which was translated into percent ligand exchange (only exchanged ligands contained 
sulfur), Table 8.2. 
 
Table 8.2 Elemental analysis and estimated % ligand exchange of AuNP’s. 
AuNP’s 11-Mercaptoundecanoic acid 11-Mercaptoundecan-1-ol 
Elemental 
composition 
C=5.62%; H=0.75%; 
N=0.05%; S=1.20% 
C=5.04%; H=0.66%; 
N=<0.05%; S=1.36% 
Sulfur : Nitrogen 10 : 1 12 : 1 
Estimated % 
Ligand exchanged 
~90% ~90% 
8.4 Discussion 
8.4.1 Assessing ligand exchange reactions 
The TEM images obtained for the seven, homomeric nanoparticle assemblies clearly 
show that ligand exchange occurs.  Replacing the methyl terminated ligands with ligands 
terminated with a hydrogen-bond functionality plays a significant role in the ordering of 
nanoparticles.  Dodecylamine gold nanoparticles form an ordered superlattice, whereas particles 
appended with ligands terminated with hydrogen-bond moieties, produce a different 
arrangement, Figure 8.21.  In the case of 11-mercaptoundecanoic acid particles, fractal type 
aggregation of particles was observed.  This is consistent with particles coated with hydrogen-
bond terminated ligands,12a with relatively strong interactions (compared to no hydrogen bonding 
in dodecylamine nanoparticles) between particles causing a chain type arrangement. 
In comparison, only a few interactions are observed between 11-mercaptoundecan-1-ol 
nanoparticles however still significantly different to dodecylamine gold nanoparticles. 
Bis(8-imidazol-1-yloctyl) disulfide nanoparticles, which do not form self-complementary 
hydrogen bonds show a similar assembly to the superlattice obtained with dodecylamine 
nanoparticles, although less ordered.  
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Figure 8.21 Effect of ligand exchange on arrangement of gold nanoparticles; magnification = 
130000x; scale = 100nm in all images. 
 
Silver nanoparticles also demonstrate a dramatic change in nanoparticle aggregation upon 
exchange with hydrogen-bond terminated ligands, Figure 8.22.  The fractal aggregation in 11-
mercaptoundecanoic acid nanoparticles is observed and confirms ligand exchange.  Similarly, 
11-mercaptoundecan-1-ol particles show a significant change from the initial dodecanethiol 
silver nanoparticles.  
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Figure 8.22 Effect of ligand exchange on arrangement of silver nanoparticles; magnification = 
92000x; scale = 100nm in all images. 
8.4.2 Predicting extent of ligand exchange 
Gold nanoparticles were initially functionalised with dodecylamine in order to achieve a 
high level of exchange.  The preference of the gold-sulfur interaction over gold-nitrogen favours 
ligand exchange and elemental analysis of gold nanoparticles after ligand exchange infer ~90% 
of dodecylamine ligands were replaced, Figure 8.23. 
 
Figure 8.23 Estimated extent of exchange in gold nanoparticles. 
HS 10
OH
HS 10
OH
O
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8.4.3 Assessing interparticle distances 
Interparticle distances were measured from the TEM images of all nanoparticle 
assemblies, Table 8.3.  The noticeable increase in spacing from ‘inert’ methyl and imidazole 
groups to hydrogen-bonding functionalities (carboxylic acid and hydroxyl moieties) confirms 
that hydrogen bonding is taking place between adjacent nanoparticles and is significant enough 
to adjust interparticle spacing between particles and consequently overall nanoparticle assembly. 
 
Table 8.3 Interparticle distances between nanoparticles. 
 Dodecylamine Dodecanethiol 
11-Mercapto- 
undecanoic acid 
11-Mercapto- 
undecan-1-ol 
Bis(8-imidazol-
1-
yloctyl)disulfide 
AuNP’s ~1.5nm N/A ~3nm ~2.3nm ~1.5nm 
AgNP’s N/A ~1.8nm ~2.4nm ~2.4nm N/A 
 
8.4.4 Addressing communication between complementary gold nanoparticles 
The 1900 cm-1 O-H•••N hydrogen-bond stretch was observed in the IR spectra when 
complementary gold nanoparticles were combined, Figure 8.24.  This confirms that heteromeric 
hydrogen bonding is taking place between the -OH of the acid or alcohol and the nitrogen atom 
of the imidazole.  Similarly, the TEM images of heteromeric nanoparticle assemblies show a 
different arrangement compared to the homomeric nanoparticle assemblies. 
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Figure 8.24 Complementary hydrogen bonding between gold nanoparticles. 
8.4.5 Addressing communication between complementary gold and silver nanoparticles 
Similarly, when complementary gold and silver nanoparticles were combined, the 1900 
cm-1 O-H•••N hydrogen-bond stretch was observed in both cases confirming heteromeric 
hydrogen bonding is taking place between gold and silver nanoparticles, Figure 8.25. 
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Figure 8.25 Complementary hydrogen bonding between gold and silver nanoparticles. 
 
IR and TEM analysis of homomeric and heteromeric nanoparticle assemblies have 
provided answers to the questions addressed at the beginning of this chapter. 
 
I. Can nanoparticles be synthesised with hydrogen-bond functionalised ligands? 
Elemental analysis confirmed that ligand exchange was successful on nanoparticles with 
~90% of ligands replaced for AuNP’s, Figure 8.26, allowing for hydrogen-bond functionalised 
ligands to be appended to the surface of the nanoparticles. 
 
Figure 8.26 Estimated ligand exchange. 
 
TEM images also confirmed ligand exchange, with significant changes observed in the 
nanoparticle assemblies before and after exchange. 
 
II. Do hydrogen bonds form between nanoparticles? 
TEM images of nanoparticle assemblies infer that hydrogen bonding is taking place 
between nanoparticles.  Assemblies in which hydrogen bonding can occur (i.e homomeric acid-
acid and alcohol-alcohol as well as heteromeric acid-imidazole and alcohol-imidazole) show 
major differences (i.e. arrangement of nanoparticles and interparticle distances) in nanoparticle 
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assemblies, compared to those that cannot form hydrogen bonding (i.e homomeric 
dodecylamine, dodecanethiol and 8-(imidazol-1-yloctyl)disulfide functionalised nanoparticles). 
IR data of heteromeric nanoparticle assemblies confirmed hydrogen bonding between (i) 
complementary gold nanoparticles and (ii) complementary gold and silver nanoparticles, with the 
1900 cm-1 O-H•••N hydrogen-bond stretch observed, Figure 8.27. 
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Figure 8.27 Heteromeric hydrogen bonding between complementary nanoparticles. 
 
III. Can supramolecular synthons be used to manipulate nanoparticle assemblies? 
It is clear from the TEM images of homomeric and heteromeric nanoparticle assemblies 
that hydrogen bonding plays a major role in nanoparticle aggregation. 
By simply replacing dodecylamine with 11-mercaptoundecanoic acid, the aggregation 
changes from ordered superlattice to fractal aggregates, Figure 8.28, with an increase in 
interparticle spacing from ~1.5nm to ~3nm. 
      
Figure 8.28 Extent of hydrogen bonding on the aggregation of nanoparticles; magnification = 
130000x; scale = 100nm. 
 
Ligand Exchange
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8-(imidazol-1-yloctyl)disulfide 
functionalised AuNP’s 
magnification = 130000x 
scale = 100nm 
Additionally, when complementary nanoparticles are combined, the formation of 
heteromeric O-H•••N hydrogen bonds causes dramatic changes in nanoparticle aggregation, 
Figure 8.29. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.29 Effect of O-H•••N hydrogen bonds on nanoparticle aggregation. 
 
Although the extent of hydrogen bonding is not quantifiable, the formation of 
heteromeric imidazole•••acid/alcohol interactions demonstrates the robustness of synthons, even 
with building blocks significantly larger and more complex than coordination complexes. 
11-mercaptoundecan-1-ol  
functionalised AuNP’s 
+ 
8-(imidazol-1-yloctyl)disulfide 
functionalised AuNP’s 
magnification = 64000x 
scale = 100nm 
11-mercaptoundecan-1-ol  
functionalised AuNP’s 
magnification = 130000x 
scale = 100nm 
Nanoparticles
combined
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CHAPTER 9 - Summary 
The concept of using molecular electrostatic potential (MEP) surfaces to control the 
outcome of co-crystallisation reactions has been shown to be a highly effective tool. 
By utilising such an approach, a hierarchy of hydrogen-bond interactions has been 
developed for systems containing (i) a N-heterocycle and an amide moiety and (ii) two different 
N-heterocycles. 
We designed and synthesised a family of pyrazole benzamide supramolecular reagents 
(SR’s), which contained a poor hydrogen-bond acceptor (pyrazole) and an amide moiety, Figure 
9.1. 
Co-crystals between these SR’s and hydrogen-bond donors (carboxylic acids) show a 
change in preference for the incoming carboxylic acid compared to better (based on MEP 
surfaces) hydrogen-bond acceptors (e.g. pyridine and benzimidazole).  The incoming carboxylic 
acid opts to form a heteromeric acid-amide dimer via an O-H•••O and a N-H•••O hydrogen bond 
oppose to forming an O-H•••N hydrogen bond to the pyrazole nitrogen atom.   
Furthermore, the acceptor strength (based on MEP surfaces) of the pyrazole nitrogen 
atom was successfully turned up through simple covalent modifications (i.e. isomer change or 
addition of methyl groups to the pyrazole ring), Figure 9.1.   
 
Figure 9.1 Fine-tunability of pyrazole as a hydrogen-bond acceptor based on MEP surface 
calculations. 
 
This demonstrates the ability to fine-tune the hydrogen-bond acceptor strength and 
suggests MEP surfaces can be effective as a tool to control the product of co-crystallisation 
reactions, Figure 9.2. 
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Figure 9.2 Co-crystals between pyrazole benzamide SR’s and di-carboxylic acids showing 
improved hydrogen-bond acceptor ability of pyrazole nitrogen. 
 
The use of MEP surface calculations as a tool for proposing best acceptor/second best 
acceptor sites was further validated through a more stringent examination of SR’s containing two 
different N-heterocycles.  Ditopic pyridine-indazole and pyrimidine-pyrazole SR’s were 
designed and synthesised and subsequent co-crystallisations with carboxylic acids confirm that 
MEP surface calculations can be an effective tool, even when the calculated charges on the 
acceptor sites are somewhat similar.  In all cases, the incoming carboxylic acid forms an O-
H•••N hydrogen bond with the better, more negative hydrogen-bond acceptor (pyridine and 
pyrazole respectively), Figure 9.3. 
 
Figure 9.3 Validity of MEP surface calculations in ditopic heterocycle SR’s. 
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The reliability of the amide-amide dimer was exploited to construct inorganic-organic 
hybrid materials.  Combination of pyrazole benzamide ligands with copper(II)carboxylate 
“paddle-wheel” complexes resulted in the self-assembly of 1-D chains via pyrazole coordination 
to the neutral metal complex coupled with the formation of the amide-amide dimer, Figure 9.4. 
 
Figure 9.4 Self-assembly of 1-D inorganic-organic chains via combination of pyrazole 
benzamide ligands and copper “paddle-wheel” complexes. 
 
The influence of supramolecular synthons on much larger architectures was demonstrated 
by “decorating” the surface of gold and silver nanoparticles with ligands capable of forming 
reliable hydrogen bonds.  Replacing ligands possessing an ‘inert’ non hydrogen-bonding 
terminus (i.e. a methyl functionality) with those capable of forming homo- and/or heteromeric 
hydrogen bonds (i.e. a carboxylic acid, alcohol or imidazole), it is possible to control the 
interparticle distance between nanoparticles and consequently overall nanoparticle assembly, 
Figure 9.5. 
   
Figure 9.5 From interdigitation to tip-to-tip interactions, the effect of hydrogen bonding on 
nanoparticle assembly. 
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The overall ordering of the nanoparticles is dramatically effected by these ‘small’, yet 
significant interactions.  By changing the terminus on the stabilising ligand from a methyl group 
to a carboxylic acid, the aggregation of nanoparticles changed from an ordered superlattice to a 
more ‘fractal’ assembly, Figure 9.6.  Furthermore, the interparticle distance increased from 
~1.5nm (the estimated length of one ligand) to ~3nm. 
      
Figure 9.6 Extent of hydrogen bonding on the aggregation of nanoparticles. 
  
Finally, the ability to form O-H•••N hydrogen bonds between carboxylic acid or alcohol 
functionalised silver nanoparticles and the nitrogen atom of an imidazole moiety, appended to 
gold nanoparticles, Figure 9.7, shows that, construction of bimetallic nanoparticle assemblies is 
possible.   
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Figure 9.7 Complementary hydrogen bonding between gold and silver nanoparticles. 
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The results reported herein provide an insight into the versatility and influence of 
supramolecular synthons.  From small molecules to nano-scale architectures, these reliable 
hydrogen-bond motifs play a major role in assembly, Figure 9.8, and therefore, having a degree 
of control over supramolecular synthons is of the utmost importance for reliable supramolecular 
synthesis.  
MEP surfaces, shown to be highly effective within the systems discussed herein, could 
provide the supramolecular chemist with this degree of control. 
Consequently, it is necessary to assess the effectiveness of MEP surface calculations as a tool 
for determining a hierarchy of acceptor or donor sites.  Investigating a range of multiple 
hydrogen-bond donors (i.e. carboxylic acids, alcohols or oximes), more complex hydrogen-bond 
acceptors (i.e. 3 or more acceptor sites) and halogen-bond donors/acceptors, it will be possible to 
paint an overall picture of the reliability of MEP surface calculations, which would be invaluable 
for supramolecular synthesis. 
Supramolecular
Synthons
1:1 co-crystal 2:1 co-crystal
M
M
Inorganic-organic 
hybrid material
(M = complex ion)
Nanoparticle
assembly  
Figure 9.8 The versatility of supramolecular synthons, from small molecules to nano-scale 
architectures. 
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Appendix A - Crystal Structure Data 
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Table A.1 Crystal data and structure refinement for 2. 
 
Empirical formula  C11 H11 N3 O 
Formula weight  201.23 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 21.660(4) Å α = 90°. 
 b = 4.7544(9) Å β = 93.912(3)°. 
 c = 9.9321(19) Å γ = 90°. 
Volume 1020.4(3) Å3 
Z 4 
Density (calculated) 1.310 Mg/m3 
Absorption coefficient 0.088 mm-1 
F(000) 424 
Crystal size 0.42 x 0.28 x 0.08 mm3 
Theta range for data collection 1.88 to 28.40°. 
Index ranges -28<=h<=27, -6<=k<=6, -13<=l<=9 
Reflections collected 7149 
Independent reflections 2429 [R(int) = 0.0494] 
Completeness to theta = 28.40° 94.3 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2429 / 0 / 142 
Goodness-of-fit on F2 0.974 
Final R indices [I>2sigma(I)] R1 = 0.0522, wR2 = 0.1146 
R indices (all data) R1 = 0.1042, wR2 = 0.1342 
Largest diff. peak and hole 0.302 and -0.229 e.Å-3  
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Table A.2 Crystal data and structure refinement for 4. 
 
Empirical formula  C13 H15 N3 O 
Formula weight  229.28 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 8.4005(7) Å α = 90°. 
 b = 8.0671(7) Å β = 102.621(6)°. 
 c = 18.0477(18) Å γ = 90°. 
Volume 1193.50(19) Å3 
Z 4 
Density (calculated) 1.276 g/cm3 
Absorption coefficient 0.084 mm-1 
F(000) 488 
Crystal size 0.30 x 0.25 x 0.10 mm3 
Theta range for data collection 2.31 to 28.26°. 
Index ranges -10<=h<=10, -10<=k<=10, -22<=l<=23 
Reflections collected 8390 
Independent reflections 2789 [R(int) = 0.0919] 
Completeness to theta = 28.26° 94.1 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2789 / 0 / 162 
Goodness-of-fit on F2 0.934 
Final R indices [I>2sigma(I)] R1 = 0.0491, wR2 = 0.1184 
R indices (all data) R1 = 0.0892, wR2 = 0.1309 
Largest diff. peak and hole 0.168 and -0.197 e.Å-3  
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Table A.3 Crystal data and structure refinement for 6. 
 
Empirical formula  C13 H14 Br N3 O 
Formula weight  308.18 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 12.437(3) Å α = 90°. 
 b = 8.8195(17) Å β = 114.488(6)°. 
 c = 12.468(2) Å γ = 90°. 
Volume 1244.7(4) Å3 
Z 4 
Density (calculated) 1.645 g/cm3 
Absorption coefficient 3.294 mm-1 
F(000) 624 
Crystal size 0.15 x 0.15 x 0.15 mm3 
Theta range for data collection 2.93 to 33.14°. 
Index ranges -18<=h<=19, -12<=k<=13, -19<=l<=19 
Reflections collected 58663 
Independent reflections 4624 [R(int) = 0.0353] 
Completeness to theta = 33.14° 97.4 %  
Absorption correction None 
Max. and min. transmission 0.6378 and 0.6378 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4624 / 0 / 161 
Goodness-of-fit on F2 1.026 
Final R indices [I>2sigma(I)] R1 = 0.0234, wR2 = 0.0588 
R indices (all data) R1 = 0.0319, wR2 = 0.0622 
Largest diff. peak and hole 0.681 and -0.405 e.Å-3 
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Table A.4 Crystal data and structure refinement for 8. 
 
Empirical formula  C11 H11 N3 O 
Formula weight  201.23 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.7873(5) Å α = 77.6610(10)°. 
 b = 8.1130(6) Å β = 74.4600(10)°. 
 c = 8.8400(6) Å γ = 68.3980(10)°. 
Volume 496.14(6) Å3 
Z 2 
Density (calculated) 1.347 Mg/m3 
Absorption coefficient 0.091 mm-1 
F(000) 212 
Crystal size 0.25 x 0.22 x 0.20 mm3 
Theta range for data collection 2.41 to 30.00°. 
Index ranges -10<=h<=10, -10<=k<=11, -12<=l<=11 
Reflections collected 5729 
Independent reflections 2838 [R(int) = 0.0165] 
Completeness to theta = 30.00° 97.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.798 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2838 / 0 / 142 
Goodness-of-fit on F2 1.081 
Final R indices [I>2sigma(I)] R1 = 0.0449, wR2 = 0.1249 
R indices (all data) R1 = 0.0489, wR2 = 0.1292 
Largest diff. peak and hole 0.476 and -0.232 e.Å-3 
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Table A.5 Crystal data and structure refinement for 10. 
 
Empirical formula  C13 H15 N3 O 
Formula weight  229.28 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.0162(4) Å α = 97.253(2)°. 
 b = 8.0603(4) Å β = 106.060(2)°. 
 c = 10.4542(5) Å γ = 109.335(2)°. 
Volume 594.57(5) Å3 
Z 2 
Density (calculated) 1.281 g/cm3 
Absorption coefficient 0.084 mm-1 
F(000) 244 
Crystal size 0.25 x 0.20 x 0.15 mm3 
Theta range for data collection 2.09 to 31.00°. 
Index ranges -11<=h<=11, -11<=k<=11, -14<=l<=15 
Reflections collected 21375 
Independent reflections 3757 [R(int) = 0.0318] 
Completeness to theta = 31.00° 98.9 %  
Absorption correction None 
Max. and min. transmission 0.9875 and 0.9793 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3757 / 0 / 162 
Goodness-of-fit on F2 1.083 
Final R indices [I>2sigma(I)] R1 = 0.0434, wR2 = 0.1205 
R indices (all data) R1 = 0.0556, wR2 = 0.1299 
Largest diff. peak and hole 0.478 and -0.251 e.Å-3 
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Table A.6 Crystal data and structure refinement for 12. 
 
Empirical formula  C13 H14 Br N3 O 
Formula weight  308.18 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.9062(12) Å α = 73.396(9)°. 
 b = 11.6933(18) Å β = 74.274(9)°. 
 c = 14.146(2) Å γ = 70.553(9)°. 
Volume 1305.8(3) Å3 
Z 4 
Density (calculated) 1.568 g/cm3 
Absorption coefficient 3.140 mm-1 
F(000) 624 
Crystal size 0.35 x 0.25 x 0.08 mm3 
Theta range for data collection 1.53 to 27.33°. 
Index ranges -10<=h<=11, -14<=k<=13, -17<=l<=18 
Reflections collected 15905 
Independent reflections 5716 [R(int) = 0.0716] 
Completeness to theta = 27.33° 97.1 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.144 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5716 / 0 / 329 
Goodness-of-fit on F2 1.020 
Final R indices [I>2sigma(I)] R1 = 0.0699, wR2 = 0.1906 
R indices (all data) R1 = 0.1446, wR2 = 0.2351 
Largest diff. peak and hole 1.254 and -1.006 e.Å-3  
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Table A.7 Crystal data and structure refinement for 2a. 
 
Empirical formula  C18 H16 N4 O5 
Formula weight  368.35 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  Cc 
Unit cell dimensions a = 14.485(4) Å α = 90°. 
 b = 4.6366(11) Å β = 99.831(3)°. 
 c = 25.758(6) Å γ = 90°. 
Volume 1704.5(7) Å3 
Z 4 
Density (calculated) 1.435 g/cm3 
Absorption coefficient 0.107 mm-1 
F(000) 768 
Crystal size 0.36 x 0.34 x 0.09 mm3 
Theta range for data collection 2.85 to 25.19°. 
Index ranges -17<=h<=13, -5<=k<=5, -29<=l<=29 
Reflections collected 3961 
Independent reflections 1401 [R(int) = 0.0156] 
Completeness to theta = 25.00° 92.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.646 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1401 / 2 / 253 
Goodness-of-fit on F2 1.138 
Final R indices [I>2sigma(I)] R1 = 0.0320, wR2 = 0.0818 
R indices (all data) R1 = 0.0322, wR2 = 0.0820 
Absolute structure parameter 0.4(12) 
Largest diff. peak and hole 0.212 and -0.271 e.Å-3  
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Table A.8 Crystal data and structure refinement for 2b. 
 
Empirical formula  C18 H15 N5 O7 
Formula weight  413.35 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 17.0583(16) Å α = 90°. 
 b = 6.9273(7) Å β = 112.161(2)°. 
 c = 16.3728(15) Å γ = 90°. 
Volume 1791.8(3) Å3 
Z 4 
Density (calculated) 1.532 g/cm3 
Absorption coefficient 0.121 mm-1 
F(000) 856 
Crystal size 0.34 x 0.26 x 0.22 mm3 
Theta range for data collection 2.50 to 30.02°. 
Index ranges -23<=h<=23, -9<=k<=9, -23<=l<=22 
Reflections collected 20001 
Independent reflections 5218 [R(int) = 0.0320] 
Completeness to theta = 30.02° 99.8 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5218 / 0 / 283 
Goodness-of-fit on F2 1.062 
Final R indices [I>2sigma(I)] R1 = 0.0434, wR2 = 0.1147 
R indices (all data) R1 = 0.0492, wR2 = 0.1196 
Largest diff. peak and hole 0.471 and -0.285 e.Å-3  
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Table A.9 Crystal data and structure refinement for 2c. 
 
Empirical formula  C18 H16 F N3 O3 
Formula weight  341.34 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 4.3453(7) Å α = 90°. 
 b = 10.8147(17) Å β = 90.541(2)°. 
 c = 34.003(5) Å γ = 90°. 
Volume 1597.8(4) Å3 
Z 4 
Density (calculated) 1.419 g/cm3 
Absorption coefficient 0.106 mm-1 
F(000) 712 
Crystal size 0.14 x 0.20 x 0.35 mm3 
Theta range for data collection 1.98 to 26.01°. 
Index ranges -5<=h<=5, -13<=k<=13, -40<=l<=41 
Reflections collected 9978 
Independent reflections 2909 [R(int) = 0.0362] 
Completeness to theta = 26.01° 92.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.801 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2909 / 0 / 236 
Goodness-of-fit on F2 1.034 
Final R indices [I>2sigma(I)] R1 = 0.0407, wR2 = 0.1013 
R indices (all data) R1 = 0.0485, wR2 = 0.1053 
Largest diff. peak and hole 0.297 and -0.465 e.Å-3  
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Table A.10 Crystal data and structure refinement for 2d. 
 
Empirical formula  C18 H16 F N3 O3 
Formula weight  341.34 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 20.362(3) Å α = 97.170(3)°. 
 b = 21.994(4) Å β = 115.814(2)°. 
 c = 22.540(5) Å γ = 110.216(2)°. 
Volume 8062(3) Å3 
Z 20 
Density (calculated) 1.406 g/cm3 
Absorption coefficient 0.105 mm-1 
F(000) 3560 
Crystal size 0.48 x 0.15 x 0.12 mm3 
Theta range for data collection 1.22 to 28.44°. 
Index ranges -27<=h<=26, -28<=k<=28, -29<=l<=30 
Reflections collected 69882 
Independent reflections 36885 [R(int) = 0.0535] 
Completeness to theta = 28.44° 90.7 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 36885 / 0 / 1865 
Goodness-of-fit on F2 1.078 
Final R indices [I>2sigma(I)] R1 = 0.1051, wR2 = 0.2598 
R indices (all data) R1 = 0.2841, wR2 = 0.3387 
Largest diff. peak and hole 1.680 and -1.208 e.Å-3  
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Table A.11 Crystal data and structure refinement for 2e. 
 
Empirical formula  C18 H17 N3 O3 
Formula weight  323.35 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.0434(8) Å α = 101.8070(10)°. 
 b = 10.5552(9) Å β = 102.1260(10)°. 
 c = 17.4323(15) Å γ = 94.3700(10)°. 
Volume 1580.1(2) Å3 
Z 4 
Density (calculated) 1.359 g/cm3 
Absorption coefficient 0.095 mm-1 
F(000) 680 
Crystal size 0.28 x 0.28 x 0.15 mm3 
Theta range for data collection 1.99 to 28.27°. 
Index ranges -11<=h<=11, -13<=k<=14, -22<=l<=23 
Reflections collected 14134 
Independent reflections 7283 [R(int) = 0.0270] 
Completeness to theta = 28.27° 93.0 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7283 / 0 / 451 
Goodness-of-fit on F2 1.058 
Final R indices [I>2sigma(I)] R1 = 0.0438, wR2 = 0.1121 
R indices (all data) R1 = 0.0537, wR2 = 0.1184 
Largest diff. peak and hole 0.260 and -0.276 e.Å-3  
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Table A.12 Crystal data and structure refinement for 2f. 
 
Empirical formula  C24 H24 N6 O6 
Formula weight  492.49 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 4.2359(8) Å α = 90°. 
 b = 49.029(9) Å β = 92.780(4)°. 
 c = 5.5087(11) Å γ = 90°. 
Volume 1142.7(4) Å3 
Z 2 
Density (calculated) 1.431 Mg/m3 
Absorption coefficient 0.106 mm-1 
F(000) 516 
Crystal size 0.34 x 0.22 x 0.01 mm3 
Theta range for data collection 2.49 to 28.39°. 
Index ranges -5<=h<=5, -63<=k<=64, -4<=l<=6 
Reflections collected 8069 
Independent reflections 2638 [R(int) = 0.0362] 
Completeness to theta = 28.39° 91.5 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2638 / 0 / 172 
Goodness-of-fit on F2 1.253 
Final R indices [I>2sigma(I)] R1 = 0.0735, wR2 = 0.1489 
R indices (all data) R1 = 0.0811, wR2 = 0.1529 
Largest diff. peak and hole 0.434 and -0.310 e.Å-3  
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Table A.13 Crystal data and structure refinement for 2g. 
 
Empirical formula  C26 H28 N6 O6 
Formula weight  520.54 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 9.5363(9) Å α = 90°. 
 b = 7.3143(6) Å β = 96.130(7)°. 
 c = 17.6580(15) Å γ = 90°. 
Volume 1224.63(19) Å3 
Z 2 
Density (calculated) 1.412 g/cm3 
Absorption coefficient 0.103 mm-1 
F(000) 548 
Crystal size 0.40 x 0.35 x 0.25 mm3 
Theta range for data collection 2.32 to 27.85°. 
Index ranges -12<=h<=12, -9<=k<=9, -21<=l<=23 
Reflections collected 8075 
Independent reflections 2790 [R(int) = 0.1114] 
Completeness to theta = 27.85° 95.8 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2790 / 0 / 182 
Goodness-of-fit on F2 1.067 
Final R indices [I>2sigma(I)] R1 = 0.0639, wR2 = 0.1527 
R indices (all data) R1 = 0.0816, wR2 = 0.1686 
Extinction coefficient 0.079(10) 
Largest diff. peak and hole 0.496 and -0.354 e.Å-3  
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Table A.14 Crystal data and structure refinement for 2h. 
 
Empirical formula  C26 H26 N6 O6 
Formula weight  518.53 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 9.4746(6) Å α = 90°. 
 b = 7.2787(4) Å β = 94.562(3)°. 
 c = 17.6857(12) Å γ = 90°. 
Volume 1215.79(13) Å3 
Z 2 
Density (calculated) 1.416 g/cm3 
Absorption coefficient 0.103 mm-1 
F(000) 544 
Crystal size 0.40 x 0.35 x 0.25 mm3 
Theta range for data collection 2.31 to 28.30°. 
Index ranges -12<=h<=11, -8<=k<=9, -23<=l<=23 
Reflections collected 14011 
Independent reflections 2905 [R(int) = 0.1233] 
Completeness to theta = 28.30° 96.0 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2905 / 0 / 182 
Goodness-of-fit on F2 1.129 
Final R indices [I>2sigma(I)] R1 = 0.0557, wR2 = 0.1467 
R indices (all data) R1 = 0.0667, wR2 = 0.1602 
Extinction coefficient 0.084(10) 
Largest diff. peak and hole 0.458 and -0.318 e.Å-3  
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Table A.15 Crystal data and structure refinement for 4a. 
 
Empirical formula  C20 H20 N4 O5 
Formula weight  396.40 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 8.0769(6) Å α = 90°. 
 b = 25.5225(18) Å β = 98.457(4)°. 
 c = 9.1601(6) Å γ = 90°. 
Volume 1867.8(2) Å3 
Z 4 
Density (calculated) 1.410 g/cm3 
Absorption coefficient 0.104 mm-1 
F(000) 832 
Crystal size 0.20 x 0.20 x 0.08 mm3 
Theta range for data collection 1.60 to 31.50°. 
Index ranges -11<=h<=11, -37<=k<=37, -13<=l<=13 
Reflections collected 44009 
Independent reflections 6203 [R(int) = 0.0603] 
Completeness to theta = 31.50° 99.8 %  
Absorption correction None 
Max. and min. transmission 0.9918 and 0.9796 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6203 / 0 / 273 
Goodness-of-fit on F2 1.404 
Final R indices [I>2sigma(I)] R1 = 0.0720, wR2 = 0.2000 
R indices (all data) R1 = 0.1117, wR2 = 0.2185 
Largest diff. peak and hole 0.472 and -0.427 e.Å-3  
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Table A.16 Crystal data and structure refinement for 4b. 
 
Empirical formula  C20 H21 N3 O4 
Formula weight  367.40 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 8.2057(6) Å α = 90°. 
 b = 10.8322(8) Å β = 90.027(3)°. 
 c = 20.4551(14) Å γ = 90°. 
Volume 1818.2(2) Å3 
Z 4 
Density (calculated) 1.342 g/cm3 
Absorption coefficient 0.095 mm-1 
F(000) 776 
Crystal size 0.30 x 0.25 x 0.20 mm3 
Theta range for data collection 1.99 to 30.48°. 
Index ranges -10<=h<=11, -12<=k<=15, -29<=l<=29 
Reflections collected 33960 
Independent reflections 5529 [R(int) = 0.0348] 
Completeness to theta = 30.48° 99.8 %  
Absorption correction None 
Max. and min. transmission 0.9812 and 0.9721 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5529 / 0 / 258 
Goodness-of-fit on F2 1.035 
Final R indices [I>2sigma(I)] R1 = 0.0412, wR2 = 0.1088 
R indices (all data) R1 = 0.0544, wR2 = 0.1175 
Largest diff. peak and hole 0.362 and -0.240 e.Å-3 
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Table A.17 Crystal data and structure refinement for 4c. 
 
Empirical formula  C17 H19 N3 O5 
Formula weight  345.35 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 14.6443(14) Å α = 90°. 
 b = 5.8392(5) Å β = 99.294(2)°. 
 c = 19.4017(18) Å γ = 90°. 
Volume 1637.3(3) Å3 
Z 4 
Density (calculated) 1.401 g/cm3 
Absorption coefficient 0.105 mm-1 
F(000) 728 
Crystal size 0.36 x 0.34 x 0.14 mm3 
Theta range for data collection 1.90 to 28.28°. 
Index ranges -15<=h<=19, -7<=k<=7, -24<=l<=24 
Reflections collected 9283 
Independent reflections 3777 [R(int) = 0.0256] 
Completeness to theta = 28.28° 93.2 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3777 / 0 / 240 
Goodness-of-fit on F2 1.038 
Final R indices [I>2sigma(I)] R1 = 0.0440, wR2 = 0.1170 
R indices (all data) R1 = 0.0519, wR2 = 0.1232 
Largest diff. peak and hole 0.391 and -0.266 e.Å-3  
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Table A.18 Crystal data and structure refinement for 8a. 
 
Empirical formula  C15 H17 N3 O6 
Formula weight  335.32 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 21.5505(18) Å α = 90°. 
 b = 5.3999(5) Å β = 108.270(5)°. 
 c = 27.549(2) Å γ = 90°. 
Volume 3044.3(5) Å3 
Z 8 
Density (calculated) 1.463 g/cm3 
Absorption coefficient 0.115 mm-1 
F(000) 1408 
Crystal size 0.45 x 0.40 x 0.15 mm3 
Theta range for data collection 1.56 to 28.22°. 
Index ranges -27<=h<=26, -7<=k<=7, -32<=l<=35 
Reflections collected 10307 
Independent reflections 3538 [R(int) = 0.1314] 
Completeness to theta = 28.22° 94.1 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3538 / 23 / 254 
Goodness-of-fit on F2 1.042 
Final R indices [I>2sigma(I)] R1 = 0.0686, wR2 = 0.1719 
R indices (all data) R1 = 0.0997, wR2 = 0.1893 
Largest diff. peak and hole 0.408 and -0.463 e.Å-3 
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Table A.19 Crystal data and structure refinement for 8b. 
 
Empirical formula  C25 H19 N7 O13 
Formula weight  625.47 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 26.096(6) Å α = 90°. 
 b = 17.294(4) Å β = 118.080(4)°. 
 c = 13.247(3) Å γ = 90°. 
Volume 5275(2) Å3 
Z 8 
Density (calculated) 1.575 g/cm3 
Absorption coefficient 0.130 mm-1 
F(000) 2576 
Crystal size ? x ? x ? mm3 
Theta range for data collection 2.67 to 27.15°. 
Index ranges -32<=h<=32, -22<=k<=22, -16<=l<=16 
Reflections collected 24280 
Independent reflections 5515 [R(int) = 0.0696] 
Completeness to theta = 27.15° 94.5 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5515 / 0 / 418 
Goodness-of-fit on F2 1.006 
Final R indices [I>2sigma(I)] R1 = 0.0475, wR2 = 0.1015 
R indices (all data) R1 = 0.1027, wR2 = 0.1231 
Largest diff. peak and hole 0.221 and -0.318 e.Å-3 
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Table A.20 Crystal data and structure refinement for 15a. 
 
Empirical formula  C20 H16 N4 O4 
Formula weight  376.37 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 6.9835(4) Å α = 90°. 
 b = 30.8648(16) Å β = 93.4490(10)°. 
 c = 8.0398(4) Å γ = 90°. 
Volume 1729.79(16) Å3 
Z 4 
Density (calculated) 1.445 Mg/m3 
Absorption coefficient 0.104 mm-1 
F(000) 784 
Crystal size 0.53 x 0.36 x 0.17 mm3 
Theta range for data collection 2.62 to 28.32°. 
Index ranges -9<=h<=9, -39<=k<=40, -10<=l<=10 
Reflections collected 13938 
Independent reflections 4014 [R(int) = 0.0231] 
Completeness to theta = 25.00° 99.8 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4014 / 0 / 256 
Goodness-of-fit on F2 1.050 
Final R indices [I>2sigma(I)] R1 = 0.0423, wR2 = 0.1059 
R indices (all data) R1 = 0.0454, wR2 = 0.1081 
Largest diff. peak and hole 0.383 and -0.238 e.Å-3 
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Table A.21 Crystal data and structure refinement for 15b. 
 
Empirical formula  C20 H15 N5 O6 
Formula weight  421.37 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 12.2436(14) Å α = 90°. 
 b = 7.3976(8) Å β = 95.480(2)°. 
 c = 20.422(2) Å γ = 90°. 
Volume 1841.2(4) Å3 
Z 4 
Density (calculated) 1.520 g/cm3 
Absorption coefficient 0.116 mm-1 
F(000) 872 
Crystal size 0.34 x 0.24 x 0.14 mm3 
Theta range for data collection 2.93 to 30.00°. 
Index ranges -9<=h<=17, -5<=k<=10, -28<=l<=25 
Reflections collected 10436 
Independent reflections 5160 [R(int) = 0.0363] 
Completeness to theta = 30.00° 95.8 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5160 / 0 / 283 
Goodness-of-fit on F2 1.082 
Final R indices [I>2sigma(I)] R1 = 0.0580, wR2 = 0.1453 
R indices (all data) R1 = 0.0649, wR2 = 0.1510 
Largest diff. peak and hole 0.591 and -0.388 e.Å-3  
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Table A.22 Crystal data and structure refinement for 15c. 
 
Empirical formula  C17 H17 N3 O4 
Formula weight  327.34 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 37.956(2) Å α = 90°. 
 b = 4.9029(3) Å β = 93.700(3)°. 
 c = 17.0897(12) Å γ = 90°. 
Volume 3173.6(4) Å3 
Z 8 
Density (calculated) 1.370 g/cm3 
Absorption coefficient 0.100 mm-1 
F(000) 1376 
Crystal size 0.40 x 0.35 x 0.20 mm3 
Theta range for data collection 2.15 to 28.30°. 
Index ranges -49<=h<=50, -6<=k<=6, -21<=l<=21 
Reflections collected 11312 
Independent reflections 3742 [R(int) = 0.1244] 
Completeness to theta = 28.30° 94.5 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3742 / 0 / 223 
Goodness-of-fit on F2 1.069 
Final R indices [I>2sigma(I)] R1 = 0.0604, wR2 = 0.1624 
R indices (all data) R1 = 0.0813, wR2 = 0.1844 
Largest diff. peak and hole 0.366 and -0.269 e.Å-3  
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Table A.23 Crystal data and structure refinement for 17a. 
 
Empirical formula  C27 H21 N5 O8 
Formula weight  543.49 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.4037(5) Å α = 90.0880(10)°. 
 b = 10.9449(6) Å β = 101.5130(10)°. 
 c = 13.4142(8) Å γ = 92.0180(10)°. 
Volume 1208.19(12) Å3 
Z 2 
Density (calculated) 1.494 g/cm3 
Absorption coefficient 0.113 mm-1 
F(000) 564 
Crystal size 0.56 x 0.40 x 0.28 mm3 
Theta range for data collection 2.41 to 30.05°. 
Index ranges -11<=h<=11, -15<=k<=15, -18<=l<=18 
Reflections collected 13938 
Independent reflections 6908 [R(int) = 0.0244] 
Completeness to theta = 30.05° 97.4 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6908 / 0 / 367 
Goodness-of-fit on F2 1.051 
Final R indices [I>2sigma(I)] R1 = 0.0449, wR2 = 0.1227 
R indices (all data) R1 = 0.0494, wR2 = 0.1268 
Largest diff. peak and hole 0.480 and -0.367 e.Å-3  
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Table A.24 Crystal data and structure refinement for 17b. 
 
Empirical formula  C20 H15 N5 O6 
Formula weight  421.37 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 19.2124(16) Å α = 90°. 
 b = 13.4369(12) Å β = 104.943(6)°. 
 c = 15.1052(14) Å γ = 90°. 
Volume 3767.6(6) Å3 
Z 8 
Density (calculated) 1.486 g/cm3 
Absorption coefficient 0.113 mm-1 
F(000) 1744 
Crystal size 0.25 x 0.20 x 0.20 mm3 
Theta range for data collection 1.10 to 28.36°. 
Index ranges -25<=h<=22, -17<=k<=17, -19<=l<=17 
Reflections collected 26918 
Independent reflections 8695 [R(int) = 0.1702] 
Completeness to theta = 28.36° 92.3 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8695 / 0 / 559 
Goodness-of-fit on F2 1.066 
Final R indices [I>2sigma(I)] R1 = 0.1039, wR2 = 0.2468 
R indices (all data) R1 = 0.2584, wR2 = 0.2952 
Largest diff. peak and hole 1.018 and -0.415 e.Å-3  
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Table A.25 Crystal data and structure refinement for 20. 
 
Empirical formula  C14 H16 N6 
Formula weight  268.33 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 15.1130(16) Å α = 90°. 
 b = 3.9871(4) Å β = 95.549(6)°. 
 c = 22.050(2) Å γ = 90°. 
Volume 1322.4(2) Å3 
Z 4 
Density (calculated) 1.348 g/cm3 
Absorption coefficient 0.087 mm-1 
F(000) 568 
Crystal size 0.25 x 0.10 x 0.05 mm3 
Theta range for data collection 1.86 to 30.50°. 
Index ranges -21<=h<=20, -5<=k<=5, -31<=l<=31 
Reflections collected 22961 
Independent reflections 3970 [R(int) = 0.0434] 
Completeness to theta = 30.50° 98.0 %  
Absorption correction None 
Max. and min. transmission 0.9956 and 0.9785 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3970 / 0 / 185 
Goodness-of-fit on F2 1.026 
Final R indices [I>2sigma(I)] R1 = 0.0471, wR2 = 0.1099 
R indices (all data) R1 = 0.0867, wR2 = 0.1261 
Largest diff. peak and hole 0.295 and -0.253 e.Å-3 
 
 
 
 
 
 199
Table A.26 Crystal data and structure refinement for 19a. 
 
Empirical formula  C17 H13 N7 O4 
Formula weight  379.34 
Temperature  133(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 3.7754(5) Å α = 87.131(7)°. 
 b = 11.0619(13) Å β = 89.574(7)°. 
 c = 19.509(2) Å γ = 85.800(7)°. 
Volume 811.53(17) Å3 
Z 2 
Density (calculated) 1.552 g/cm3 
Absorption coefficient 0.116 mm-1 
F(000) 392 
Crystal size 0.30 x 0.16 x 0.08 mm3 
Theta range for data collection 1.85 to 29.57°. 
Index ranges -5<=h<=5, -15<=k<=15, -27<=l<=27 
Reflections collected 26179 
Independent reflections 4556 [R(int) = 0.0532] 
Completeness to theta = 29.57° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9908 and 0.9660 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4556 / 0 / 256 
Goodness-of-fit on F2 1.020 
Final R indices [I>2sigma(I)] R1 = 0.0504, wR2 = 0.1146 
R indices (all data) R1 = 0.0987, wR2 = 0.1363 
Largest diff. peak and hole 0.247 and -0.300 e.Å-3 
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Table A.27 Crystal data and structure refinement for 19b. 
 
Empirical formula  C17 H12 N8 O6 
Formula weight  424.35 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbca 
Unit cell dimensions a = 19.6259(15) Å α = 90°. 
 b = 14.3503(10) Å β = 90°. 
 c = 37.921(3) Å γ = 90°. 
Volume 10680.0(13) Å3 
Z 24 
Density (calculated) 1.583 g/cm3 
Absorption coefficient 0.125 mm-1 
F(000) 5232 
Crystal size 0.35 x 0.30 x 0.20 mm3 
Theta range for data collection 1.07 to 28.38°. 
Index ranges -24<=h<=26, -18<=k<=19, -50<=l<=50 
Reflections collected 77223 
Independent reflections 12702 [R(int) = 0.1344] 
Completeness to theta = 28.38° 94.9 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 12702 / 0 / 847 
Goodness-of-fit on F2 0.945 
Final R indices [I>2sigma(I)] R1 = 0.0532, wR2 = 0.1265 
R indices (all data) R1 = 0.1220, wR2 = 0.1549 
Largest diff. peak and hole 0.295 and -0.285 e.Å-3 
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Table A.28 Crystal data and structure refinement for 20a. 
 
Empirical formula  C14 H16 Cl2 Cu N6 
Formula weight  402.77 
Temperature  133(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 10.6585(6) Å α = 90°. 
 b = 16.5865(9) Å β = 92.459(3)°. 
 c = 18.4152(11) Å γ = 90°. 
Volume 3252.6(3) Å3 
Z 8 
Density (calculated) 1.645 g/cm3 
Absorption coefficient 1.679 mm-1 
F(000) 1640 
Crystal size 0.25 x 0.15 x 0.10 mm3 
Theta range for data collection 1.91 to 29.57°. 
Index ranges -14<=h<=14, -23<=k<=16, -25<=l<=21 
Reflections collected 69657 
Independent reflections 9108 [R(int) = 0.0677] 
Completeness to theta = 29.57° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.8501 and 0.6790 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9108 / 0 / 423 
Goodness-of-fit on F2 1.012 
Final R indices [I>2sigma(I)] R1 = 0.0494, wR2 = 0.1162 
R indices (all data) R1 = 0.0923, wR2 = 0.1368 
Largest diff. peak and hole 0.588 and -1.623 e.Å-3 
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Table A.29 Crystal data and structure refinement for 2i. 
 
Empirical formula  C42 H26 Cu2 F24 N6 O10 
Formula weight  1357.77 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 9.7354(11) Å α = 90°. 
 b = 11.1497(12) Å β = 96.985(2)°. 
 c = 23.870(3) Å γ = 90°. 
Volume 2571.8(5) Å3 
Z 2 
Density (calculated) 1.753 g/cm3 
Absorption coefficient 0.975 mm-1 
F(000) 1348 
Crystal size 0.41 x 0.13 x 0.13 mm3 
Theta range for data collection 2.02 to 30.01°. 
Index ranges -13<=h<=13, -15<=k<=15, -33<=l<=29 
Reflections collected 24508 
Independent reflections 7477 [R(int) = 0.0295] 
Completeness to theta = 30.01° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.672 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7477 / 0 / 385 
Goodness-of-fit on F2 1.021 
Final R indices [I>2sigma(I)] R1 = 0.0365, wR2 = 0.0933 
R indices (all data) R1 = 0.0430, wR2 = 0.0972 
Largest diff. peak and hole 0.620 and -0.279 e.Å-3  
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Table A.30 Crystal data and structure refinement for 2j. 
 
Empirical formula  C86 H78 N6 Ni2 O12 
Formula weight  1504.96 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.0170(6) Å α = 86.3190(10)°. 
 b = 12.3493(8) Å β = 78.0890(10)°. 
 c = 17.6357(12) Å γ = 72.2410(10)°. 
Volume 1830.0(2) Å3 
Z 1 
Density (calculated) 1.366 Mg/m3 
Absorption coefficient 0.584 mm-1 
F(000) 788 
Crystal size 0.38 x 0.24 x 0.16 mm3 
Theta range for data collection 2.09 to 30.02°. 
Index ranges -12<=h<=12, -17<=k<=17, -24<=l<=24 
Reflections collected 21060 
Independent reflections 10465 [R(int) = 0.0193] 
Completeness to theta = 30.02° 97.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.811 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10465 / 0 / 481 
Goodness-of-fit on F2 1.044 
Final R indices [I>2sigma(I)] R1 = 0.0490, wR2 = 0.1206 
R indices (all data) R1 = 0.0584, wR2 = 0.1260 
Largest diff. peak and hole 1.129 and -0.284 e.Å-3  
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Table A.31 Crystal data and structure refinement for 8c. 
 
Empirical formula  C42 H26 Cu2 F24 N6 O10 
Formula weight  1357.77 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 10.0325(10) Å α = 90°. 
 b = 15.1765(15) Å β = 99.957(2)°. 
 c = 16.6440(16) Å γ = 90°. 
Volume 2496.0(4) Å3 
Z 2 
Density (calculated) 1.807 g/cm3 
Absorption coefficient 1.005 mm-1 
F(000) 1348 
Crystal size 0.36 x 0.26 x 0.13 mm3 
Theta range for data collection 2.06 to 30.11°. 
Index ranges -14<=h<=12, -21<=k<=21, -23<=l<=23 
Reflections collected 28577 
Independent reflections 7318 [R(int) = 0.0302] 
Completeness to theta = 30.11° 99.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.784 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7318 / 0 / 413 
Goodness-of-fit on F2 1.114 
Final R indices [I>2sigma(I)] R1 = 0.0356, wR2 = 0.0925 
R indices (all data) R1 = 0.0417, wR2 = 0.0956 
Largest diff. peak and hole 0.601 and -0.455 e.Å-3  
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Table A.32 Crystal data and structure refinement for 2k. 
 
Empirical formula  C34 H40 Cu2 N8 O10 
Formula weight  847.82 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.5896(5) Å α = 68.531(4)°. 
 b = 10.0990(7) Å β = 82.310(3)°. 
 c = 13.3959(8) Å γ = 72.114(3)°. 
Volume 909.07(10) Å3 
Z 1 
Density (calculated) 1.549 g/cm3 
Absorption coefficient 1.238 mm-1 
F(000) 438 
Crystal size 0.30 x 0.25 x 0.15 mm3 
Theta range for data collection 1.63 to 28.28°. 
Index ranges -10<=h<=10, -12<=k<=13, -17<=l<=17 
Reflections collected 14172 
Independent reflections 4271 [R(int) = 0.1187] 
Completeness to theta = 28.28° 94.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.763 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4271 / 0 / 253 
Goodness-of-fit on F2 1.080 
Final R indices [I>2sigma(I)] R1 = 0.0529, wR2 = 0.1370 
R indices (all data) R1 = 0.0600, wR2 = 0.1436 
Largest diff. peak and hole 0.861 and -0.783 e.Å-3  
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Table A.33 Crystal data and structure refinement for 2l. 
 
Empirical formula  C50 H38 Cu2 F4 N6 O10 
Formula weight  1085.94 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 10.8218(9) Å α = 90°. 
 b = 19.4000(14) Å β = 108.346(4)°. 
 c = 12.0541(8) Å γ = 90°. 
Volume 2402.0(3) Å3 
Z 2 
Density (calculated) 1.501 g/cm3 
Absorption coefficient 0.966 mm-1 
F(000) 1108 
Crystal size 0.40 x 0.25 x 0.15 mm3 
Theta range for data collection 2.07 to 28.33°. 
Index ranges -14<=h<=14, -23<=k<=25, -15<=l<=14 
Reflections collected 17581 
Independent reflections 5679 [R(int) = 0.1125] 
Completeness to theta = 28.33° 94.8 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5679 / 23 / 353 
Goodness-of-fit on F2 1.069 
Final R indices [I>2sigma(I)] R1 = 0.0548, wR2 = 0.1367 
R indices (all data) R1 = 0.0674, wR2 = 0.1467 
Largest diff. peak and hole 0.436 and -1.095 e.Å-3  
 
 
 
 
 
 
 207
Table A.34 Crystal data and structure refinement for 8d. 
 
Empirical formula  C30 H34 Cu2 N6 O10 
Formula weight  765.71 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.0173(4) Å α = 110.1640(10)°. 
 b = 10.1615(5) Å β = 109.1250(10)°. 
 c = 11.4846(6) Å γ = 90.5040(10)°. 
Volume 821.95(7) Å3 
Z 1 
Density (calculated) 1.547 g/cm3 
Absorption coefficient 1.359 mm-1 
F(000) 394 
Crystal size 0.38 x 0.30 x 0.07 mm3 
Theta range for data collection 2.02 to 30.00°. 
Index ranges -11<=h<=10, -13<=k<=14, -16<=l<=16 
Reflections collected 9572 
Independent reflections 4714 [R(int) = 0.0210] 
Completeness to theta = 30.00° 98.2 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4714 / 0 / 223 
Goodness-of-fit on F2 1.082 
Final R indices [I>2sigma(I)] R1 = 0.0304, wR2 = 0.0783 
R indices (all data) R1 = 0.0325, wR2 = 0.0794 
Largest diff. peak and hole 0.660 and -0.311 e.Å-3  
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Table A.35 Crystal data and structure refinement for 33. 
 
Empirical formula  C21 H18 N6 
Formula weight  354.41 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.7801(6) Å α = 88.323(4)°. 
 b = 10.0149(6) Å β = 63.239(3)°. 
 c = 10.7647(6) Å γ = 83.908(3)°. 
Volume 935.92(10) Å3 
Z 2 
Density (calculated) 1.258 g/cm3 
Absorption coefficient 0.079 mm-1 
F(000) 372 
Crystal size 0.25 x 0.20 x 0.10 mm3 
Theta range for data collection 2.95 to 32.57°. 
Index ranges -14<=h<=14, -15<=k<=15, -16<=l<=16 
Reflections collected 39688 
Independent reflections 6760 [R(int) = 0.0597] 
Completeness to theta = 32.57° 99.0 %  
Absorption correction None 
Max. and min. transmission 0.9921 and 0.9805 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6760 / 0 / 250 
Goodness-of-fit on F2 0.997 
Final R indices [I>2sigma(I)] R1 = 0.0495, wR2 = 0.1210 
R indices (all data) R1 = 0.0942, wR2 = 0.1423 
Largest diff. peak and hole 0.325 and -0.291 e.Å-3 
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Table A.36 Crystal data and structure refinement for 31a. 
 
Empirical formula  C21 H17 Cl2 Co N5 
Formula weight  469.23 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 14.0489(19) Å α = 90°. 
 b = 8.2425(11) Å β = 105.025(7)°. 
 c = 18.746(3) Å γ = 90°. 
Volume 2096.6(5) Å3 
Z 4 
Density (calculated) 1.487 g/cm3 
Absorption coefficient 1.091 mm-1 
F(000) 956 
Crystal size 0.40 x 0.35 x 0.05 mm3 
Theta range for data collection 1.50 to 28.19°. 
Index ranges -18<=h<=18, -10<=k<=10, -24<=l<=24 
Reflections collected 15043 
Independent reflections 4843 [R(int) = 0.1432] 
Completeness to theta = 28.19° 93.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.570 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4843 / 0 / 262 
Goodness-of-fit on F2 0.875 
Final R indices [I>2sigma(I)] R1 = 0.0555, wR2 = 0.1213 
R indices (all data) R1 = 0.1131, wR2 = 0.1422 
Largest diff. peak and hole 0.737 and -0.699 e.Å-3  
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Table A.37 Crystal data and structure refinement for 33a. 
 
Empirical formula  C27 H27 Ag F6 N9 P 
Formula weight  730.42 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pnna 
Unit cell dimensions a = 14.134(8) Å α = 90°. 
 b = 26.513(15) Å β = 90°. 
 c = 17.588(10) Å γ = 90°. 
Volume 6591(7) Å3 
Z 8 
Density (calculated) 1.472 g/cm3 
Absorption coefficient 0.726 mm-1 
F(000) 2944 
Crystal size 0.25 x 0.10 x 0.05 mm3 
Theta range for data collection 1.54 to 29.58°. 
Index ranges -19<=h<=18, -36<=k<=15, -21<=l<=21 
Reflections collected 26624 
Independent reflections 8521 [R(int) = 0.1291] 
Completeness to theta = 29.58° 91.9 %  
Absorption correction None 
Max. and min. transmission 0.9646 and 0.8393 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8521 / 63 / 451 
Goodness-of-fit on F2 1.061 
Final R indices [I>2sigma(I)] R1 = 0.0968, wR2 = 0.2666 
R indices (all data) R1 = 0.2391, wR2 = 0.3349 
Largest diff. peak and hole 1.823 and -1.411 e.Å-3 
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Appendix B - 1H and 13C NMR Data 
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Figure B.1 1H NMR of 1. 
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Figure B.2 (a) 1H NMR and (b) 13C NMR of 2. 
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Figure B.3 1H NMR of 3. 
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Figure B.4 (a) 1H NMR and (b) 13C NMR of 4. 
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Figure B.5 1H NMR of 5. 
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Figure B.6 (a) 1H NMR and (b) 13C NMR of 6. 
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Figure B.7 1H NMR of 7. 
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Figure B.8 (a) 1H NMR and (b) 13C NMR of 8. 
9 8 7 6 5 4 3 2 1
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
2.011.010.810.730.73
7
.7
4
7
.7
2
7
.6
9
7
.4
4
7
.4
4 7
.4
2
7
.2
7
6
.3
1
6
.1
8
5
.8
7
5
.3
7
 
(a) 
160 140 120 100 80 60 40 20 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
1
6
8
.9
3
1
3
9
.7
6
1
3
7
.2
5
1
3
3
.9
4
1
3
1
.0
8
1
2
9
.1
6 1
2
6
.9
7
1
2
6
.6
8
1
0
6
.3
0
7
7
.6
4
7
7
.0
0
7
6
.3
6
5
5
.4
3
 
(b) 
CONH2
N
N
50MHz; CDCl3 
400MHz; CDCl3 
 220
Figure B.9 1H NMR of 9. 
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Figure B.10 (a) 1H NMR and (b) 13C NMR of 10. 
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Figure B.11 1H NMR of 11. 
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Figure B.12 (a) 1H NMR and (b) 13C NMR of 12. 
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Figure B.13 (a) 1H NMR and (b) 13C NMR of 13. 
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Figure B.14 (a) 1H NMR and (b) 13C NMR of 14. 
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Figure B.15 (a) 1H NMR and (b) 13C NMR of 15. 
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Figure B.16 (a) 1H NMR and (b) 13C NMR of 16. 
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Figure B.17 (a) 1H NMR and (b) 13C NMR of 17. 
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Figure B.18 (a) 1H NMR and (b) 13C NMR of 18. 
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Figure B.19 (a) 1H NMR and (b) 13C NMR of 19. 
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Figure B.20 (a) 1H NMR and (b) 13C NMR of 20. 
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Figure B.21 (a) 1H NMR and (b) 13C NMR of 21. 
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Figure B.22 (a) 1H NMR and (b) 13C NMR of 22. 
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Figure B.23 (a) 1H NMR and (b) 13C NMR of 23. 
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Figure B.24 1H NMR of 24. 
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Figure B.25 1H NMR of 25. 
9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
4.001.670.781.31
7
.5
5
7
.5
4
7
.5
3
7
.3
8
7
.3
7
7
.1
9
6
.9
1
6
.2
8
6
.2
7
6
.2
6
5
.2
1
0
.0
0
 
Br Br
Br
N N
Br
N N
400MHz; CDCl3 
200MHz; CDCl3 
 236
Figure B.26 1H NMR of 26. 
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Figure B.27 1H NMR of 27. 
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Figure B.28 1H NMR of 28. 
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Figure B.29 1H NMR of 29. 
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Figure B.30 1H NMR of 30. 
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Figure B.31 (a) 1H NMR and (b) 13C NMR of 31. 
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Figure B.32 (a) 1H NMR and (b) 13C NMR of 32. 
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Figure B.33 (a) 1H NMR and (b) 13C NMR of 33. 
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Figure B.34 (a) 1H NMR and (b) 13C NMR of 34. 
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Figure B.35 1H NMR of 35. 
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Figure B.36 1H NMR of 36. 
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Figure B.37 1H NMR of 37. 
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Figure B.38 (a) 1H NMR and (b) 13C NMR of 38. 
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Figure B.39 (a) 1H NMR and (b) 13C NMR of 39. 
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Figure B.40 1H NMR of 40. 
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Figure B.41 1H NMR of 41. 
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Figure B.42 (a) 1H NMR and (b) 13C NMR of 42. 
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Figure B.43 1H NMR of 43. 
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Figure B.44 1H NMR of 44. 
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Figure B.45 1H NMR of 45. 
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Figure B.46 1H NMR of 46. 
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Figure B.47 1H NMR of 47. 
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Figure B.48 (a) 1H NMR and (b) 13C NMR of 48. 
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